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Abstract 
Plant viruses are naturally occurring nanoparticles that are fascinating nanoscale 
platforms. The use of plant viruses as multifunctional nanoplatforms and as building blocks for 
nanotechnology provides unique advantages. The versatility of Cowpea mosaic virus (CPMV) 
to template metallic coatings and site–specific attachment of desired moieties was explored. 
CPMV’s robustness, monodispersity, large–scale production, and amenability to chemical and 
genetic modification have enabled the research to be carried out as presented in this thesis.  
CPMV capsid was utilised for the formation of a wide range of metallic coatings using 
both mineralization and metallization of the CPMV exterior. Moreover, CPMV’s exterior was 
chemically modified with specifically designed functionalities (i.e. electroactive moieties, 
enzymes, peptides that favour certain types of mineralization, and therapeutic agents). The 
ability to utilise both the interior and exterior surface of CPMV empty virus–like particles 
(eVLPs) was explored. The use of eVLPs has broadened the range of potential applications of 
CPMV; for example, it is being investigated as a drug carrier. Most viruses contain pores in 
their capsid shell, through which small molecules can be loaded. Using this property, CPMV 
eVLPs were used as nanocontainers for drug encapsulation and for the formation of iron oxide 
nanoparticles, which are potentially useful as hyperthermia treatment agents. CPMV eVLP 
holds great potential to accurately deliver the treatment agents to the desired location and 
maintain the dose for an adequate duration. In addition, functionalised virus surface could 
selectively attach to specific cells and localise the bound drug. Thus, this could be explored as a 
drug delivery system without many of the limitations of synthetic nanoparticles. Polyelectrolyte 
coating of CPMV eVLPs has offered a workable loading and controlled release methodology. 
Collectively, this thesis describes covalent coupling of molecules to the exterior of CPMV, 
mineralization and metallization of CPMV exterior and mineralization within eVLPs. 
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1 Literature review  
1.1 Introduction 
The great power of material manipulation at the nano scale lies in the resultant 
properties being unpredictably different from those observed at the macro scale. 
Nanotechnology is often described as a revolutionary new field of development with the 
potential to change lives and holds great promise in many areas. “Nano” science and technology 
promise and envisage futuristic applications from the ability to construct anything precisely by 
controlling the individual atoms or molecules; this prospect thrills the optimists as much as it 
frightens the pessimists. Nanotechnology offers ways to create smaller, cheaper, lighter and 
faster devices, which use fewer raw materials and consume less energy. 
To attempt a short introduction to “nano” science and technology is an intimidating 
task. The field is incredibly broad and diverse. The SI prefix “nano” means a billionth (10–9) 
part, thus a nanometre is a billionth of a metre. A common popular image of the nanometre is 
one eighty thousandth of the width of a human hair. “Nano” is used to refer to both science and 
technology; where “nanoscience” appears within a wide range of scientific fields (physics, 
chemistry, biology, and material science). However, “nanotechnology” has potential 
applications in a range of different disciplines (energy, transport, medicine, textiles and 
electronics). 
According to the national nanotechnology initiative (www.nano.gov), an object is 
nanoscale when it is approximately in the 1–100 nm size range. In this size range, properties 
change because as things become very small, the surface shrinks less than their volumes, 
causing larger surface–to–volume ratios than for larger objects. A greater surface area can mean 
that nanomaterials have higher reactivity, conductivity and magnetic properties (Mansur, 2010).  
Nanotechnology is not only featured in science fiction books or movies but also offers 
fascinating solutions to a number of practical problems. For example, nano–coated clothes can 
repel dirt and reduce the use of harmful chemicals, and mobile phones are becoming smaller and 
smaller but are growing cleverer, faster and cheaper. 
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Nanoscience is a multidisciplinary research area, which has the ability to tune physical, 
chemical, optical, magnetic and electronic properties on nanoparticles by adjusting the size and 
the shape of the nanoparticles. Nanoscale particles often exhibit properties distinct from those 
exhibited by larger objects of the same material. Properties such as colour, conductivity, and 
reactivity can all change at the nanoscale. A classic example of this is gold nanoparticles, which 
appear red (for particles less than 100 nm) (Sardar et al, 2009) and are more reactive compared 
to the inactive bulk material. In addition, the increase in surface area to volume ratio increases 
the reactivity of nanoparticles. 
 (Bio)nanotechnology or nano(bio)technology is a subset of nanotechnology; the words 
are synonymous. Bionanotechnology is atomic–level engineering and manufacturing using 
biological molecules or organisms for guidance. The integration of nanoparticles, which exhibit 
exceptional electronic, photonic, and catalytic properties, with biomaterials, which display 
unique recognition, catalytic and inhibition properties, has resulted in the production of new 
bionanomaterials with combined properties (Wu & Payne, 2004). The integration of the 
imparted functionalities in a defined arrangement on the bionanomaterials surface while 
preserving its integrity has great potential in the development of novel materials. 
Two methods for the synthesis of miniaturised nanoscale structures and devices have 
been utilised by many research groups across the globe. The traditional method to synthesise 
such structures is a “top–down” approach involving miniaturisation processes or 
microfabrication: starting from large structures and by multiple etching processes generate the 
desired shape and structure. This approach has a size limitation of how small the structures 
could be miniaturised. Alternatively, “bottom–up” (enlargement strategy) which is starting with 
small scale materials and building something bigger offers better control over the size and shape 
of nanostructures depending on the building blocks available to start with. 
Bionanotechnology does not only offer a unique and ideal way for the synthesis of 
well–defined nanostructures from the bottom–up but also adds specific functionalities that are 
positioned at precise locations and in defined distances across all particles. Bionanotechnology 
requires different scientific disciplines to contribute collectively toward the development of new 
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nanosystems to be used in nanomedicine and nanoelectronics. Biomolecules are considered as 
naturally occurring bionanoparticles and offer novel properties for the development of 
diagnostic, analytical and drug delivery systems (Niemeyer & Mirkin, 2004). As well as, 
providing scaffolds, which add structural support, and by their chemical composition, 
biomolecules offer ligand–binding sites to generate hybrid assemblies with the desired 
properties.  
Physicist and Nobel Prize winner Richard Feynman planted the idea of “nano” in 1959. 
Feynman, in his influential speech “There’s Plenty of Room at the Bottom”, introduced the 
world to the wonders of “nanotechnology” through miniaturisation. The focus of Feynman’s 
speech was about the field of miniaturization and his belief that man would create increasingly 
smaller and more powerful devices. Eric Drexler in “Engines of Creation” introduced for the 
first time the term “nanotechnology” (Drexler, 1986). Over the past two decades, 
nanotechnology has emerged as one of the most focused fields of research. Researchers are 
focused on exploiting the advances in nanotechnology for biomedical, environmental, and 
industrials applications. 
1.1.1 Bionanoparticles: Bio–inspired nanomaterials 
Bionanoparticles include protein cages, bacteria, DNA, liposomes, virus–like particles 
(VLPs) and viruses that are naturally occurring programmed self–assembled nanoparticles. 
They are robust, self–assembled architectures, less expensive to produce than inorganic 
materials, and can be relatively easily produced in large quantities. In particular, protein cages 
such as ferritin and some plant viruses have been extensively exploited as building blocks, 
templates and scaffolds in bionanotechnology (Douglas & Young, 2006; Fischlechner & 
Donath, 2007; Lee & Wang, 2006b). Figure 1.1 features examples of bionanoparticles, which 
may be used as constrained reaction containers, scaffolds for material synthesis, and multi–
functional nanoparticles that could be constructed by modifying the external surface. 
Bionanoparticles modified with various ligands and moieties have generated new materials with 
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interesting properties, which have possible applications in the field of nanoscience. A wide 
library of such particles has been catalogued (Manchester & Steinmetz, 2009).  
 
 
Figure 1.1– Structural illustration of some protein cages which have been used in 
bionanotechnology or biomedical applications. Reproduced from (Lee & Wang, 2006a). 
 
 
Several examples of protein cages, which are capable of encapsulating molecules of 
interest, have been reported. Heat shock protein (Hsp), iron storage proteins (ferritin), and vaults 
are some examples. Each of these protein cages has particular properties (size, shape and 
function) that are suitable for many applications. 
The iron storage protein ferritin is probably the most intensively studied and best 
understood model for encapsulation or material mineralization (Chasteen & Harrison, 1999). 
Ferritin comprises 24 subunits, of two types (H and L) that self–assemble to form a hollow cage 
structure of 12 nm in diameter. In the native ferritin form, iron is stored within an 8 nm diameter 
cavity (Andrews et al, 1992; Theil, 1987). In order to encapsulate molecules within ferritin, the 
internal cavity needs to be free of its iron core (apoferritin). A variety of apoferritin is 
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commercially available and has been used for material encapsulation, Figure 1.2, e.g. the 
formation of Prussian blue in ferritin (Dominguez–V & Colacio, 2003). 
 
 
Figure 1.2– Schematic illustration of the pH–induced dissociation–reformation process of 
apoferritin to form Prussian blue complex. The protein is dissociated at pH 2.0 and after dialysis at 
pH 8.5 and the addition of Fe(II) Prussian blue is formed with the cavity. Reproduced from 
(Dominguez–V & Colacio, 2003). 
 
Encapsulated chemicals within ferritin reported so far include: uranium (Hainfeld, 
1992), copper (Ensign et al, 2004), manganese oxide (Meldrum et al, 1995), vanadium (Grady 
et al, 2000), beryllium (Price & Joshi, 1983), cadmium, zinc, nickel, magnesium (Pead et al, 
1995), cobalt oxyhydroxide (Douglas & Stark, 2000), and iron phosphate, iron arsenate, iron 
vanadate and iron molybdate (Polanams et al, 2005). Other molecules also have been 
encapsulated within ferritin such as desferrioxamine B complex (DomInguez–V. & José M., 
2004), Prussian blue (Dominguez–V & Colacio, 2003), and doxorubicin, an anticancer drug 
(Simsek & Kilic, 2005). Moreover, apo–ferritin protein is typically used for internal metal 
mineralization such as with cobalt oxide Co3O4 and Co(O)OH (Allen et al, 2003). Mann and 
co–workers showed formation of Fe3O4 (or γ–Fe2O3) under conditions of elevated temperature 
and pH (Douglas et al, 1995; Mann et al, 1993) 
Heat shock protein (Hsp) forms a hollow spherical 24–subunit complex. The complex 
exhibits octahedral symmetry with an outer diameter of 120 Å and an inner diameter of 65 Å. 
Hsp was also used as template for external and internal modification and as a container for iron 
oxide encapsulation (Allen et al, 2003) and drug delivery systems (Flenniken et al, 2006).  
Vaults are another type of self–assembled naturally occurring cellular protein 
nanocapsule, which are so–named as their morphology, with multiple arches, resembles that of 
cathedral ceilings (Kickhoefer et al, 2005). Vaults are found in high copy number in many 
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higher eukaryotes (including humans). Vaults are 13–MDa ribonucleoprotein particles with an 
internal volume of 5 x 107 Å
3
. Vaults tend to have a hollow, barrel–like structure with two 
protruding caps and a thicker waist with overall dimensions of 420 x 420 x 750 Å as seen in 
Figure 1.3 (Kong et al, 2000). Due to the large structure, vault particles can encapsulate and 
accommodate large molecules such as green fluorescent protein (GFP) and luciferase 
(Kickhoefer et al, 2005). 
 
Figure 1.3– Cryo–transmission electron microscopy of vault particles. (A) cryo–EM. (B), half and 
full capsid images representing the inner and outer structure. The scale bar corresponds to 1000 Å. 
Reproduced from (Kong et al, 2000). 
 
1.1.2 Viruses  
The word virus is derived from Latin and means "poison". Viruses are obligate 
intracellular parasites, which only replicate within a host cell. Particles of simple (non–
enveloped) virus typically consist of two components: one or more capsid proteins and the 
genome. The genome encodes the proteins necessary for the replication of the virus and the 
capsid protein(s), while the capsid is mainly for the protection of the genetic material. Virus 
capsids also have roles in host cell targeting and cell entry (Harrison, 1990). Virus particles 
typically represent very stable structures that have evolved to withstand a broad range of 
environments yet are sensitive enough to release their nucleic acid when they infect a 
susceptible cell (Liepold et al, 2005).  
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1.1.3 Why virus nanoparticles (VNPs) 
Virus nanoparticles are no longer considered only as disease transmitting agents. All 
viruses encode, package, and transport viral nucleic acid. However, many virus coat proteins 
will assemble in vitro naturally or through genetic manipulation into non–infectious containers 
called virus–like particles (VLPs). Viruses can be found in a variety of distinct shapes (most 
commonly icosahedrons, spheres, and rod–shaped) though more complicated structures can be 
formed especially in the case of bacteriophage. 
Material scientists view viruses as nanoscale building blocks and scaffolds. Their 
unique properties; ease of functionalisation, ability to self–assemble, monodispersity (every 
particle looks virtually identical in size and shape to all other particles), structural symmetry, 
stability over a wide range of pHs and temperatures, amenability to genetic and chemical 
modification, and diversity of sizes and shapes make them ideal work–horses with a variety of  
possible applications in nanotechnology. Besides, plant viruses are non–infectious towards 
organisms other than plants; therefore, they do not present any biological hazard. Fundamental 
research in the understanding of viruses as pathogens resulted in a wealth of information about 
their structure, stability, assembly, and physical and chemical properties. This knowledge, and 
the close collaboration between the fields of virology, material science and biomedical research, 
has pushed forward the use of VNPs in nanotechnology.  
Viruses display a remarkable plasticity in their capsid structure and dynamics 
(coordinated assembly, disassembly, and their uniformity). Viruses can be produced in large 
scale at low cost in a relatively short time. Viruses have emerged as platforms for chemical 
manipulation with a range of applications from the creation of new materials to nanomedicine. 
Chemical or genetic manipulation makes it possible to attach new functions to protein cage 
architectures. This provides the possibility of arranging different chemical functionalities with 
nanometric precision. 
Viruses offer three different surfaces that can be exploited: the exterior, the interior, and 
the interface between subunits (Figure 1.4). The inner cavity of the virus capsid is accessible to 
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small molecules and impermeable to larger ones, which allows the use of the interior space of 
the empty virus like particles (eVLPs) as nanotemplates and nanoreactors. Furthermore, the 
exterior surface is widely considered as a robust platform and is used for both chemical and 
genetic modification allowing multivalent ligand display. The viral architectural interface is 
crucial for the assembly and offers another route for the manipulation of the capsid architecture. 
Herein, the focus will be on the manipulation of the interior and the exterior of the viral capsid. 
 
Figure 1.4– Scheme of the three important interfaces available for chemical and genetic 
manipulation in an assembled viral protein cage architecture. The interior, exterior and the interface 
have all been used for the construction of multifunctional viral–cage–based materials. Reproduced 
from (Douglas & Young, 2006). 
 
1.1.4 Empty virus capsids–eVLPs  
Virus–like particles (VLPs) resemble viruses, but are non–infections because they do 
not contain any viral genetic material. The expression of the virus structural proteins, can result 
in the self–assembly of VLPs. Libraries of virus platforms including; (CCMV) (Douglas & 
Young, 1998a), Tobacco mosaic virus (TMV) (Shenton et al, 1999), MS2 bacteriophage 
(Mastico et al, 1993; Wu et al, 1995) and polyoma virus–like particles (capsoids) (Abbing et al, 
2004) have been used as constrained reaction vessels for packaging and nucleation sites for 
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mineralization (Douglas & Young, 1998a; Douglas & Young, 1999). In addition, intact 
enzymes have been encapsulated within the CCMV capsid (Comellas et al, 2007).  
Therefore, many attempts to generate VLPs have been developed over the past three 
decades. In vitro assembly and re–assembly methods have been exploited for VLPs. Generally, 
particles are exposed to a disassembly buffer followed by dialysis against an assembly buffer. 
These disassembly approaches allow release of the nucleic acid and are used to generate VLPs 
or encapsulating materials of interest in the reassembly technique. VLPs of TMV and CCMV 
have been demonstrated to efficiently self–assemble in vitro (Miller et al, 2007). Alternatively, 
an alkaline hydrolysis method was developed to extract nucleic acid from T7 to generate ghost 
(empty) T7 particles (Liu et al, 2006a). 
1.1.4.1 Entrapment of small molecules within VLPs 
In many cases, the entrapment of small molecules within VLPs is dependent on the 
structural transitions of, for example, Brome mosaic virus (BMV), CCMV, and Red clover 
necrotic mosaic virus (RCNMV). The material is infused into particles when they are in the 
swollen “open” conformation. Dialysis against appropriate buffers allows reversible structural 
conformation to the “closed” form, taking with it whatever materials of interest are available in 
solution. 
CCMV has been used as nanobuilding blocks (Wang et al, 2002d), for mineralization of 
iron oxide (Basu et al, 2003b), and as a host–guest encapsulation model of tungstate and 
vanadate (Douglas & Young, 1998a). The stability of the CCMV capsid is pH–dependent, 
which alters the opening of 60 separate pores of 2 nm each and exposes the interior to the 
surrounding medium. This conformation has been used to induce the formation of metal cores 
inside the CCMV capsid. 
1.1.4.2  Encapsulation of preformed particles via templating 
The decoration of preformed synthetic nanoparticles with origin of assembly site (OAS) 
that initiates coat protein monomer binding and leads to self–assembled VLPs with synthetic 
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nanoparticles within has been accomplished in RCNMV. Thiolated artificial OAS was attached 
to gold nanoparticles (Wu et al, 1995). OAS–gold nanoparticles were mixed with RCNMV coat 
protein monomers and templated in vitro self–assembly of VLPs around the gold nanoparticle, 
the process is depicted in Figure 1.5 (Loo et al, 2006). This approach was expanded to include 
encapsulation of QDs with sizes of 5, 10, and 15 nm (Loo et al, 2006; Loo et al, 2007). 
 
Figure 1.5– Assembly of RCNMV VLPs around a gold nanoparticle via OAS templating.  (A) 
conjugation of nanoparticle with DNA–2; (B) addition of RNA–1, which interacts with DNA–2 to 
form the functional OAS; (C) the artificial OAS templates the assembly of coat protein; and (D) 
formation of virus–like particle with nanoparticle encapsulated. Reproduced from (Loo et al, 2006). 
 
Alternatively, the nanoparticle is coated with negatively charged polymers to mimic 
RNA an approach, which was pioneered by Dragnea’s group. Although citrate–stabilised gold 
nanoparticles resulted in encapsulated VLPs with preformed gold nanoparticles the process was 
not efficient (Dragnea et al, 2003). Alternatively, covalent functionalisation of nanoparticles 
with carboxylate–terminated polyethylene glycol (PEG) (Chen et al, 2006; Dixit et al, 2006) 
was used to mimic RNA nucleation and promote efficient in vitro self–assembly (Figure 1.6). 
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Figure 1.6 – Proposed mechanism of VLP assembly from coat proteins (CP). Electrostatic 
interaction leads to the formation of disordered protein–gold nanoparticle complexes. The second 
step is a crystallization phase in which the protein–protein interactions lead to the formation of a 
regular capsid. (b) Schematic depiction of the encapsidated nanoparticle functionalized with 
carboxyl–terminated TEG chains. Right: Cryo–EM micrograph of a single VLP. The protein 
structure coating the 12 nm diameter gold nanoparticle (black disk). Reproduced from (Chen et al, 
2006). 
 
1.1.4.3  Encapsulation during self–assembly 
The self–assembly of a virus is initiated by electrostatic interactions between RNA and 
the protein subunits. In the case of CCMV, mixing the coat protein monomers with different 
sized polystyrene sulfonate (PSS) polymer to mimic the RNA resulted in two different size 
morphologies: 22 nm–sized particles generated by using PSS with molecular weight below 2 
MDa; 27 nm–sized particles with PSS of 2 MDa or higher was used (Hu et al, 2008). Hibiscus 
chlorotic ringspot virus (HCRSV) particles have also been used to encapsulate negatively 
charged polymers including polystyrenesulfonic acid (PSA) and polyacrylic acid (PAA). Re–
assembly yielded VLPs encapsulating the polymers. However, attempts to encapsulate neutral 
molecules such as fluorescein–labelled dextran failed, suggesting the encapsulation is based on 
electrostatic interactions (Ren et al, 2006b). 
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1.1.4.4 Infusion of materials into assembled eVLPs  
Material encapsulation into assembled empty CCMV particles has triggered wide 
research interest. For example, pH–dependent gating of the CCMV pores (Douglas & Young, 
1998a) controls the encapsulation of anionic polyanetholesulfonic acid (PASA) and polydextran 
sulfate (PDS). Small lanthanide molecules have been infused and entrapped into CPMVwt by 
taking advantage of the negatively charged RNA interaction with Gd
3+
 and Tb
3+
 cations 
(Prasuhn et al, 2007b). 80  20 Gd
3+
 or Tb
3+
 ions can be encapsulated within CPMV particles 
(Prasuhn et al, 2007b). Similar approaches for lanthanide entrapment in CCMV have been 
reported (Allen et al, 2005b). In addition, a similar approach has been adopted to infuse 
fluorescent dyes and drugs within RCNMV (Loo et al, 2008). 
1.1.5 Biomineralization on viruses  
Biomineralization is defined as the formation, structure and properties of inorganic 
material intentionally formed in biological systems (Mann, 2001). Familiar examples of such 
structures include sand dollars and shells, as well as the human skeleton and teeth (Mann, 
2001). Recently, interest from material scientists has focused on mimicking the methods that 
nature uses to create such inorganic materials. This process is called biomimetics. Biomimetics 
may also include materials that resemble the structure or properties of materials produced by 
biological entities (Mann, 1996; Mann, 2001). Biomineralization techniques can create 
incredibly precise and complicated structures under ambient conditions such as such as 
platinum, gold, and silicon dioxide (Sarikaya, 2003).  
Over the past few decades, biological hard tissues have been an inspiration for the 
engineering and design of inorganic structures with controlled structure and properties. 
Biomineralization seeks to understand the mechanism by which biosystems can uptake elements 
from its surroundings, and organise them into complex highly ordered structures of defined 
functionality (Mann, 1996; Seeman & Belcher, 2002; Tamerler et al, 2010). Although these 
materials provide essential life function for many organisms (Weiner & Traub, 1992), their 
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unique properties and inherently precise control have generated much attention from material 
scientists. Furthermore, biomineralization reactions proceed under aqueous conditions at 
ambient temperature; for example, the organisation of a lipid–based closed membrane 
incorporating a magnetic nanoparticle that forms within the bacteria Aquaspirillum 
magnetotacticium. The magnetite (Fe3O4) aligns inside the bacteria to create a magnetic field 
large enough to sense the earth’s magnetic field (0.5 Gauss). The Fe3O4 is formed as perfect 
cubo–octahedral single crystals, about 35–120 nm in diameter, each having a superparamagnetic 
domain and the particles are aligned with respect to each other in order to maximise magnetic 
field sensing that allows the cell to have a directional mobility (Schuler, 2002; Staniland, 2007).   
The successful isolation of protein sequences that play a role in the biomineralization 
process has provided some insight in understanding the mechanisms behind biomineralization. 
However, the complexity of natural systems has hindered the complete understanding of the 
biomineralization process. The exploitation of the tremendous advantages of biomineralization; 
a rapid method for utilising functional, material–specific peptides is needed to be developed for 
applications in semiconductors, conductors and magnetic materials synthesis.  
 
1.1.5.1 Mineralization using natural properties of VNPs   
Almost all of the adopted biological systems for templated mineralization are based 
around the natural properties of the VNPs. The first system to be used was CCMV using its pH–
dependent gating system. The mineralization reaction within CCMV is electrostatically driven. 
The interior is highly positively charged and therefore provides an interface for inorganic 
nucleation. The negatively charged WO4
–
 and VO3
–
 anions interact with the interior capsid 
surface via electrostatic interactions (Douglas & Young, 1998b). The same principle was used 
to generate titanium oxide (TiO2) (Klem et al, 2008) and Prussian Blue nanoparticles (de la 
Escosura et al, 2008). Furthermore, the substitution of all the basic residues on the N–terminus 
of the coat protein with negatively charged amino acid Glu (Brumfield et al, 2004) resulted in 
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the mutant favouring interaction with ferrous and ferric ions leading to the formation of iron 
oxide (Fe2O3) within the capsid. 
Empty T7 ghost particles were filled with metallic cobalt (Liu et al, 2006b). Similarly, 
the high charge density on the interior surface of ferritin leads to the nucleation of soluble 
Fe(II), which is subsequently oxidized, resulting in encapsulated iron oxide (Fe2O3) 
nanoparticles (Uchida et al, 2007).  
The exterior and interior of TMV was utilised for inorganic material synthesis via metal 
electroless deposition (ELD). The interior surface of TMV is predominantly carboxylic acids, 
hence the capsid interior is negatively charged under physiological conditions, whereas the 
exterior surface exhibits positive charge (Namba & Stubbs, 1986). The exterior of TMV was 
coated with PbS, CdS, amorphous iron oxide, silica (Shenton et al, 1999), platinum, gold, and 
silver incorporated inside the central channel (Bromley et al, 2008; Dujardin et al, 2003a). The 
differential nucleation is electrostatically driven and resulted from the difference in surface 
charge. In addition, TMV particles were engineered to encode unique cysteine residues 
(TMV1cys); this allowed the assembly of TMV1cys onto a gold patterned surface, the particles 
assembled in a vertically oriented fashion. The subsequent ELD resulted in uniform metal 
coatings up to 40 nm thick (Royston et al, 2007). 
1.1.6 Mineralization using phage display  
Many biological processes in biosystems rely on specific, protein–ligand interactions. 
Biomineralization is no different in that the inorganic substrate serves as the ligand, and highly 
specific peptides dictate the organization and construction of the inorganic structure. 
Combinatorial screening is a routinely used technique for isolating peptides that exhibit the 
necessary affinity for specific targets; in this case an inorganic substrate. The research team led 
by Belcher developed the use of phage display screening and selection to identify peptide 
sequences that bind and nucleate specific inorganic materials (Mao et al, 2004; Seeman & 
Belcher, 2002; Whaley et al, 2000). Insertion of nucleic acid sequences into certain proteins 
(PIII (peptide displayed on the end structure) or PVIII (throughout the body) within a phage 
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genome (M13) (Figure 1.7) generated phage that present the peptides of interest on their 
surfaces (Kwon et al, 2009). Peptide–M13 then binds to the substrate (e.g., gold or platinum). 
Stringent washing steps are used to remove phage lacking surface peptides that strongly interact 
with the inorganic material. The eluted phages are cultured and the cycle repeated until only 
phage with high affinity to the specific inorganic surface remains. 
 
Figure 1.7– Peptides expressed in phage display and cell–surface display. This figure is reproduced 
from (Kwon et al, 2009). 
 
A variety of peptides that are specific for binding to different materials are summarised 
in Table 1.1. The peptides are highly selective and the binding motif is small; the selected 
peptides are typically from (7–11)–mer libraries. Besides, dual peptides have been engineered 
on PVIII specific for ZnS and CdS. When the M13 was incubated with both Zn(II) and Cd(II) in 
the presence of sulfide anions the M13 particles nucleated both CdS and ZnS nanocrystals with 
a random distribution such that both CdS and ZnS nanocrystals appeared on the same phage 
constructs (Mao et al, 2003). 
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Viruses Material Synthesis mechanism Reference 
CPMV (exterior) Silica (SiO2) Peptide–mediated synthesis 
(YSDQPTQSSQRP) 
(Steinmetz et al, 
2009c) 
CPMV (exterior) CoPt, FePt 
and ZnS 
Chemical conjugation of peptide–
mediated synthesis (see chapter 3) 
(Aljabali et al, 2011) 
CPMV (exterior– 
Chimaera) 
FePt Peptide–mediated synthesis 
(HNKHLPSTQPLA) 
(Shah et al, 2009b) 
M13 (exterior– 
Chimaera) 
ZnS Peptide–mediated synthesis 
(CNNPMHQNC) 
(Mao et al, 2004) 
M13 
(exterior) 
CdS Peptide–mediated synthesis 
(SLTPLTTSHLRS)  
(Mao et al, 2004) 
M13 
(exterior) 
FePt Peptide–mediated synthesis 
(HNKHLPSTQPLA) 
(Reiss et al, 2004b) 
M13 
(exterior) 
CoPt Peptide–mediated synthesis 
(CNAGDHANC) 
(Mao et al, 2004; 
Reiss et al, 2004b) 
M13 
(exterior) 
Co
2+ 
Peptide–mediated synthesis 
(EPGHDAVP) 
(Lee et al, 2006) 
M13 
(exterior) 
Gold Peptide–mediated synthesis 
(VSGSSPDS) 
(Khalil et al, 2007; 
Nam et al, 2006) 
M13 (exterior) Co3O4 Peptide–mediated synthesis (EEEE) (Khalil et al, 2007; 
Nam et al, 2008) 
M13 (exterior) CoPt Peptide–mediated synthesis 
(CNAGDHANC) 
(Reiss et al, 2004b) 
T7 (interior) Cobalt Electrostatically driven synthesis (Liu et al, 2006b) 
Table 1.1 – Overview of the inorganic materials generated by peptides using viruses as templates. 
  
1.1.7 Cowpea mosaic virus (CPMV) 
CPMV is a non–enveloped plant mosaic virus, which is the type member of the 
comovirus genus of the family Comoviridae (Lin & Johnson, 2003). The virus is normally 
propagated in Vigna unguiculata, commonly known as cowpeas or black–eyed peas or beans. 
The virus is introduced into the plant by means of mechanical inoculation, which results in 
mosaic and yellowing symptoms of the leaves. CPMV is considered one of the best investigated 
viruses and is widely used in bionanotechnology (Evans, 2010; Sainsbury et al, 2010). 
CPMV capsids have pseudo T=3 icosahedral symmetry and a diameter of 
approximately 28 nm. The CPMV capsid structure comprises 60 small coat proteins (S, domain 
A) which folds into one jelly roll β–sandwich arranged as 12 pentamers at the 5–fold axis and 
60 large coat proteins (L, domains B and C) arranged as trimers at the 3–fold axis and fold into 
two jelly roll β–sandwich domains. The three domains form the asymmetric unit (Figure 1.8). 
The crystal structure is known to 2.8 Å resolution (Lin et al, 1999b). CPMV is a single stranded 
positive–sense bipartite RNA virus. Both of the separately encapsidated RNA segments are 
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required for infection (Bruening & Agrawal, 1967; Liu & Lomonossoff, 2002; van Kammen, 
1967). However, it was later demonstrated that RNA–1 is independently capable of replicating 
CPMV particles in protoplasts (Goldbach et al, 1980). RNA–1 encodes the virus replication 
machinery (Goldbach et al, 1980) as well as the virus proteinase and the viral protein genome–
linked (VPg), which plays an essential role in initiating RNA synthesis. On the other hand, the 
smaller RNA–2 encodes the movement protein and the two–capsid proteins.  
 
Figure 1.8– The structure of Cowpea mosaic virus (CPMV) capsid and the asymmetric unit. CPMV 
capsid is comprised of small (S) and large (L) protein. The A domain (in blue), B domain (in green) 
and C domain (in yellow). 
 
CPMV particles produced during the infection process can be separated into three 
components on caesium chloride density gradients. These have identical protein compositions, 
but differ in their RNA contents (Bruening & Agrawal, 1967). The three centrifugal components 
are termed top (T), middle (M), and bottom (B) and contain no RNA, RNA–2, and RNA–1, 
respectively as shown in Figure 1.9–A (Bruening & Agrawal, 1967; Lomonossoff & Johnson, 
1991a; van Kammen, 1967). 
The three components generated during CPMV infection also exist as two 
electrophoretic forms, slow and fast (Figure 1.9–B) (Semancik, 1966). The slow form can be 
converted to the fast form by proteolytic cleavage at the carboxyl (C)–terminus of the S protein 
(Kridl & Bruening, 1983; Niblett & Semancik, 1969b). The conversion occurs naturally during 
infection, with the fast (C–terminally processed) form of the S protein (Sf) predominating at 
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later times (Niblett & Semancik, 1969b). Cleavage of the S protein was shown to occur after 
Leu189 of the S protein resulting in the loss of the carboxyl–terminal 24 amino acids (Taylor et 
al, 1999).  
 
Figure 1.9– Separation of the different components of Cowpea mosaic virus. (A) In a caesium 
chloride gradient by ultracentrifugation, (B) different electrophoretic forms of particles containing 
the different forms of the S subunit, the slow (s) and the fast (f), separated on agarose gel 
electrophoresis: (a) ethidium bromide stained (b) and (c) are Coomassie stained, mobility shift from 
the s to the f form is due to carboxy–terminal cleavage of 24 amino acids of the S subunit. Caesium 
chloride gradient photographic image courtesy of Dr. Keith Saunders. 
 
As the importance of eVLPs is apparent, some attempts to inactivate or eliminate the 
viral RNA within CPMV capsids have been reported including UV irradiation (254 nm) using a 
dosage of 2.0–2.5J/cm2. The inactivated particles were deemed as non–infectious to plants. 
However, particles remained intact and maintained chemical reactivity (Rae et al, 2008). 
Moreover, the RNA content remains encapsidated so that the internal cavity of the particles is 
not accessible for material loading. Additionally, alkaline hydrolysis was used to generate 
artificial empty CPMV particles (Ochoa et al, 2006). This approach was very difficult to 
reproduce in our laboratory and the majority of the particles remain intact during the 
disassembly step. In addition, these processes risk altering the structural properties of the 
particles and generally do not actually remove RNA from the particles.  
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1.1.7.1 CPMVwt exploitable surface 
The structure of CPMV is known to near atomic resolution (Lin et al, 1999a). The 
particles have an average diameter of 28 nm diameter as confirmed by X–ray diffraction 
analysis (Lin et al, 1999b) and the capsid protein is 3.9 nm thick. The capsid of CPMV is 
comprised of 60 copies of the L and S coat proteins. As a result, the external surface of a virus 
capsid consists of highly symmetrical and repetitive amino acids such as glutamate, aspartate, 
arginine and lysine. These functional groups have been exploited to serve as a template for 
nanoparticle synthesis. The surface–exposed amino acids have served as targets for 
bioconjugation chemistry since 2002 when, for the first time, CPMV was considered as an 
addressable nanobuilding block (Wang et al, 2002d).  
The functional groups (–NH2 or –COOH) on the surface offer a precise addressable site 
and are the most frequently used for chemical modification. This can be achieved using various 
techniques of covalent coupling (Aljabali et al, 2010a; Evans, 2010; Hermanson, 2008; Laufer 
et al, 2009; Meunier et al, 2004; Pokorski & Steinmetz, 2011; Steinmetz et al, 2011) and by 
“click” chemistry (Manchester & Singh, 2006). Both wild–type and genetic variants of CPMV 
have been used as scaffolds for chemical modification; early investigations of the chemical 
reactivity of CPMVwt was aimed at lysine– and cysteine–selective derivatives (Wang et al, 
2002). The X–ray structure and coordinates of CPMV (VIPER database) indicated the presence 
of five solvent–exposed Lys per asymmetric unit, which equates to 300 exposed Lys side chains 
per CPMV particle, (Figure 1.10) (Chatterji et al, 2004). Four of the five solvent–exposed Lys 
have been modified with different moieties (Aljabali et al, 2010a; Steinmetz et al, 2006d). In a 
proof–of–concept study on CPMV, single, double, triple, and quadruple Lys–minus mutants, in 
which the addressable lysines were sequentially replaced with arginines, were generated and 
chemical labelling efficiency was measured. The studies indicated that all of the five Lys are 
available for functionalisation; the degree of labelling efficiency varies between the different 
sites, and normally only four per subunit are modified. The most reactive groups were found to 
be Lys 38 on the S protein and Lys 99 on L (Chatterji et al, 2004).  
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Additionally, carboxylates derived from Asp and Glu have been utilized. Chemical 
attachment of amine–containing compounds can be achieved by making use of the coupling 
reagents EDC and NHS. A fundamental problem with this strategy is that interparticle linkage 
can occur; this can be reduced by using short linkers. 180 surface addressable carboxylates per 
virion have been modified with different moieties (Aljabali et al, 2010a; Steinmetz et al, 2006c). 
 
 
Figure 1.10– Schematic representation of the surface exposed addressable amines and carboxylates 
of the CPMV capsid.  
  
The aromatic group of Tyr side chains also provides a possible target for chemical 
modification. However, the aromatic group is only moderately reactive and to achieve 
bioconjugation the tyrosine phenol has to be oxidised by one electron with, for example, peracid 
or persulfate reagents mediated by nickel complex of the Gly–Gly–His (GGH) tripeptide 
(Manchester & Steinmetz, 2009). Commercial reagents for this reaction are typically not 
available; therefore, the starting materials and coupling reagents must be chemically 
synthesized. The most common reaction utilizing Tyr side chains on viruses is diazonium 
coupling and this has been widely used on MS2 and TMV (Kovacs et al, 2007; Schlick et al, 
2005a). CPMV particles display two accessible Tyr side chains located in the S subunit, which 
are available for chemical modification. In a proof–of–concept study, fluorescein has been 
covalently attached to CPMV Tyr side chains (Meunier et al, 2004).  
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Thiols derived from Cys side chains are typically not found in the free reactive form on 
the solvent–exposed surface of viruses, whereas, Cys side chains have been identified on the 
interior solvent–exposed surface of CPMV (Wang et al, 2002c; Wang et al, 2003a). Thiols are 
nevertheless useful groups to use for bioconjugation, therefore a range of viruses have been 
generated via genetic modification to add Cys side chains. Cys–added versions of CCMV, 
CPMV, FHV, MS2, TMV, and M13, for example, are available (Destito et al, 2009; Khalil et al, 
2007; Klem et al, 2003; Kreppel et al, 2005; Miller et al, 2007; Peabody, 2003; Wang et al, 
2002b(Wu et al, 1995). 
1.1.8 Applications of viruses in nanotechnology  
The use of viruses in nanotechnology offers the prospect of rich and diverse 
technological advancements. As mentioned earlier, the outer surface of a virus capsid can be 
exploited as a nucleation site for growth of nanoparticles. For example, the deposition of Pt
2+
 
ions on the TMV capsid to form nanoparticles with an average diameter of 10 nm (Gorzny et al, 
2008; Tseng et al, 2006). When TMV–Pt was placed between two aluminium electrodes, a 
unique memory effect was observed in which the RNA and the TMV capsid acted as charge 
donor and energy barrier, respectively. When current was applied, the charge transferred from 
the aromatic rings such as guanine in the RNA and was trapped in the Pt nanoparticles. The 
reversible charge transfer and charge trapped process created a memory device. Similarly, 
another memory device was designed using CPMV with the exterior of the capsid modified 
with quantum dots (QD) (Portney et al, 2007). The ZnS capped layer of the QD acted as a 
charge store while the aromatic residues (tryptophan) on the CPMV capsid acted as a charge 
transport. Ferromagnetic materials play an important role in the development of high–density 
storage devices, e.g. a computer disk contains a two–dimensional (2–D) ferromagnetic thin film, 
where information is stored. Ferromagnetic nanoparticles like FePt and CoPt (Sun et al, 2004) 
emerged as potential high–density storage media. Therefore, the ability to generate highly 
monodisperse FePt– and CoPt–CPMV might be an alternative route to synthesise these particles 
(Aljabali et al, 2011). However, the properties of such particles are yet to be established. 
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Throughout this thesis, many VNPs are used to synthesise magnetic and metallic 
nanoparticles of various shapes. Besides, hollow metallic nanoparticles and nanoshells, which 
can differ in their properties, might hold great potential in nanomaterial development. 
Furthermore, viruses are considered as naturally biocompatible and biodegradable, which is 
particularly important for medical applications. Plant viruses are less likely to interact with 
human receptors and the virus replication or gene expression is not supported in mammalian 
systems (Koudelka & Manchester, 2010; Steinmetz et al, 2011). Although foreign proteins have 
the potential to cause an immune response, there is currently no evidence to assume the 
immunogenicity of plant viruses induced in mice. 
Nanoparticles and VNPs are currently under investigation in the field of nanomedicine 
(broadly defined as the application of nanotechnology to medicine) and with the aim of 
controlling drug delivery and targeting to cancerous cells. Tumours have numerous traits that 
make their treatment daunting. These traits include self–sufficiency, the ability to evade 
programmed cell death, limitless potential to replicate, and the ability to invade tissues and form 
metastases that can induce the growth of blood vessels to support them (Ptak et al, 2010). 
Therefore, nanotechnology has the capacity to deal with the complexity of cancer, by providing 
tools to diagnose cancer and deliver therapeutics to specific targets whilst sparing normal cells 
by using different targeting agents by using agents that specifically guide molecules to the 
diseased cells.  
VNPs are less likely to interact specifically with the mammalian system and therefore 
are less likely to cause potential side effects (Koudelka et al, 2009). For CPMV it was shown 
that, even up to dosages of 10
16
 CPMV particles/kg body weight, no apparent toxic side effects 
were observed in mice (Singh et al, 2007). It has been reported that CPMV and CCMV have a 
broad biodistribution and were detected in a wide variety of tissues throughout the body with no 
apparent toxic effects (Kaiser et al, 2007; Rae et al, 2005). CPMV particles mostly accumulated 
in the liver and spleen (Singh et al, 2007). Additionally, VNPs can be PEGylated (modified with 
polyethylene glycol, PEG) to reduce the immunogenicity (Destito et al, 2007; Lewis et al, 
2006b; Steinmetz & Manchester, 2009).  
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VNPs have been modified with fluorophores, QDs, metallic nanoparticles, and 
gadolinium (Gd) complexes have been developed for in vivo imaging agents (Manchester & 
Steinmetz, 2009; Singh et al, 2006; Steinmetz & Evans, 2007; Steinmetz et al, 2009a). 
Fluorescent
CPMV particles allowed high–resolution imaging of major blood vessels to a depth of 
up to 500 µm in comparison to fluorescent–labelled nanospheres (Lewis et al, 2006a). 
Furthermore, It has been shown that Gd
3+
 ions can be covalently attached to the exterior or 
interior surface of CPMV or electrostatically interacted with the encapsidated RNA molecules 
(Allen et al, 2005; Anderson et al, 2006; Hooker et al, 2007a; Prasuhn et al, 2007a) indicating 
that VNPs could serve as excellent candidates for magnetic resonance imaging (MRI) contrast 
agents. 
1.2 Summary  
In this chapter, many different examples of protein–based nanomaterials have been 
described. The natural, self–assembling properties of viruses, including monodisperse structure, 
amenable to chemical or genetic modification, as well as ease of production make them ideal 
templates for a variety of applications in nanotechnology. The monodispersity of the generated 
nanoparticles within the protein cages is another attractive property as the particles size is 
confined by the coat protein. As viruses exist in diverse sizes and shapes, this enables the 
formation of a wide range of nanoparticles. Broad ranges of mineralization and metal deposition 
techniques have been discussed. The interior of protein cages has also been used for 
biomineralization reactions. CPMV and CPMV eVLPs are the focus of this thesis for new 
material synthesis and imparting new functionalities. 
 
1.3 Aim and outline of this thesis  
The aim of the work presented in this thesis is to develop CPMV as a template for 
material synthesis and for biomedical applications. The chemical coupling of peptides that 
favour certain types of mineralization was proven to be a very successful way in generating 
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valuable metallic coatings in a range not otherwise been possible to produce. The following 
questions are addressed: 
1 Can CPMV be used as a template for mineralization and metallization processes to 
generate monodisperse metallic nanoparticles? 
2 Can charge alone initiate the mineralization of CPMV particles? 
3 Can polyelectrolyte coated CPMV particles template mineralization? 
4 Is it possible to develop 
Ferrocene
CPMV as a nanoelectronic device or component? 
5 What is the effect of the linker length on the number of moieties bound to the virus 
capsid? 
6 Can a monolayer of 
Ferrocene
CPMV be assembled on an electrode surface? 
7 Is it possible to generate 
Enzyme
CPMV nanoparticles? 
8 Can CPMV eVLPs be used to encapsulate magnetic materials? 
9 Can CPMV eVLPs be developed as drug carriers for targeted therapy? 
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2 General methods 
2.1 Sodium phosphate buffer 
1 litre of 0.2 M Na2HPO4 (27.0 g) and 1 litre of 0.2 M NaH2PO4 (28.39 g) were 
prepared in Milli–Q water and autoclaved before mixing. To prepare 0.1 M buffer solution; 305 
ml of Na2HPO4 solution and 195 ml of NaH2PO4 solution was added to 500 ml Milli–Q water 
that gave a pH of 7.0.  
2.2 Phosphate buffered saline (PBS) 
To make 1 litre of 1 x PBS mix 140 mM NaCl, 27 mM KCl, 80 mM Na2HPO4 and 15 
mM of KH2PO4. The pH was adjusted to 7.4 with HCl, and the buffer was autoclaved before 
use. 
2.2.1 Acetate buffer solution pH 5.3 
1 litre of 0.1 M acetic acid and 1 litre of 0.1 M sodium acetate (tri–hydrate) (13.6 g) 
were prepared in Milli–Q water and autoclaved before mixing. To prepare 0.1 M buffer solution 
with pH of 5.3; 357 ml of 0.1 M acetic acid solution and 643 ml of 0.1 M sodium acetate 
solution mixed together to give pH of 5.3. 
2.2.2 Native gel electrophoresis 
2.2.2.1 Buffers and solutions  
10X TBE buffer 900 mM tris–base; 900 mM boric acid; 25 mM 
ethylenediaminetetraacetic acid (EDTA); made 
up with MilliQ water to 1000 ml 
Coomassie staining solution 50 % (v/v) methanol; 10 % (v/v) acetic acid; 
0.25 % (w/v) Coomassie Brilliant Blue G–250 in 
Milli–Q water 
Destaining solution for native gel 50 % (v/v) methanol; 10 % (v/v) acetic acid in 
MilliQ water 
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2.2.3 SDS–PAGE Buffers 
Running buffer (RunBlue, Expedeon) 30 ml of 20x SDS RunBlue buffer in 600 ml 
Milli–Q water  
Coomassie staining solution 20 ml of Instant blue ready to use (Expedeon) 
for ~ 30 minutes. 
Coomassie destaining solution See section 2.4.1 
 
2.3 Virus propagation in V. unguiculata. 
Approximately 10–12 days after sowing, the plants were infected with CPMV by 
mechanical inoculation as follows. The leaves were treated with Carborundum (silicon carbide 
abrasive). The inoculation of the primary leaves was performed by using 50 μl per leaf of 
purified CPMV virions of 0.1 mg ml
–1
 particles suspended in 10 mM sodium phosphate buffer 
pH 7.0. The leaves were washed with tap water after inoculation of the plants to remove the 
Carborundum. 11–12 days after infection, the symptomatic leaves were harvested and stored at 
–20 °C prior to use. Plants were grown under the following conditions: supplementary lighting 
for 16 hours a day with temperature set points 25 °C at day and 22 °C at night. Plants were 
maintained by the horticultural services of JIC. 
2.4 CPMV purification  
CPMV was purified from infected leaves using a modified protocol 
(http://www.dpvweb.net/dpv/showdpv.php?dpvno=378). Leaf tissue was homogenized, using 
an electrical blender, with 100 mM sodium phosphate buffer pH 7.0, and then squeezed through 
two layers of muslin and centrifuged at 9000 rpm for 20 min in a FAS–14C rotor. The 
supernatant fluid was kept and stirred for 5–10 minutes at 4 °C with 0.7 volumes of 1:1 (v: v) 
chloroform/n–butanol. After centrifugation at 6000 rpm in FAS–14C rotor for 20 min at 4 °C, 
the clear aqueous layer was removed and incubated with 0.25 of the volume with 20% (w/v) 
PEG/1M NaCl overnight at 4° C. The solution was then centrifuged at 15000 rpm for 20 min 
and the pellet was recovered with 9 ml of 10 mM sodium phosphate buffer pH 7.0. The solution 
was spun at 9000 rpm for 20 minutes, the pellet was suspended and the solution was 
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ultracentrifuged for 2.5 hours at 36 000 rpm at 4 °C in a T–1270 rotor (Beckman, USA). The 
pellet was resuspended in a small volume of 10 mM sodium phosphate buffer. The suspension 
was centrifuged at 14000 rpm for 15 min at ambient temperature, and the supernatants were 
pooled and dialysed against 10 mM sodium phosphate buffer using 100 kDa MWCO cassettes 
(Spectrum laboratories). The clear virus pellet was again suspended in 10 mM sodium 
phosphate buffer and centrifuged at 14000 rpm for 15 min to remove possible contaminants. 
The final virus samples were stored at 4 °C in 10 mM sodium phosphate buffer prior to use. 
Virus concentration was measured by using an extinction coefficient of 8.1 ml mg
–1
 cm
–1
 at 260 
nm. The yields obtained were about 1–1.3 g of virions per kg–infected leaves.  
2.4.1 Agarose–gel electrophoresis 
5–10 µg of CPMV particles suspended in 10 mM sodium phosphate buffer pH 7.0 with 
2 µl of loading dye (Coomassie staining solution or MBI Fermentas dye) were analysed on 1.2 
% (w/v) agarose gels in TBE using an electric field of 1–5 V cm–2 for 1–2 hours. For ethidium 
bromide staining (nucleic acid staining) 0.1 µg/ ml ethidium bromide (4–5 µl) in 1x TBE buffer 
was added to the gel. Particles were visualised on a UV transilluminator at 302 nm using Gene 
Genius Bio Imaging System with Gene Snap software (Syngene). For coat protein, visualisation 
gels were stained with Coomassie solution overnight. Gel images were recorded using a camera 
or scanner.  
2.4.2 SDS–PAGE  
2.4.2.1 SDS–PAGE procedure 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) was 
performed on 5–10 μg of virus in 10 mM sodium phosphate buffer pH 7.0 mixed with 3 µL of 
4x RunBlue LDS Sample Buffer (Expedeon). Samples were heated for 5–10 minutes at 100 ºC 
in a thermoblock in order to denature the protein. In the case of the mineralized particles, they 
were heated for 20 minutes with 10% sodium dodecyl sulfate. The samples were analysed on 12 
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% TEO–CI SDS RunBlue precast gels (Expedeon) under non–reducing conditions at 180 V for 
30–70 minutes using 600–700 ml of 20:1 dilution of 20x RunBlue SDS Running Buffer 
(Expedeon). The bands when stained with 20 ml of InstantBlue (Expedeon) were visible after a 
few minutes. Gels were washed with Milli–Q water prior to imaging.  
2.5 Transmission electron microscopy (TEM) 
Purified particles were transferred into MilliQ water using 100 kDa cut–off columns 
(Millipore). 5–10 µl of 0.1 mg ml–1 particles were allowed to settle briefly (1 minute) onto 
pyroxylin and carbon–coated copper grids (400 mesh, Agar Scientific), and then blotted dry 
with filter paper; grids were then washed with Milli–Q water. For negative staining 2% (w/v) 
uranyl acetate was used, the excess solution was removed with filter paper and the grids left to 
air dry until needed. Grids were viewed at 200 Kv in an FEI Tecnai20 TEM (FEI UK Ltd, 
Cambridge) and images were obtained using a bottom–mounted AMT XR60 CCD camera 
(Deben UK Ltd, Bury St. Edmunds). 
2.6 UV–Vis Spectroscopy 
Virion (CPMV or eVLP) concentration was determined by photometrical measurement 
using either a Perkin Elmer Lambda 25 UV–VIS spectrophotometer with UVWINLab Software 
or a NanoDrop® ND–1000 spectrophotometer and ND–1000 software at room temperature by 
using a 1 cm quartz cuvette (light path: 1 cm). 
CPMV particles have an absorption maximum at a wavelength of λ = 260 nm (derived 
from the encapsidated RNA molecules) with molar extinction coefficient of ε = 8.1 ml mg–1 cm–
1
. CPMV eVLPs have an absorption maximum at λ = 280 nm with molar extinction coefficient 
of ε = 1.28 ml mg–1 cm–1 as determined by (van Kammen, 1967). The law of Beer Lambert can 
be used to calculate the concentration: 
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Where; A is the absorbance, c is the concentration of the particles in mg ml
–1
, d is the length of 
the light path in cm and ε the molar extinction coefficient in ml mg–1 cm–1. 
2.7 Dynamic light scattering (DLS) 
DLS was measured on a DynaPro Titan, Wyatt Technology Corporation (laser 
wavelength 830 nm, scattering angle 20 º) with Dynamics software Version 6.9.2.11. Particles 
at a concentration of 0.5–1 mg–1 cm–1 in 10 mM sodium phosphate buffer pH 7.0 were filtered 
through 0.1–0.4 micron filters (Millipore) prior to analysis. Four independent measurements 
were performed; each single measurement presents an average of ten measurements. Data were 
recorded at 20 °C. DLS determines the hydrodynamic diameter and refers to how a particle 
diffuses within a fluid by recording the laser scattering from the particles. The particles undergo 
Brownian motion leading to time-dependent fluctuation. The diameter obtained by this 
technique is that of a sphere that has the same translational diffusion coefficient as the particle 
being measured. The translational diffusion coefficient will depend not only on the size of the 
particle “core”, but also on any surface structure, as well as the concentration and type of ions in 
the medium. This means that the size can be larger than that measured by electron microscopy. 
2.8 Nanoparticle tracking analysis (NTA)  
A NanoSight LM 10 instrument was used for NTA (ca. 80–micron wide 640 nm 
wavelength laser beam; cell depth 0.5 mm; cell volume ca. 0.25 ml). Samples for NTA were 
prepared with 300 µl (0.2–0.5 mg–1 cm–1) of mineralized–CPMV particles suspended in 10 mM 
sodium phosphate buffer pH 7.0 and analysed by recording a 30–second video of the 
nanoparticles’ motion when illuminated by laser light mounted under the microscope objective 
lens. The particle movement was tracked using conventional CCD camera, operating at 30 
frames per second. NTA is a method for visualizing and analyzing particles in liquids that 
relates the rate of Brownian motion to particle size. The rate of movement is related only to the 
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viscosity and temperature of the liquid, it is not influenced by particle density or refractive 
index. NTA allows the determination of a size distribution profile of small particles (10-
1000nm) in liquid suspension. 
2.9 Energy dispersive X–ray spectroscopy (EDXS) 
An Oxford Instruments INCA Energy 200Premium is attached to a TEM or JEOL JSM 
5900LV scanning electron microscope (SEM). EDXS works by detecting X–rays that are 
produced by the sample of interest in an electron beam. The electron beam excites the atoms in 
the sample that subsequently produce X–rays to discharge the excess energy. The energy of the 
X–rays is characteristic of the atoms that produced them giving a spectral pattern. EDXS is an 
analytical technique used for the elemental analysis or chemical characterization of a sample. It 
relies on the investigation of an interaction of some source of X-ray excitation and a sample. Its 
characterization capabilities are due in large part to the fundamental principle that each element 
has a unique atomic structure allowing X-rays that are characteristic of an element's atomic 
structure to be identified uniquely from one another. 
2.10 Mössbauer analysis 
Mössbauer spectra were recorded in zero magnetic field at 80 or 298 K on an ES–
Technology MS–105 Mössbauer spectrometer with a 100 MBq 57Co source in a rhodium matrix 
at ambient temperature. Spectra were referenced against a 25 μm iron foil at 298 K and 
spectrum parameters were obtained by fitting with Lorentzian curves (errors < ± 0.02 mms
–1
; 
half–width–at–half–maxima 0.21–0.26 mms–1). Samples of iron oxide–CPMV were prepared as 
above except 
57
FeCl3 was used that had been enriched with 
57
Fe (95.4% enriched metal powder, 
Isoflex, Russia) (Oganesyan et al, 2004). Spectra were recorded either as frozen solutions or in 
the solid state. Prof. Dave Evans and Mrs Elaine Barclay conducted experiments. 
Mössbauer spectroscopy probes tiny changes in the gamma energy levels of an atomic 
nucleus in response to its environment. Mössbauer spectroscopy is limited by the need for a 
suitable gamma-ray source. Usually, this consists of a radioactive parent that decays to the 
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desired isotope. For example, the source for 
57
Fe consists of 
57
Co, which decays by electron 
capture to an excited state of 
57
Fe, then subsequently decays to a ground state emitting the 
desired gamma-ray. 
2.11 Vibrating sample magnetometry (VSM) of eVLPiron oxide or iron oxide–
CPMV 
Magnetic measurements were made on 1.65 mg of dried sample of eVLPiron oxide or 2 mg 
of iron oxide–CPMV, using a vibrating sample magnetometer (VSM) from Oxford Instruments 
operating at temperatures from 4 to 275 K, and fields of up to 5 Tesla. The typical noise level 
was below 10 microemu, and the maximum sample moment at low temperatures was of the 
order of 25 memu. VSM was operated at 55 Hz with vibration amplitude of 1.5 mm. The 
temperature was changed with a heating resistor and a needle valve that allows the flow of 
helium from the cryostat into the sample space. The temperature was controlled through a PID 
loop feedback, providing stability better than 10 mK at low temperatures. (The magnetic 
measurements were conducted as a collaborative project with Drs. Oscar Céspedes and Sarah 
Staniland, School of Physics and Astronomy, University of Leeds, United Kingdom). 
A sample is placed inside a uniform magnetic field to magnetize the sample. The 
sample is then physically vibrated sinusoidally, typically through the use of a piezoelectric 
material. The induced voltage in the pickup coil is proportional to the sample's magnetic 
moment, but does not depend on the strength of the applied magnetic field. In a typical setup, 
the induced voltage is measured through the use of a lock-in amplifier using the piezoelectric 
signal as its reference signal. By measuring in the field of an external electromagnet, it is 
possible to obtain the hysteresis curve of a material. 
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2.12 Immunological detection of CPMV coat proteins  
2.12.1 Buffers and reagents 
Solution Composition 
10x PBS 1.37 M NaCl; 27 mM KCl; 81 mM Na2HPO4; 15 mM KH2PO4 in MilliQ water; 
pH 7.0 
1x PBST 0.05 % (v/v) Tween–20 (Sigma Aldrich) in 1x PBS 
1x PBSTM 5% (w/v) dry milk (Marvel) in 1x PBST 
2.12.2 Immunological detection procedure  
Step Reagents Time/temperature 
Blocking 1x PBSTM 2 hours at ambient temperature or 
overnight at 4 °C 
1
st
 antibody  anti–CPMV antibody/1:1000 in 1x 
PBSTM (20 µl of G49 in 20 ml ) 
freshly prepared 
3 hours at ambient temperature 
while gently shaking 
2
nd
 
antibody 
anti–rabbit IgG–HRP/1:2000 in 1x 
PBSTM (2 µl) 
2 hours at ambient temperature 
while gently shaking 
After each step, the membranes were washed three times for approximately 15 min each run 
with 1x PBST at ambient temperature on a shaker. After the 2
nd
 antibodies addition the 
membranes were washed once with 1x PBST and twice with 1x PBS 
 
2.12.3 Immunological detection (Dot blot): 
For protein detection, 10 µg of intact wild–type CPMV (positive control) and any 
materials to be tested suspended in 10 mM phosphate buffer, were spotted onto a nitrocellulose 
membrane (Amersham) and air dried for 30 minutes. Nonspecific binding sites were blocked 
using a solution consisting of 5% (w/v) skim–milk powder in phosphate buffered saline (PBS) 
plus 0.025% (v/v) Tween–20. The membrane was then probed with a polyclonal antibody 
specific to CPMV (G49) followed by a horseradish peroxdiase–conjugated anti–rabbit antibody. 
Both antibodies were diluted (1:1000) in blocking solution. Signals were generated by 
chemiluminescence using a SuperSignal West Dura substrate kit (Thermo Scientific) and 
captured on film (HyperfilmTM ECL, Amersham Biosciences) which was developed using a 
Curix 60 film processor (Agfa Gevaert).  
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2.13 Staining for cobalt and iron  
4 µg each of eVLP, eVLPcobalt, eVLPiron oxide, Co-CPMV and iron oxide–CPMV 
suspended in 10 mM sodium phosphate buffer, were spotted onto a nitrocellulose membrane 
(Amersham) and air dried for 30 minutes. The membranes were then probed for cobalt and iron 
using the appropriate stain.  
Cobalt stain: 20 mM 1–nitroso–2–naphthol in 1:1 (v/v) methanol/MilliQ water followed by 
destaining with 10 mM NaOH (Douglas & Stark, 2000).  
Prussian Blue stain: Equal volumes of 20% hydrochloric acid in MilliQ water and 10% 
potassium ferrocyanide in MilliQ water were mixed just prior to use and incubated with the 
membrane. 
2.14 Surface charge measurement 
Zeta potential was measured on a Malvern Instruments Zetasizer–Nano ZS where 1 ml 
of 0.5 mg ml
–1
 particles was suspended in 10 mM sodium phosphate buffer pH 7.0. Zeta cells 
were equilibrated at 21°C before recording three measurements each of 12 runs. The data were 
fitted using the Smoluchowski approximation assuming a Henry’s function f(Κa) of 1.5. The 
electrophoretic mobility is converted to the zeta potential using the Henry equation (Zhang et al, 
2008). Zeta potential determinations were based on the electrophoretic mobility of the 
nanoparticles by applying an external current.  
The Zeta potential of dispersion is measured by applying an electric field across the 
dispersion. Particles within the dispersion with a zeta potential will migrate toward the electrode 
of opposite charge with a velocity proportional to the magnitude of the zeta potential. Zeta 
potential is electric potential in the interfacial double layer (DL) at the location of the slipping 
plane versus a point in the bulk fluid away from the interface. A value of 25 mV (positive or 
negative) can be taken as the arbitrary value that separates low-charged surfaces from highly-
charged surfaces. The significance of zeta potential is that its value can be related to the stability 
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of colloidal dispersions. The zeta potential indicates the degree of repulsion between adjacent, 
similarly charged particles in dispersion (Malvern Instruments catalogue).  
2.15 Carbodiimide method to generate O–succinimide esterified CPMV 
particles 
Carboxylic acid groups were activated by the carbodiimide method using EDC and 
NHS or sulfo–NHS as depicted in Figure 2.1. CPMV particles in either 10 mM or 0.1M sodium 
phosphate buffer pH 7.4 or any other carboxylic acid–containing moieties were incubated with a 
freshly prepared Milli–Q water solution of EDC (1 molar equivalent) for 5 minutes followed by 
the addition of a freshly prepared dimethylsulfoxide solution of NHS (4 molar equivalents). The 
reaction was allowed to proceed for 2 hours at room temperature with gentle stirring. The 
resulted O–succinimide esterified CPMV particles were purified by any of the methods 
described below. Further information about the carbodiimide method is provided in (Gillitzer et 
al, 2002; Hermanson, 2008). 
 
Figure 2.1– Derivatives of carboxylic acids can be prepared with EDC to generate active 
intermediates that react with amine containing molecules in the presence of NHS or Sulfo–NHS to 
generate peptide bond route (1). Alternatively, thiolated or cysteine containing molecules could be 
used with the active ester intermediate to generate thioester bond. 
2.16 SPDP method  
CPMV particles (10 – 20 mg ml–1), suspended in 10 mM sodium phosphate buffer pH 
7.0, were incubated with a solution of SPDP (1000 molar excess) in dimethylsulfoxide 
(DMSO), the final concentration of DMSO was adjusted to 20% (v/v). The reaction was stirred 
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gently overnight at 4 °C. The modified CPMV particles were dialyzed using 100 kDa molecular 
weight cut–off membranes against 10 mM sodium phosphate buffer for 24–36 hours and then 
concentrated using 100 kDa cut–off columns. 3–(2–pyridyldithio)propionateCPMV modified particles 
were incubated overnight at 4 °C with thiol– or cysteine–containing molecules (1000 molar 
excess) in either DMSO or DMF; the final concentration of organic solvent was adjusted to 20% 
(v/v). 
Thiol–containing molecules
CPMV particles were purified by gel filtration (Sephacryl S–500 
column) and the eluted fractions were collected and concentrated on 100 kDa cut–off columns. 
The recovered yield of virions was about 60–70 % of starting materials. The modified particle 
integrity was established by agarose gel electrophoresis, TEM and DLS. 
2.17 Particle purification 
2.17.1 Sucrose gradients 
Sucrose solutions of 50%, 40%, 30%, 20%, and 10% (w/v) in 10 mM sodium phosphate 
buffer pH 7.4 were prepared and used within 2 weeks. Gradients were prepared by underlying 
sucrose solutions of decreasing density (175 or 500 µl) in a centrifuge tube of (2.1 ml or 5 ml, 
respectively) and carefully overlaying the sample to fill the tube (normally 300–500 µl). 
Gradients were ultracentrifuged in a swing–out rotor (AH–650) and centrifuged at 137000 g for 
1.5–2.5 hours at 4 ºC; 175–300 μl fractions containing modified particles were collected and 
buffer exchanged for 10 mM sodium phosphate buffer pH 7.4.  
 
Figure 2.2– An example of sucrose gradient profile for modified CPMV particles. Number of 
fractions 5-8 contains the modified particles. 2.1 ml sucrose gradient and 175 µl fractions. 
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2.17.2 Size–exclusion chromatography 
Low molecular weight impurities are retarded in the gel filtration matrix, while virus 
particles eluted first from the column. Gel filtration (AKTA Purifier–900) on a Sephacryl S–500 
column (GE Healthcare) and PD–10 desalting columns (Amersham) were used according to the 
manufacturer’s instruction and were pre–equilibrated with 10 mM sodium phosphate buffer 
unless otherwise indicated. 
2.17.3 Ultrafiltration 
Ultrafiltration was used as a method for purification and concentration of virus 
particles. Samples were applied to various volume tubes (500 µl – 15 ml) of 100, 300, and 
10000 kDa molecular–weight cut–off columns (Microcon, Amicon Millipore, and Sartorius 
Stedim) and centrifuged. The particles are retained on the filter of these tubes while the buffer 
and small impurities pass through the membrane. This is a very efficient method in virus 
concentration. Specific details are provided in each Chapter.  
2.17.4 Dialysis   
This method is very efficient in buffer exchange and particle purification. The semi–
permeable membrane retains the particles within, while small molecules diffuse to the lower 
concentration in the buffer reservoir, and vice versa. Slide–A–Lyzer cassettes (Pierce), Float–
A–Lyze tubing, and Snakeskin tubing have been used throughout the research. Specific details 
are provided in each Chapter. 
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3 Chemically–coupled– of peptide promoted mineralization 
3.1 Introduction 
When a biomolecule inorganic material interaction is accomplished with molecular 
specificity, it leads to the formation of controlled structures and functions. Molecular specificity 
of probe–target interactions, e.g., ligand–receptor, antigen–antibody, is always based on specific 
peptide molecular recognition (Tamerler et al, 2010). The exploitation of peptide–material 
interaction as a tool for novel nanomaterial synthesis has been fuelled by the availability of 
short peptides that are specific to a variety of inorganic materials. Such peptides can selectively 
bind, interact with and direct the formation of inorganic materials. 
Much effort has been invested by many groups around the globe in understanding 
protein recognition of, and binding to, inorganic materials (Descalzo et al, 2006; Flynn, 2003; 
Merzlyak & Lee, 2006; Tamerler & Sarikaya, 2009). The main challenge remains to establish 
sequence–reactivity relationships from peptides either isolated from biological sources or 
generated by combinatorial peptide libraries (Tan et al, 2010). In addition, the abundance of 
neutral amino acid (e.g., glycine, alanine, valine, leucine and isoleucine) sequences in the 
peptides is poorly understood and is thought not to be charge related. Despite this, the gained 
insight allowed the making of practical materials using peptides engineered to bionanoparticles 
(Flynn et al, 2003a; Mao et al, 2004; Shah et al, 2009a; Steinmetz. N. F. et al, 2009). Moreover, 
it enhanced the general understanding of the importance of sequence and the composition of the 
peptides on nanoparticle formation. 
The preparation of nanoparticles with controlled size and composition is of major 
fundamental and technological interest (Sun, 2000). For example, mixed–metal nanoparticles, 
such as those of FePt and CoPt, have been identified as important materials for use in catalysis 
and in ultra–high density magnetic storage devices (Hyeon, 2003), and semiconducting zinc 
sulfide nanoparticles promise applications in a range of optoelectronic devices, such as solar 
cells (Chen & Lockwood, 2002; Gao et al, 2004). To be useful, the size and size distribution of 
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the nanoparticle needs to be accurately controlled (Nanda, 2000; Sun, 2006). Further, hollow 
nanospheres may have many applications in, for example, catalysis, where a hollow nanosphere 
has potentially a higher catalytically active surface area than its solid analogue and consumes 
less of the costly and limited metal resources in its synthesis (Liang, 2004). 
3.1.1 Peptides specificity for material synthesis (general insight) 
Screening peptide libraries for sequences that might be useful in the synthesis of 
interesting materials has resulted in gigantic databases. Displaying random peptides on the 
surface of filamentous phage began with G. P. Smith, who showed that fragments of a target 
protein could be fused to the pIII protein of the filamentous bacteriophage M13 and the resulting 
particles captured by immobilized antibodies against the target protein (Scott & Smith, 1990; 
Smith & Scott, 1993). Peptide libraries expanded by size and included various screening 
approaches. However, peptide affinity toward its binding target remains vital for peptide 
selection. Some peptides have been used as molecular templates to synthesis inorganic materials 
and others have been used to synthesise the inorganic material that they were selected against 
(Slocik & Naik, 2006).  
Peptides which bind to inorganic materials were first identified by Brown, who isolated 
peptides that selectively adhere to Fe2O3 surfaces (Brown, 1992). This was the first 
demonstration of the selectivity of a peptide, which could bind to Fe2O3 but not Cr2O3 or Fe3O4 
(Brown, 1992). Multiple copies of the peptides were expressed on the surface of genetically 
modified E. coli. Belcher and co–workers further developed Brown’s pioneering work using a 
combinatorial phage–display library to identify peptides with sequences that specifically 
bind/interact with inorganic material (Whaley et al, 2000). After sequential washes to remove 
weak binding or non–bound sequences, the bacteriophage presenting the remaining peptide 
sequences were amplified in E.coli and the peptides with the highest affinity for the target 
material were selected and used (See Introduction chapter). The screening approach to identify 
substrate–specific binding peptides and the use of bionanoparticles is no longer restricted to 
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native mineralization conditions. Peptides can also be engineered as scaffolds and templates for 
hybrid structure formation (Tamerler et al, 2010). Peptides with affinity for several inorganic 
materials have been identified using the phage–display method and some examples are shown in 
Table 3.1. For example, Naik and colleagues identified peptides, which possess affinity for the 
surface of silica (Naik et al, 2002a). This finding, that peptides specifically bind to inorganic 
material and may initiate or control the formation of the same material has advanced the 
synthesis of new materials (Baeuerlein, 2004). 
Peptide sequences Inorganic materials Salt 
AYSSGAPPMPPF Ag nanoparticles AgNO3 
 Au nanoparticles  HAuCl4 
NPSSLFRYLPSD Ag nanoparticles AgNO3 
AHHAHHAAD Au nanoparticles ClAuPMe3 
HYPTLPLGSSTY CoPt nanoparticles (NH4)2PtCl6 + 
Co(CH3COO)2 
HNKHLPSTQPLA FePt nanoparticles FeCl2 + H2PtCl6 
VCATCEQIADSQHRSHRQMV ZnS nanoparticles Zinc 2,9,16,23–
tetrakis(phenylthio)–29–
H,31H–phthalocyanine   + 
Na2S 
NNPMHQN ZnS nanoparticles ZnCl2 + Na2S 
Table 3.1– Examples of peptides known to direct the mineralization of inorganic nanomaterials. 
The peptide sequences revealed that, in some cases, the same sequence could interact/promote for 
two different materials or two different sequences could interact/promote for the same material. 
The data is adapted from (Chun–Long & Nathaniel, 2010). 
 
3.1.2 Peptides for templated mineralization  
Viruses assemble to give high precision architectures of simple symmetry; this allows 
identical subunits to come together with a maximum number of non–covalent interactions, 
which in turn form the largest cavity from the least number of subunits (this only applies to 
spherical symmetries). Currently, there is a growing library of virus and protein virus 
architectures, which provide different functionalities for the synthesis of magnetic particles, 
imaging agents, and cell specific targeting agents, and for gene therapy and drug encapsulation 
(Manchester & Steinmetz, 2009). The exploitation of biomaterials for chemical design has 
become an important area of materials science (Evans, 2008). For example, bacteriophage and 
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plant viruses provide a variety of morphologies and are robust enough to support reactions to 
produce new organic and inorganic materials (Flynn et al, 2003a; Shenton et al, 2001). The 
bacteriophage M13 can template mineralization of several materials (Mao et al, 2004), and has 
been utilised, for example, in the development of lithium ion battery electrodes (Nam et al, 
2006). In addition, the exterior and interior of the rod–shaped plant virus Tobacco mosaic virus 
has been utilised for material synthesis (Kind, 1998; Royston et al, 2006; Royston et al, 2009). 
Although peptides are not complicated molecules, they still encode unique recognition 
properties. Tan et al 2010) showed that the 20 amino acids have different reduction capabilities 
of gold solution, with tryptophan being the fastest reducing agent. However, peptides gave a 
different faster rate reaction than a mixture of free amino acids with the same overall 
composition because the amino acid residues acted collectively (Tan et al, 2010).  
Although the origin of peptide specificity toward target material not fully understood, 
the fact of peptide selectivity is well established. The literature is full of examples of the ability 
of certain peptides to direct the formation of inorganic materials such as gold and silver (Brown 
et al, 2000; Naik et al, 2002b), CaCO3 (Li et al, 2002), CdS (Flynn et al, 2003c) and many more. 
Flynn et. al. have also utilised this method to identify peptides which induce synthesis of ZnS. 
Their work demonstrated for the first time that phage–display peptides were essential to both 
bind to and induce the precipitation of inorganic material (Flynn, 2003). Ahmad et. al. 
determined calcium molybdate (CM) peptides (AAPNSPWYAYEY, SWSPAFFMQNMP, 
YESIRIGVAPSQ and DSYSLKSQLPRQ) that induce the precipitation of CaMoO4 from an 
aqueous precursor solution. Any changes in the peptide sequence or even reordering the amino 
acids in these peptides had an impact on the yield of the precipitated CaMoO4 (Ahmad, 2006).  
3.1.3 Mineralization of chimaeric CPMV particles 
CPMV particles have the characteristics of an ideal nanotemplate in terms of their size 
(~ 28 nm diameter) and their regular symmetric structure. The structure of the virus particle is 
known to near atomic resolution and its genetic, biological and physical properties are well–
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characterised (Lin & Johnson, 2003; Lomonossoff & Johnson, 1991b).
 
Functional groups on the 
exterior surface of the virion make CPMV a useful nanoscaffold allowing attachment of a 
multitude of different moieties (Aljabali et al, 2010a; Steinmetz & Evans, 2007; Steinmetz et al, 
2006d).  
The term virus chimaera refers to genetically modified virus particles. Chimaeric virus 
technology allows multiple genetic deletion or insertions of foreign sequences into the coat 
protein sequence; an important advantage over synthetic nanoparticles. Short peptide sequences 
can be introduced into surface loops that alter the particle surface properties. To display the 
insertion of a peptide that selectively promotes mineralization is a very attractive methodology 
for the development of nanomaterials. 
The first approach to displaying inserted peptides on the surface of CPMV involved the 
use of infectious cDNA clones to modify the capsid surface, thereby allow the presentation of 
foreign peptides on the external CPMV surface (Dessens & Lomonossoff, 1993; Lin et al, 1996; 
Lomonossoff, 1996). It has been established that additional amino acids can be inserted into the 
highly surface exposed βB–βC loop of the small subunit of CPMV as shown in (Figure 3.1). 
CPMV–based chimaeric virus technology was then adapted for the environmentally benign 
synthesis of virus–templated monodisperse silica (Steinmetz et al, 2009b) and amorphous iron–
platinum nanoparticles (Shah et al, 2009a).   
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Figure 3.1– Genetic insertion sites of peptide into the CPMV particle. (Left) Space filling model of 
CPMV, with the insertion site βB–βC of small subunit (red) and βE–βF (purple) on ribbon diagram 
of CPMV asymmetric unit.  
 
Despite success with chimaeric CPMV for mineralization with silica and iron–platinum, 
the expression, propagation, isolation and purification of chimaeric CPMVs can be problematic. 
The chimaeras can revert to wild–type as the inserts, in some cases, are not well tolerated (Porta 
et al, 2003). In addition, the genetic stability of chimaeras and there is the potential for reversion 
to wild–type is another disadvantage; this was found in the case of a chimaera with a peptide 
insert designed to promote mineralization with CoPt. In some cases, the appropriate chimaera 
cannot be produced at all, as was found in the case of a chimaera that presented a peptide 
designed to direct mineralization with ZnS. This was the driving force behind the search for 
seeking alternative routes for the presentation of peptides on the surface of CPMV.  
3.1.4 Chemically–coupled–peptide–promoted mineralization 
To avoid the lengthy process of generating chimaeric CPMV particles, and to avoid 
some of the aforementioned disadvantages of the genetic engineering route, the possibility of 
chemically attaching peptides that promote specific mineralisation to the surface of CPMV 
particles was investigated. It was found that the appropriate N–protected peptides with the 
shown sequence in, Table 3.2 can be easily chemically coupled to lysine residues on the surface 
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of wild–type CPMV. The PeptideCPMV conjugate can then template the directed and controlled 
fabrication of monodisperse nanoparticles, of approximately 32 nm diameter, at ambient 
temperature and pressure in aqueous solution. The reaction scheme is depicted in Figure 3.2. 
 
Figure 3.2– Schematic representation of chemical coupling of peptides to CPMV capsid 
(PeptideCPMV). The red ring on the peptide representation depicts the protected N–terminus that 
prevents peptide self–aggregation. The numbers of peptides bound to the virus capsid were 
quantified to be 180 per virus. 
 
Peptide Sequence  Material selectivity  
(Cbz)–CNAGDHANC Peptide–CoPt 
(Cbz)–CNAHDGANC peptide’CoPt (reversed sequence) 
(Cbz)–HNKHLPSTQPLA Peptide–FePt 
(Cbz)–CNNPMHQNC Peptide–ZnS 
Table 3.2– Peptide sequences used for peptide promoted mineralization. (Cbz) denotes a 
carboxybenzyl group coupled to the N– terminus to prevent self–aggregation. The subscript refers 
to the specific peptide sequence (un–mineralized). Peptide’CoPt refers to the reverse sequence of 
Peptide–CoPt. Peptide sequences are generated from http://www.phagedisplay.net/  
3.2 Experimental  
3.2.1 Materials 
The N–protected peptides carboxybenzyl (Cbz)–CNAGDHANC (peptide–CoPt), Cbz–
CNAHDGANC (peptide’CoPt), Cbz–HNKHLPSTQPLA (peptide–FePt) and Cbz–
CNNPMHQNC (peptide–ZnS) were purchased from GeneCust, Luxembourg. All general 
reagents were bought from Sigma–Aldrich UK and used without further purification. 1–ethyl–
3–(3–dimethlyaminopropyl) carbodiimide hydrochloride (EDC) was purchased from 
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Novabiochem and N–hydroxysuccinimide (NHS) from Fluka. Nanocyl S.A., Belgium, supplied 
amine–functionalised short, thin, multiwall carbon nanotubes (MWCNT), 95% C purity, with 
average diameter of 9.5 nm and average length of 1 µm.  
3.2.2  Chimaeric CPMV preparation and mineralization 
Oligonucleotides encoding the peptide of interest, flanked by appropriate restriction 
sites (NheI and AatII), were cloned into the CPMV RNA2–based vector. In a second cloning 
step, the chimaeric sequence was cloned via the enzymes BamHI and EcoRI into the CPMV 
RNA–2 based binary vector pBinP–NS1 (The chimaeric particles were prepared by Drs. Nicole 
Steinmetz and Sachin Shah). The resulting recombinant, termed pBin–NS1–FEPT, was used to 
agroinoculate cowpea plants in the presence of the full–length clone of RNA–1. Chimaeric 
particles were extracted as described for the wild–type and used for the mineralization process 
(Shah et al, 2009a; Steinmetz. N. F. et al, 2009).  
3.2.3 General method for chemical coupling of peptide to CPMV  
The carboxylic acid terminus of the peptide was activated by the carbodiimide method 
using EDC and NHS (see scheme in section 2.15). Cbz–peptide in Milli–Q water (Millipore) 
was incubated with a freshly prepared Milli–Q water solution of EDC (1 molar equivalent) for 5 
minutes followed by the addition of a freshly prepared solution of NHS in DMSO (4 molar 
equivalents). The reaction was allowed to proceed for 2 hours at room temperature with gentle 
stirring. The activated peptide was then added to a solution of CPMVwt in 10 mM sodium 
phosphate buffer pH 7.0 in a molar ratio of 2000:1, the reaction was incubated at 4 ºC overnight 
with gentle stirring. The resultant 
Peptide
CPMV conjugate was purified by gel filtration (AKTA 
Purifier–900) on a Sephacryl S–500 column (GE Healthcare). Fractions containing only the 
Peptide
CPMV conjugate were pooled, concentrated using 100 kDa cut–off membranes 
(Millipore), and analysed by native agarose gel electrophoresis and TEM to ensure the presence 
and integrity of the modified CPMV particles. The 
Peptide
CPMV conjugate concentration was 
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determined by UV–visible spectrophotometry; the yield of PeptideCPMV conjugate was between 
70–90% based on the initial virus concentration. Peptidetop component (naturally occurring 
eVLPs) conjugate was prepared by the same method and in similar yield. 
3.2.4 Preparation of mineralized virus nanoparticles 
To 
Peptide
CPMV (400 µl of 10 mg ml
–1
) in 10 mM sodium phosphate buffer pH 7.0 was 
added, with constant stirring, over 10 min at room temperature either: (a) a 1:1:1 mixture of 
CoCl2 (0.05 mol dm
–3
), H2PtCl6  (0.05 mol dm
–3
) and NaBH4 (0.1 mol dm
–3
) each in Milli–Q 
water (400 µl); (b) a 1:1:1 mixture of FeCl3 (0.05 mol dm
–3
), H2PtCl6  (0.05 mol dm
–3
) and 
NaBH4 (0.1 mol dm
–3
) each in Milli–Q water (400 µl); or (c) a 1:1 mixture of ZnCl2 (0.05 mol 
dm
–3
) and Na2S (0.05 mol dm
–3
) each in Milli–Q water (400 µl). The mixture was incubated, 
with gentle stirring at ambient temperature, for 40–48 hours. The FePt–CPMV, CoPt–CPMV 
and ZnS–CPMV nanoparticles (this nomenclature refers to externally coated particles with the 
corresponding metals), respectively, were recovered by centrifugation at 14000 rpm (bench top
centrifuge, Eppendorf) for 20 minutes. The supernatant containing the mineralized–CPMV 
nanoparticles was further purified using 100 kDa cut–off columns and washed several times 
with Milli–Q water to remove all excess reagents. The yield of nanoparticles was 70–80% as 
determined by UV–visible spectrophotometry based on the initial virus concentration. The 
method can be scaled up at least two–and–a–half fold; at larger scales a combination of dialysis 
(100 kDa membrane) and sucrose gradient (2.1 ml 10–50% sucrose gradients centrifuged at 
137000 g for 1.5 hours at 4 ºC as described in section 2.17.1. Fractions containing mineralized 
particles were collected and dialysed against 10 mM sodium phosphate buffer pH 7.0 for 15 
hours). The integrity, characterisation and composition of the mineralized–CPMV nanoparticles 
were determined by TEM, EDXS, NTA, DLS and zeta potential measurements.  
Peptide
top component mineralization: top component (naturally occurring eVLPs) (400 µg/ml, 
500 µl) was incubated with cobalt and platinum salts and a reductant as described for the wild–
type particles. The same purification steps were followed as above. 
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3.2.5 Peptide–CoPtCPMV quantification 
The number of peptides per particle was determined for 
Peptide–CoPt
CPMV conjugate as 
follows. 
Peptide–CoPt
CPMV in 10 mM sodium phosphate buffer pH 7 was reacted with a 2000 
molar excess of NHS ester–activated amine specific dye, DyLight594, in DMSO. The DMSO 
level was adjusted to 20% v/v  and the reaction left to proceed at 4 °C overnight while gently 
stirring. The doubly functionalised particles were purified on a PD–10 column equilibrated with 
10 mM sodium phosphate buffer pH 7.0, and eluted samples were concentrated on 100 kDa cut–
off columns before being layered onto 5 ml 10%–50% sucrose gradients. The gradients were 
centrifuged at 137000g for 1 to 1.5 hours at 4 °C as described in section 2.17.1. After further 
concentration on 100 kDa cut–off columns, the number of free reactive lysines was calculated, 
from the absorbance spectrum (Figure 3.5), to be ~ 66 per virion. . 
3.2.6 External surface mineralization of amine–functionalised MWCNT 
Cbz–CNAGDHANC (peptide–CoPt; 1.0 mg ml–1) was activated with a freshly prepared 
solution of EDC (1 molar equivalent) in Milli–Q water for 5 minutes followed by the addition 
of a freshly prepared DMSO solution of NHS (4 molar equivalents). The reaction was allowed 
to proceed for 2 hours at room temperature with gentle stirring. The solution of activated 
peptide–CoPt was added to a suspension of amine surface–functionalised, short, thin, multiwall 
carbon nanotubes (MWCNT; 0.30 mg) in Milli–Q water (1 ml) and then gently stirred at 4 ºC 
overnight. The resultant peptide–functionalised MWCNT (Peptide–CoPtMWCNT) was purified on a 
100 kDa cut–off column. A suspension of Peptide–CoPtMWCNT (100 µl) was treated with a 1:1:1 
mixture of CoCl2 (0.05 mol dm
–3
), H2PtCl6 (0.05 mol dm
–3
) and NaBH4 (0.1 mol dm
–3
) each in 
Milli–Q water (500 µl). The reaction was allowed to proceed at ambient temperature with gentle 
stirring. After 24 hours the reaction mixture was centrifuged at 14000 rpm (bench top) for 10 
minutes, the pellet was re–suspended in Milli–Q water and purified further on a 100 kDa cut–off 
column and washed thoroughly with Milli–Q water. TEM examination showed partial 
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mineralization of the nanotube external surface. The process described above was repeated 
sequentially over each of seven days to give external surface–mineralized MWCNT. 
3.2.7 Scanning electron microscopy 
FePt–CPMV coated particles were air–dried on a freshly prepared mica surface. The 
surface was mounted onto an aluminium pin stub using double–sided adhesive carbon discs 
(Agar Scientific Ltd). The stubs were then sputter–coated with approximately 10–15 nm 
platinum in a high–resolution sputter coater (Agar Scientific Ltd) and transferred to a Zeiss 
Supra 55 VP FEG scanning electron microscope (Zeiss SMT). The samples were viewed at 3 
kV with 5mm inLens signal. 
3.3 Results and Discussion 
3.3.1 Chimaera CPMV mineralization   
The previously defined dodecapeptide sequence HNKHLPSTQPLA (Reiss et al, 2004a) 
was inserted by a well–established cloning method between alanine–22 and proline–23 in the 
βB–βC loop of the small subunit of CPMV and the chimaeric CPMVFePt construct was 
introduced into cowpea plants by agroinoculation. The extracted and purified chimaeric 
CPMVFePt presents 60 copies of the inserted peptide was incubated with iron and platinum 
precursors and, after reduction with borohydride, generated monodisperse FePt coated CPMV 
chimaeric particles as confirmed by TEM (Shah et al 2009a) (Figure 3.3). The DLS was also 
consistent with monodisperse nanoparticles of ~ 30 nm diameter  this implies an FePt coating of 
approximately 1 nm on each particle. 
Zeta potential is the electrostatic potential that exists at the shear plane of a particle, 
which is related to both surface charge and the surrounding environment (Zhang et al, 2008). 
The instrument measures the electrophoretic mobility (or zeta potential) by applying an external 
CHAPTER 3 
 
58 
 
current in liquid suspensions. Zeta potential values have regularly been used as an indicator of 
the stability of colloidal particles. The higher the absolute values, the higher the net electrical 
charge on the particle surface and, therefore, the larger the electrical repulsion between 
particles. The suggested theoretical limit of stability is │25│mV. Particles are considered to 
exist as stable colloids if their zeta potential is higher than 25 mV or lower than –25 mV. The 
zeta potential of chimaeric CPMVFePt of –49.6 mV in buffer indicated that the colloid has good 
stability and no propensity to aggregate. For a detailed discussion of these results, see (Shah et 
al, 2009a).  
The inserted peptide showed specificity for the target material and the chimaeric CPMV 
particles acted as a template for metal deposition. The chimaeric particle does not generate a
metallic coating when incubated with metals other than the ones the peptide sequence favours.  
For example, chimaeric CPMVFePt when treated with reagents for cobalt or zinc sulfide did not 
generate mineralized particles. The peptide exhibited control over the mineralization process; 
CPMVwt particles (genetically unmodified) showed no templated mineralized particles but,
rather, the non–specific formation of nanoparticles with a wide size distribution as shown by 
TEM (data not shown). These findings suggested that nanoparticles of desired composition and 
size could be produced by engineering viral particles with specific peptides selected through 
phage display. Furthermore, silica coated CPMV particles had been generated following the 
same approach as described above (Steinmetz et al, 2009b). 
 
Figure 3.3– Unstained TEM image of monodisperse FePt–coated chimaeric CPMV particles. 
Reproduced from (Shah et al, 2009a). 
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3.3.2 PeptideCPMV conjugates 
Peptides previously identified by using phage–display that specifically direct 
mineralization by CoPt (Cbz–CNAGDHANC), FePt (Cbz–HNKHLPSTQPLA), and ZnS (Cbz–
CNNPMHQNC) as shown in Table 3.2 were chosen (Mao et al, 2004; Reiss et al, 2004a). To 
prepare 
Peptide
CPMV conjugates, the carboxyl–terminus of the relevant peptide was first pre–
activated by conversion to the O–succinimide active ester, the simplified reaction scheme is 
shown in Figure 3.2 and the chemical scheme is depicted in section 2.13. Reaction of the 
peptide ester with surface amines, derived from lysine groups exposed on the external surface of 
wild–type CPMV, generated PeptideCPMV conjugates in 70–90% recovered yield based on the 
initial virus concentration.  
The integrity of the modified particles was confirmed by TEM (data not shown) and 
agarose gel electrophoresis. Figure 3.4 shows an ethidium bromide stained agarose gel of 
CPMVwt, a positive control of O–succinimide esterified CPMV and the three PeptideCPMV 
conjugates. According to their migration in an electric field towards the anode, intact virions of 
CPMVwt can be separated into a higher– and lower–mobility form, depending on their RNA 
content. The O–succinimide esterified CPMV particles migrate more slowly toward the anode 
than wild–type and each of the three PeptideCPMV conjugates. 
 
Figure 3.4– Agarose gel (1.2%) electrophoresis of CPMV particles visualised by ethidium bromide 
staining. M represents a 1–kbp DNA ladder. Lane 1, wild–type CPMV; 2, NHS–esterCPMV; 3, Peptide–
CoPtCPMV; 4, Peptide–FePtCPMV; 5, Peptide–ZnSCPMV. 
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The number of peptides per virus particle was determined for 
Peptide–CoPt
CPMV 
conjugate. 
Peptide–CoPt
CPMV in sodium phosphate buffer pH 7.0 was reacted with an excess of 
NHS ester–activated amine specific dye, DyLight594. The doubly functionalised particles Peptide–
CoPt
CPMV
DyLight594
 were purified rigorously (as described in section 2.17) and the number of free 
reactive lysines was calculated, from the absorbance spectrum Figure 3.5, to be on average ~66 
± 4 per virion. This equates to approximately 180 peptides [maximum addressable amines (240) 
– free amines remaining in conjugate (66) = 170–174] being bound to each CPMV virus 
particle; whereas in the case of genetically engineered chimaera the total number of peptides 
was 60 per virus. The 
Peptide
CPMV conjugates were found to be monodisperse by DLS and the 
particle size did not increase significantly compared to wild–type. 
 
 
Figure 3.5– UV–visible spectrum of doubly functionalised Peptide–CoPtCPMV particles. CPMVwt (blue 
line) and Peptide–CoPtCPMVDyLight594 (red line). The number of peptides bound to the virus capsid was 
174 peptide/virus, which means 3 of the 4 regularly addressable lysine are coupled to peptide. 
 
The integrity of the doubly–functionalised particles was confirmed by agarose gel 
electrophoresis. Unstained native agarose gel electrophoresis revealed a visible fluorescent band 
as a result of the fluorescently labelled 
PeptideCoPt
CPMV
DyLight594
 virus capsid and also revealed 
that no free dyes are present in the sample (Figure 3.6–A). In addition, staining with both 
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ethidium bromide and Coomassie blue confirmed the integrity of the intact particles (Figure 
3.6–B and C, respectively).  
 
Figure 3.6– Native 1.2% agarose gel electrophoresis (A) unstained; (B) ethidium bromide stained; 
(C) Coomassie blue stained. Lane 1, wild–type CPMV; 2, NHS–esterCPMV; 3, Peptide–CoPtCPMV 
conjugate; 4, Peptide–CoPtCPMVDyLight594 conjugate. 
3.3.3 Mineralization of PeptideCPMV conjugates 
Reaction of 
Peptide
CPMV conjugates with reagents for mineralization produced 
monodisperse nanoparticles. For example, treatment of 
Peptide–CoPt
CPMV in buffer with an 
equimolar mixture of cobalt(II)chloride and hexachloroplatinic acid together with two molar 
equivalents of sodium borohydride reductant, within 48 hours, generated virus–templated CoPt–
CPMV particles. A similar approach was used to prepare FePt–CPMV nanoparticles using 
iron(III)chloride and hexachloroplatinic acid. For ZnS–CPMV, the reagents used were zinc 
chloride and sodium sulfide in an equimolar ratio. After purification, the mineralized particles 
were obtained in 70–80% recovered yield based on the initial virus concentration. This protocol 
requires neither high temperature nor pressure, is performed in aqueous buffer, and produces 
little waste so is environmentally benign. It has been found that this process can be readily 
scaled–up to 10 mg ml–1 of virus particles. The PeptideCPMV conjugates are specific to their 
corresponding mineralization process. CPMVwt, when incubated under identical conditions 
with the reagents for mineralization did not mineralize; no monodisperse, templated 
nanoparticles were formed but some non–specific mineralization and bulk precipitation was 
observed (Figure 3.7). Similarly, the peptide alone does not promote formation of monodisperse 
nanoparticles.  
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Figure 3.7– Unstained TEM image for unmodified CPMVwt particles incubated with equimolar 
quantities of FeCl3 and H2PtCl6 in the presence of sodium borohydride. The apparent virus particle 
is possibly because of platinum staining. 
 
 
When the conjugate that is specific for directed CoPt mineralization 
Peptide–CoPt
CPMV 
was reacted with the reagents for mineralization with FePt or ZnS, and vice versa, there was no 
evidence for templated–mineralization observed by TEM. This is direct evidence and 
demonstration of the selectivity of the peptides. Figure 3.8 shows the selectivity of 
Peptide–
ZnS
CPMV, when incubated with Fe and Pt salt precursors only non–specific and bulk 
precipitation was observed. 
 
Figure 3.8– Unstained TEM image for Peptide–ZnSCPMV incubated with equimolar quantities of FeCl3 
and H2PtCl6 in the presence of sodium borohydride. The black spheres are believed to be iron–
platinum either as an alloy or as separate metals. 
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In the case of 
Peptide–CoPt
CPMV, the mineralization occurs irrespective of the C– to N–
terminus ordering of the peptide; that is, peptide can be bound by the C–terminus carboxylate to 
amine groups on the virus surface as Cbz–CNAGDHANC or Cbz–CNAHDGANC without the 
mineralization process being affected. TEM images (data not shown) are very similar to those 
obtained in Figure 3.9. 
The unstained TEM images for CoPt–CPMV, Figure 3.9–A, FePt–CPMV, Figure 3.9–
B, and ZnS–CPMV, Figure 3.9–C, reveal dense, mineralized nanoparticles of ca. 32 nm, which 
is in agreement with the particle size measured by DLS (Table 3.4). Wild–type CPMV when 
treated under identical mineralization conditions and after purification cannot be visualised in an 
unstained TEM image and can only be seen after negative staining with uranyl acetate. These 
images are similar to those previously observed for templated mineralized–CPMV particles 
prepared using CPMV–chimaeras (Shah et al, 2009a) and confirm that the PeptideCPMV 
conjugates direct templated surface mineralization. Comparison between the two approaches is 
summarised in Table 3.3.  
 
Figure 3.9– Unstained TEM images for mineralized CPMV particles. (A) CoPt–CPMV mineralized 
particles, (B) FePt–CPMV mineralized particles and (C) ZnS–CPMV mineralized particles. 
 
FePt coated particles Chimaeric mineralization  Chemical modification  
Diameter     30.0 ± 0.2 nm    32.0 ± 0.5 nm 
Zeta potential  – 49.6 ± 1.0 nm – 60.3 ± 1.9 nm 
Yield Very low Depending on starting 
material, with 80% recovery 
Table 3.3– Comparison between CPMV–templated FePt particles synthesised by either genetic 
insertion or chemical modification.  
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Elemental analysis using EDXS confirmed that cobalt and platinum, iron and platinum, 
and zinc and sulfur coated the external surfaces of CoPt–, FePt– and ZnS–CPMV nanoparticles, 
respectively, Figure 3.10.  
 
 
Figure 3.10– EDX spectrum of mineralized particles. (A) CoPt–CPMV, (B) FePt–CPMV and (C) 
ZnS–CPMV. Major peaks for each metal indicated with arrows; red for cobalt, green for platinum, 
white for iron, pink for zinc and blue for sulphide.  
 
 
Electron microscopy revealed two distinct morphologies in the unstained TEM image of 
CoPt–CPMV, Figure 3.9–A. One is as expected for an externally mineralized virus capsid but 
the other, with a darker core, is similar to that observed for internally–mineralized CPMV empty 
(devoid of RNA) virus–like particles (eVLPs) in which the internal cavity contains cobalt or 
iron oxide metals (Aljabali et al, 2010c). During a normal plant infection with wild–type 
CPMV, up to 10% of the virions isolated are devoid of RNA. It is proposed that the particles 
exhibiting the darker core are naturally occurring eVLPs that have been loaded with cobalt or 
cobalt/platinum as well as being externally mineralized because of the peptide bound to the 
exterior of the particles. 
To support the proposed hypothesis, naturally occurring eVLPs (top component) that 
have been chemically modified to display peptide–CoPt on their outer surface, showed a similar 
morphology in the TEM to the CoPt–CPMV, Figure 3.11, when mineralized with 
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cobalt/platinum. Later studies on the mineralization of the eVLPs confirmed the ability to 
internally mineralize the cavity of the eVLPs without the need for any further modification; this 
will be discussed in Chapter 6. 
 
Figure 3.11– Unstained TEM image of Peptide–CoPtVLPs that have been mineralized both internally 
and externally. The black spots are non–templated CoPt nanoparticles that remained in the sample 
after purification. 
 
 
Further, immunological detection (as described in section 2.12) shows the presence of 
accessible coat protein for eVLPs and 
Peptide–CoPt
eVLPs but not for externally mineralized 
particles as shown in Figure 3.12. This is consistent with the two observed morphologies being 
indeed for both internal and external mineralization. 
 
Figure 3.12– Immunological detection of coat protein for eVLPs, peptide–CoPteVLPs that reveal 
accessibility to the coat protein. However, mineralized CoPt–eVLPs were not detected 
immunologically. 
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Analysis of the mineralized CoPt–eVLP particles using agarose gel electrophoresis 
cannot differentiate between the two morphologies, as the eVLPs that are both externally and 
internally mineralized do not contain encapsidated RNA, which would stain with ethidium 
bromide. 
Characterisation of CPMV mineralized particles using agarose gel electrophoresis was 
performed. For CoPt–CPMV stained with ethidium bromide some fluorescent intensity was 
observed from a band of different mobility to wild–type and to Peptide–CoPtCPMV conjugate 
(Figure 3.13–A), suggesting that the CoPt–CPMV surface has some limited porosity sufficient 
to allow intercalation of ethidium bromide with the encapsulated RNA. For FePt–CPMV and 
ZnS–CPMV, less intense fluorescence is observed implying that there is less surface porosity 
after mineralization. However, when the gel is stained with Coomassie blue, Figure 3.13–B, no 
colouration is observed for each of the mineralized samples, this is consistent with the virus 
protein surface not being accessible to the stain as it is coated with mineral. 
 
Figure 3.13– Native 1.2% agarose gel for mineralized CPMV particles. Stained with (A) ethidium 
bromide and (B) coomassie Blue. Lane 1, CPMVwt; 2, CoPt–CPMV; 3, FePt–CPMV; 4, ZnS–
CPMV. 
 
In addition, the CPMV coat protein of CoPt–CPMV, FePt–CPMV and ZnS–CPMV was 
not detected immunologically (Figure 3.14). Only in the case of CPMVwt was a signal 
obtained, confirming the presence of CPMV coat protein; for the mineralized particles, the coat 
protein was not accessible to the antibody presumably due to the mineral coating.  
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Figure 3.14– Immunological detection of CPMVwt coat protein of mineralized particles spotted on 
a nitrocellulose membrane probed with polyclonal antibodies raised against CPMV. Only CPMVwt 
gave a detectable signal. 
 
 
Further support for the deposition of a robust mineral shell on the external surface is 
provided by comparison of the SDS–PAGE of mineralized and non–mineralized CPMV 
particles (Figure 3.15). Even under harsh denaturing conditions, such as with sodium dodecyl 
sulfate at 100 ºC for 20 minutes, there is only very partial release of coat proteins on 
denaturation of the mineralized–CPMV particles as shown by the near absence of coat protein 
on the SDS–PAGE gel. This is what would be expected if the denaturing agent either is unable 
to penetrate the mineral coat and/or the coat protein cannot be released from the mineralized 
shells.  
 
Figure 3.15– SDS–PAGE of mineralized CPMV particles. There is only very partial release of coat 
protein on denaturation of the mineralized–CPMV particles as shown by the near absence of coat 
proteins on the SDS–PAGE gel. Lane 1, CPMVwt; 2, Peptide–CoPtCPMV; 3, CoPt–CPMV; 4, Peptide–
FePtCPMV; 5, FePt–CPMV; 6, Peptide–ZnSCPMV; 7, ZnS–CPMV. Lanes 2, 4 and 6 are before 
mineralization whereas lanes 3, 5 and 7 are after mineralization. 
 
41 kDa 
23 kDa 
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The results of DLS and zeta potential measurements for the mineralized nanoparticles 
are shown in Table 3.4 (and detailed graphs are shown in Figure 3.16). The particle size in 
buffer as measured by DLS shows an increase in average hydrodynamic diameter to ca. 32 nm 
following mineralization. Prior to peptide–modification and mineralization, CPMV has a 
diameter of ca. 28 nm, implying that the coating on each particle is approximately 2 nm. This 
contrasts with a coating of 1 nm observed when FePt is templated on chimaeric CPMVFePt (Shah 
et al, 2009a). The coating thickness is significantly greater than the atomic diameter of 
individual metal atoms (0.25–0.27 nm) and the length of the coupled–peptide (ca. 1.00 – 1.50 
nm).  
 
 DLS diameter (nm) Polydispersity (%) Zeta potential (mV) 
CPMVwt 27.4 ± 0.5 14.0 –12.3 ± 1.5 
CoPt–CPMV 31.8 ± 0.5 16.7 –39.1 ± 2.1 
FePt–CPMV  32.0 ± 0.2 20.9 –60.3 ± 1.9 
ZnS–CPMV 30.8 ± 0.4 15.0 –22.2 ± 3.3 
Table 3.4– Diameter and polydispersity measured by dynamic light scattering and zeta potential 
of CPMVwt and mineralized–CPMV nanoparticles. 
 
The DLS polydispersity indicates that, by this criterion (see chapter 2) and in agreement 
with the observed TEM images, the particles are monodisperse and that the coated CPMV 
particles are uniformly mineralized on their outer surfaces.  
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Figure 3.16– DLS data comparing CPMVwt and mineralized particles (A) CoPt–CPMV (B) FePt–
CPMV (C) ZnS–CPMV. 
 
 
The zeta potential for suspensions of the mineralized particles in buffer are considerably 
more negative than that for CPMVwt (Figure 3.17), of ca. – 12 mV, and show that the colloids 
have good stability and no propensity to aggregate. Particles were stable over 2–3 months. Zeta 
potential values are summarised in Table 3.4. 
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Figure 3.17– Zeta potential measurement of mineralized (A) CoPt–CPMV (B) FePt–CPMV and (C) 
ZnS–CPMV particles. 
 
Nanoparticle tracking analysis (Figure 3.18), based on laser light scattering microscopy, 
was also consistent with mineralization of the virus. For each of the mineralized virus particles 
there was a significant increase in the relative refractive index compared with wild–type and 
with 
Peptide
CPMV conjugates. The analysis is also consistent with the mineralized particles being 
monodisperse as indicated by the particle size distribution; although for ZnS–CPMV there was a 
little non–specific aggregation under the measurement conditions employed.  
 
 
Figure 3.18– Negative image of a freeze–frame from nanoparticle tracking analysis for mineralized–
CPMV nanoparticles. Showing that the particles appear individually as point scatterers under 
Brownian motion with a high refractive index. (A) CoPt–CPMV; (B) FePt–CPMV; (C) ZnS–
CPMV. 
 
The scanning electron micrograph of FePt–CPMV (Figure 3.19) provides further 
evidence that the templated nanoparticles retain their integrity and monodispersity. 
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Figure 3.19– SEM image of sputter–coated FePt–CPMV deposited on a mica surface. 
 
Finally, the magnetic properties for the chimaeric–templated particles could not be 
obtained because of the low amount of the mineralized particles obtained. However, in order to 
demonstrate that the FePt–CPMV possesses magnetic properties, a large sample of mineralized 
FePt–CPMV (115 mg ml–1, 200 µl) was prepared by the chemical modification route and placed 
beside an external magnet as shown in Figure 3.20. Immediately, a progressive migration of the 
dark nanoparticles towards the magnet was observed. It was very difficult to demagnetise the 
particles maybe as a result of ferromagnetic properties. Particles remained in pellet form or as 
large aggregates as confirmed by TEM, Figure 3.20–C.  
 
Figure 3.20– Demonstrating magnetic properties of FePt–CPMV prepared by the chemical 
modification route. (A) (115 mg ml–1, 200 µl) FePt–CPMV particles suspended in 100 mM sodium 
phosphate buffer pH 7.0. (B) The same sample after 1 minute of exposure to the magnetic field, 
and (C) is the corresponding TEM from the accumulated pellet in (B). Arrow indicates particle 
attracted to the external magnet.  
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3.3.4 Mineralization of peptide–modified MWCNT 
Carbon nanotubes (CNTs) consist of rolled graphene sheets with diameters in the 
nanometre range and lengths in the micrometre range, and are useful materials with unique 
properties. Matsui and co–workers showed that nanotubular structures coated with a histidine–
rich peptide can serve as templates to generate mineralized gold nanoparticles on the nanotube 
surface (Djalali et al, 2003). The possibility of using CNTs as building blocks for nanoelectronic 
components or devices requires uniform and monodisperse metal coatings of the CNTs for 
conductivity purposes. With this in mind, the chemically–coupled–peptide–promoted method of 
mineralization was shown to be a general method for any suitably modified surface. The CoPt 
peptide could easily be coupled to an amine surface–functionalised MWCNT by the standard 
carbodiimide protocol to give peptide–modified MWCNT (Peptide–CoPtMWCNT). Incubation of 
Peptide–CoPt
MWCNT with cobalt chloride, hexachloroplatinic acid and sodium borohydride 
reductant, followed by purification after 24 hours shows, by TEM, the initiation of 
mineralization (Figure 3.21–B) at, presumably, the sites of peptide coupling. This process is 
analogous to that which occurs on mineralization of 
Peptide–CoPt
CPMV conjugates as described 
above. Repeating the mineralization process sequentially over seven days produced a thick, ca. 
20 nm, fairly uniform coating, of CoPt on the surface of the MWCNT as confirmed by TEM 
(Figure 3.21–C) and EDXS (Figure 3.22).  
 
 
Figure 3.21– Unstained TEM images of peptide–promoted mineralization of amine–functionalised 
MWCNT. (A) amine–functionalised MWCNT; (B) Peptide–CoPtMWCNT after 24 hours mineralization 
showing initial nucleation sites of CoPt; (C) CoPt–mineralized MWCNT after 7 days. 
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Figure 3.22– EDX spectrum of CoPt–mineralized MWCNT. Major peaks for each metal indicated 
with arrows. 
 
3.4 Conclusions  
In conclusion, the successful attachment of peptide that promote certain types of 
mineralization to the external surface of CPMVwt and MWCNT is only the beginning and may 
lead to the synthesis of metallic nanoshells with interesting magnetic and other properties. This 
approach is proven to be general to any surface that could be suitably functionalised. 
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4 Charge promoted mineralization  
4.1 Introduction  
It was apparent, from using peptides coupled to the CPMV exterior capsid to promote 
specific mineralization, that the specificity of the peptide is something imbedded within the 
peptide sequence (Aljabali et al, 2011; Mann, 2001; Willett et al, 2005) although it is not fully 
understood. The composition of the peptides identified by the phage–display peptide library and 
their ability to selectively initiate the nucleation is linked to the biochemical features of the 
peptides; this property depends on the peptide composition and structure and not the peptide 
sequence. Proteins enriched with acidic amino acids (aspartic and glutamic acid) have been 
suggested as nucleation sites for binding Ca
2+
 during the controlled formation of calcite (Addadi 
& Weiner, 1985; Wierzbicki et al, 1994) and calcite deposition on a carboxylate–terminated 
self-assembled monolayer (SAM) (Han & Aizenberg, 2003). However, the presence of charged 
amino acids (such as glutamic and aspartic acid) led me to believe that the charge within the 
peptide is involved in initiation of nucleation that can ultimately lead to mineralization of 
CPMV particles. 
Although the precise reason for selectivity of peptides toward inorganic materials is not 
known, the sequence of the peptides used in the previous chapter suggested to me that the 
overall charge within the peptide is responsible for the initiation of nucleation, although it is not 
clear if it is responsible for selectivity as well. This hypothesis has been used to generate 
mineralized CPMV particles by changing the surface charge of CPMV particles. 
This chapter will describe that there is no requirement for the use of mineral/metal 
specific peptides or the electroless deposition process for the CPMV–templated formation of 
monodisperse mineralized nanoparticles; it is sufficient to simply increase the virus surface 
negative charge by a chemical covalent modification process. The charge–modified CPMV, as 
proof–of–principle, was coated with cobalt or iron oxide to give monodisperse nanoparticles of 
about 32 nm diameter. Further, the iron oxide–CPMV nanoparticle surface can be functionalised 
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with, for example, a thiolated oligosaccharide, showing the potential for a range of 
modifications as depicted in Figure 4.1.  
 
 
Figure 4.1– Schematic representation of the covalent modification of surface–exposed amines on 
the CPMVwt with succinamate (approx. 240 per virion) followed by mineralization and 
functionalisation with a thiolated oligosaccharide. 
 
In addition, polyelectrolyte surface–modified CPMVwt can be used for the templated 
synthesis of gold coated CPMV particles (Au–CPMV). A cationic polyelectrolyte, 
poly(allylamine) hydrochloride (PAH), was electrostatically adsorbed to the external surface of 
the virus capsid, which promotes the adsorption of anionic gold complexes, which were then 
easily reduced, under mild conditions, to form a metallic gold layer. As expected, the gold 
surface can be further modified with thiol reagents. In contrast, reaction of polyelectrolyte–
modified CPMV (
PA
CPMV) with pre–formed gold nanoparticles resulted in the self–assembly 
of large, hexagonally packed, tessellated–spheres. 
4.2 Experimental 
4.2.1 Materials  
Dimethyl sulfoxide ≥ 99.9% (DMSO), iron(III) chloride hexahydrate, iron(II) chloride 
tetrahydrate, hexachloroplatinic acid, anhydrous cobalt(II) chloride, poly(allylamine 
hydrochloride) (PAH, MW~ 15,000), poly(fluorescein isothiocyanate allylamine hydrochloride) 
(FITC–PAH, MW~ 9291), gold(III) chloride trihydrate 99.9+%, tetrachloroauric acid and 
sodium borohydride were purchased from Sigma–Aldrich; succinic anhydride from Alfa Aesar; 
potassium carbonate from BDH; hydroxylamine hydrochloride, 99%, from Lancaster Synthesis; 
DyLight–594 NHS Ester from Thermo Scientific. All reagents were used without further 
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purification. Solutions were prepared using Milli–Q water with a resistivity of 18.2 MΩ cm 
(Millipore). 
4.2.2 SuccinamateCPMV 
CPMV particles (10 mg ml
–1
, 1 ml) suspended in 10 mM sodium phosphate buffer pH 
7.0 were reacted with a 2000 molar excess of succinic anhydride dissolved in DMSO and the 
final DMSO concentration was adjusted to 20% (v/v). The reaction pH was monitored and 
maintained if needed at pH 7.0 by the addition of a few drops of 1 mM NaOH. The reaction was 
left overnight at 4 °C, then the modified particles were purified on PD–10 desalting columns, 
followed by overnight dialysis using 100 kDa molecular weight cut–off membranes against 10 
mM sodium phosphate buffer pH 7.0. The yield of 
Succinamate
CPMV
 
conjugate (superscript 
proceeding the virus acronym refers to external modification), determined by UV–vis 
absorption at 260 nm, was between 80–90% based on the initial virus concentration. The 
particle integrity was established by native agarose gel electrophoresis, TEM, DLS and zeta 
potential measurements. 
4.2.3 SuccinamateCPMV quantification  
The number of succinic anhydride moieties per particle was determined for 
Succinamate
CPMV conjugate as follows. 
Succinamate
CPMV suspended in 10 mM sodium phosphate 
buffer pH 7.0 was reacted with a 2000 molar excess of NHS ester–activated amine specific dye, 
DyLight594, in DMSO. The DMSO level was adjusted to 20% (v/v) and the reaction left to 
proceed at 4 °C overnight while gently stirring. The doubly functionalised particles were 
purified on a PD–10 column equilibrated with 10 mM sodium phosphate buffer pH 7.0, and 
eluted samples were concentrated on 100 kDa cut–off columns before being layered onto 5 ml 
10%–50% sucrose gradients as described in section (2.17.1). The fractions containing the virus 
particles were collected and dialysed against 10 mM sodium phosphate buffer pH 7.0 for 2 days 
with changing buffer every 12 hours. After further concentration on 100 kDa cut–off columns, 
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fluorescence was examined by either UV–vis or on agarose electrophoresis gels, a lack of 
fluorescence indicating the complete modification of the virus by succinic anhydride. 
4.2.4 Co–CPMV   
Succinamate
CPMV pre–activated particles (3 mg ml–1, 1 ml) suspended in 10 mM sodium 
phosphate buffer pH 7.4 were incubated with 20 mM cobalt(II) chloride at ambient temperature, 
while gently shaking at 50 rpm for 1–2 hours. Freshly prepared sodium borohydride (2mM) in 
Milli–Q water was added and the mixture incubated for another 10–30 minutes at ambient 
temperature. Particles were recovered by centrifugation at 14000 rpm (bench top, Eppendorf) 
for 20 minutes. The supernatant containing the Co–CPMV nanoparticles was further purified on 
PD–10 desalting columns. The eluted fractions were layered on sucrose gradients (as described 
in section 2.17.1) and the fractions containing mineralized particles were collected and dialysed 
against 10 mM sodium phosphate buffer pH 7.0 for 15 hours. 
4.2.5 Iron oxide–CPMV  
Succinamate
CPMV pre–activated particles (1–1.2 mg ml–1, 2 ml) suspended in 10 mM 
sodium phosphate buffer pH 7.4 were incubated with 2 mM iron(II) chloride tetrahydrate and 4 
mM iron(III) chloride hexahydrate at ambient temperature, while gently shaking at 50 rpm for 
1–2 hours. The pH was raised slowly to 10.2 by dropwise addition of 1 mM sodium hydroxide 
and incubated for another hour at ambient temperature. As a control experiment, CPMVwt 
particles were incubated with the same concentration of iron salts for 1 hour prior to raising the 
pH to 10.2 for another hour and purified as described above for Co–CPMV. Sucrose gradient 
centrifugation was essential to remove all the impurities from the sample. 
4.2.6 Mössbauer spectroscopy analysis  
Samples were analysed by Professor Dave Evans and Mrs Elaine Barclay. Detailed 
experimental procedures are explained in section 2.13. 
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4.2.7 Vibrating sample magnetometry (VSM) of iron oxide–CPMV 
The magnetic measurements were conducted as a collaborative project with Drs. Oscar 
Céspedes and Sarah Staniland, School of Physics and Astronomy, University of Leeds, United 
Kingdom. Detailed experimental procedures are presented in section 2.14. 
4.2.8 Metal–CPMV functionalisation with thiolated oligosaccharide  
Freshly prepared iron oxide–CPMV or Au–CPMV particles (1 mg ml–1, 3 ml) 
suspended in 10 mM sodium phosphate buffer pH 7.0, were incubated with 0.5 mg of 1–thio–β–
D–maltoheptaose. The reaction mixture was purified on a PD–10 column, dialysed against 10 
mM sodium phosphate buffer pH 7.0 for 2 days and concentrated using 100 kDa molecular 
weight cut–off membranes. Oligosaccharidemetal–CPMV particles were analysed by mass 
spectrometry. 
4.2.9 Au–CPMV functionalisation with cysteamine 
To Au–CPMV (1 mg ml–1) suspended in 10 mM sodium phosphate buffer pH 7.4 was 
added an aqueous solution of cysteamine hydrochloride (1 mg). The reaction was left to proceed 
for ca. 12 hours at ambient temperature. 
Cysteamine
CPMV particles were dialysed for 24 hours 
against 100 mM sodium phosphate, 0.15 M NaCl, buffer pH 7.4 using 100 kDa dialysis 
membranes. 
Cysteamine
CPMV particles were incubated with amine–specific DyLight–594 NHS 
ester (65 µg) for 2 hours at ambient temperature while gently stirring. 
DyLight–594–cysteamine
Au–
CPMV particles were purified on sucrose gradient as described above, and then dialysed for 24 
hours against 10 mM sodium phosphate buffer pH 7.4.  
4.2.10 MALDI–TOF mass spectrometry (MS) 
MS analysis was performed on iron oxide–CPMV and Au–CPMV both addressed with 
thiolated oligosaccharide (1–thio–β–D–maltoheptaose). Particles were mixed in a 1:1 ratio with 
the matrix (2,4,6–trihydroxyacetophenone, 10 mg ml–1 in 70% aqueous acetonitrile) and 1 µl 
spotted onto a ground steel MALDI target plate (Bruker Daltonics, Bremen, Germany). After 
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drying, the sample was analysed on a Bruker Ultraflex TOF/TOF. The instrument was 
calibrated using Bruker standards (ca. 200 laser shots). Samples were analysed using a laser 
power of approx. 25% and spectra were summed from ca. 30 x 15 laser shots. Data were 
processed in FlexAnalysis (Bruker). MS analysis was conducted in collaboration with Dr. 
Abdul Rashid, John Innes Centre, UK. 
4.2.11 CPMV–Poly(allylamine) hydrochloride (PACPMV) 
Freshly prepared CPMV particles (1 mg ml
–1
, 1 ml) were suspended in Milli–Q water 
and added dropwise over 5 minutes, with continuous stirring, to a freshly prepared PAH (1 mg 
ml
–1
) solution in aqueous 0.25 M NaCl. The cationic polyelectrolyte was allowed to adsorb onto 
the virus capsid for 30 minutes while gently shaking at 4 °C. The polycation–coated CPMV 
particles (
PA
CPMV) were washed 3–4 times with Milli–Q water (15 ml) on 100 kDa cut–off 
membranes, followed by dialysis against 10 mM sodium phosphate buffer pH 7.0 for 3 hours. 
PA
CPMV was obtained in approximately 50% yield.  
 
FITC–PA
CPMV was prepared by a similar method except that the incubation was for 15 minutes. 
4.2.12 Gold hydroxide solution 
Gold(III) chloride trihydrate (17.4 ml of 25 mM solution) was diluted with Milli–Q 
water (982.6 ml), and then potassium carbonate (249 mg, 1.8 mM) was added. The solution was 
aged for 1–2 days in the dark (foil wrapped) at 4 °C, during which it changed colour from 
yellow to colourless due to the formation of gold hydroxide (Graf & van Blaaderen, 2002; Kuo 
et al, 2008). 
4.2.13 Gold coated CPMV nanoparticles (Au–CPMV)  
Freshly prepared 
PA
CPMV particles (1–1.5 mg ml–1, 1ml) were incubated with gold 
hydroxide solution (1 ml) as prepared above. The reaction solution was left stirring at room 
temperature for 2 hours before adding a freshly prepared aqueous solution of hydroxylamine 
hydrochloride to a final concentration of 20 mM. The reaction was left to proceed for a further 
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20 minutes at ambient temperature. Au–CPMV particles were spun at 14000 rpm (bench top 
centrifuge) for 20 minutes to remove any large aggregates before being layered onto 5 ml 10%–
50% sucrose gradients (as described in section 2.17.1). Sucrose fractions containing Au–CPMV 
particles (bluish colour) were collected and dialysed against 10 mM sodium phosphate buffer 
pH 7.0 for 15 hours using 100 kDa molecular weight cut–off membranes. The Au–CPMV 
particles were concentrated and the yield determined, by UV–vis absorption at 260 nm, to be 
approximately 50–60% based on starting concentration of PACPMV. 
4.2.14 Gold nanoparticle (AuNP) preparation 
A modification of a published protocol was used (Hone et al, 2003). In brief, 
tetrachloroauric acid trihydrate (HAuCl4.3H2O) (12.5 mg, 0.032 mM) was dissolved in water 
(100 ml) and the solution heated to 60 °C. A second solution of trisodium citrate dihydrate (50 
mg, 0.170 mM) in water (50 ml) was also heated to 60 °C. Both solutions were rapidly mixed 
and heated with stirring at 85 °C for 150 minutes. After cooling, the red wine–coloured solution 
was filtered through a syringe filter (0.22 µm) and stored at 4 °C. TEM and DLS confirmed a 
AuNP size of 10 – 18 nm. 
4.2.15 PACPMV and pre–formed AuNP (tessellated–spheres) 
PA
CPMV particles (1 mg ml
–1
, 400 μl) and a suspension of citrate–capped gold 
nanoparticles (400 μl, AuNP as prepared in 4.2.14) were reacted together with gentle stirring at 
ambient temperature for 10–15 minutes. The solution colour changed from red to light purple. 
UV–vis spectroscopy was used to monitor the formation of tessellated–spheres as confirmed by 
TEM. 
For the characterisation methods used in this chapter (immunological detection, TEM, 
SEM, NTA, agarose gels, EDXS, and ZP) refer to chapter 2. 
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4.3 Results and Discussion 
4.3.1 Charge promoted mineralization  
The previous studies on CPMV mineralization as described in chapter 3, and those of 
others (Addadi & Weiner, 1985; Wierzbicki et al, 1994), suggested that the initiation of 
mineralization is related to the presence of negatively charged amino acids. CPMV can be 
considered as an anionic macromolecule at neutral pH with an isoelectric point (pI) of 4.3 ± 0.1 
(Kewalramani et al, 2011). In order to create suitable conditions for templated surface 
mineralization, CPMV particles were covalently modified with succinic anhydride to increase 
the virus capsid surface negative charge. Succinic anhydride has a cyclic structure that is highly 
reactive toward nucleophiles (amines). Attack of a nucleophile at one of the carbonyl groups 
opens the anhydride ring, forming a covalent bond to the lysine amine–nitrogen and a free 
carboxylate group at the other end of the ring–opened molecule (Hermanson, 2008); Figure. 4.1. 
Coverage of at least 240 surface addressable lysines with succinamate was achieved. No amine–
specific dye could be coupled to the virus capsid post–modification, as shown by the lack of dye 
absorbance in the UV–vis spectrum following rigorous purification (as described in section 
2.17), confirming that no addressable lysine groups remain.  
Succinamate
CPMV particle integrity was established by uranyl acetate–stained TEM images 
as shown in Figure 4.2–A. As expected, there was no significant difference in size or structure 
compared with CPMVwt. 
Succinamate
CPMV was found to be stable for at least two months in 10 
mM sodium phosphate buffer pH 7.0. In addition, TEM shows no aggregation of 
Succinamate
CPMV particles on any of the samples prepared during this study.  
Succinamate
CPMV particles in buffer were incubated with the appropriate reagents for 
mineralization. 
Succinamate
CPMV when incubated with cobalt chloride followed by reduction with 
sodium borohydride gave cobalt coated CPMV nanoparticles (Co–CPMV). Treatment under 
alkaline hydrolysis conditions that favour the formation of magnetite (Wu et al, 2009), Fe3O4, 
by incubation with a 2:1 mixture of iron(II) and iron(III) salts followed by raising the pH to 
approximately 10.2 for 1 hour, gave iron oxide coated CPMV particles (iron oxide–CPMV).  
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The unstained TEM images of the mineralized particles reveal monodisperse 
nanoparticles of ca. 32 nm. The appearance of the mineralized CPMV particles is similar to that 
which has been previously observed for templated mineralized–CPMV as discussed in chapter 
3. For particles obtained by alternative methods see chapters 3, 4, and 5 (Aljabali et al, 2010b; 
Aljabali et al, 2011; Shah et al, 2009a; Steinmetz et al, 2009b). 
 
Figure 4.2– TEM images for (A) uranyl acetate stained SuccinamateCPMV, (B) unstained Co–CPMV 
and (C) unstained iron oxide–CPMV particles from sucrose gradient. Inset shows higher 
magnification particles. 
 
The presence of succinamate, and hence the extra surface negative charge, was essential 
for templated–mineralization. CPMVwt when incubated under identical conditions, with the 
same concentration of reagents, resulted in visible bulk precipitation and only non–specific 
mineralization; particles with a wide size distribution were obtained as shown by TEM in Figure 
4.3. 
 
Figure 4.3– Unstained TEM of positive control of CPMVwt under identical mineralization 
conditions as those to form templated iron oxide–CPMV, only non–specific mineral formation of 
variable particle size was observed. 
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Succinamate
CPMV particles have a zeta potential almost two–and–a–half fold more 
negative than CPMVwt, consistent with successful surface modification and the consequent 
increase in surface negative charge; the data is summarised in Table 4.1. The ZP values for 
suspensions of mineralized Co–CPMV and iron oxide–CPMV are considerably more negative 
than that for CPMVwt, of ca. –12 mV, and for SuccinamateCPMV of ca. –28 mV, indicating that the 
colloids have good stability and show no propensity to aggregate. 
 
 Diameter (nm) Polydispersity (%) Zeta potential (mV) 
CPMVwt 28.2 ± 0.4 13.0 –12.3 ± 1.40 
SuccinamateCPMV 28.9 ± 0.3 16.5 –28.2 ± 2.34 
Co–CPMV 31.2 ± 0.5 18.4 –41.2 ± 1.15 
Iron oxide–CPMV 32.4 ± 0.5 20.9 –39.0 ± 2.4 
Table 4.1– Dynamic light scattering and zeta potential measurements. 
 
Native agarose gel electrophoresis as shown in Figure 4.4, visualised by ethidium 
bromide staining of encapsidated RNA or Coomassie blue staining of protein, also reflected the 
increased surface negative charge of 
Succinamate
CPMV, as the particles migrate further in the gel 
than CPMVwt particles. Agarose gel electrophoresis of iron oxide–CPMV (Figure 4.4–A), 
stained with ethidium bromide, shows some weak fluorescent intensity associated with bands of 
different mobility to CPMVwt and 
Succinamate
CPMV, suggesting limited porosity of the iron oxide 
surface to ethidium bromide, which intercalates with encapsidated RNA. However, Coomassie 
blue stained gels detect no colouration for the mineralized particles, consistent with the 
mineralized virus surface being inaccessible to this stain (Figure 4.4–B). Co–CPMV when run 
on an agarose gel (Figure 4.4) cannot be visualised by either ethidium bromide or Coomassie 
staining, implying that the cobalt forms an impervious shell on the virus surface. 
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Figure 4.4– Agarose gel electrophoresis (1.2%) of intact CPMV particles visualised by (A) ethidium 
bromide staining, (B) coomassie staining. Lane 1, CPMVwt; 2, SuccinamateCPMV; 3, mineralized–
CPMV. 
 
Energy dispersive X–ray spectroscopy (EDXS, Figure 4.5) of Co–CPMV and iron 
oxide–CPMV confirmed the presence of cobalt, and iron and oxygen, respectively. There was 
no significant amount of oxygen in the EDXS of Co–CPMV, so there is no evidence of cobalt 
surface oxidation.  
 
Figure 4.5– EDX spectrum of mineralized–CPMV particles. (A) Co–CPMV, cobalt peak indicated 
by red arrow, and (B) Iron oxide–CPMV, iron and oxygen peaks indicated by red arrows. 
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Immunological detection (dot blots) of the surface of both CPMVwt and 
Succinamate
CPMV 
can be detected immunologically (Figure 4.6). However, both iron oxide–CPMV and cobalt–
CPMV, when probed immunologically, could not be observed (Figure 4.6), consistent with the 
mineral surface–coating preventing access of the antibody. Co–CPMV particles were detected 
when stained with a cobalt specific dye, 1–nitroso–2–naphthol, whereas CPMVwt and 
Succinamate
CPMV were not stained (Figure 4.6–B). Similarly, iron oxide–CPMV particles stained 
with Prussian blue (Figure 4.6–B) confirming the presence of iron (Aljabali et al, 2010c). 
 
Figure 4.6– Intact particles spotted on a nitrocellulose membrane probed with (A) polyclonal 
antibodies raised against CPMV particles–dark spots show CPMV coat protein; (B) specific 
staining, 1–nitroso–2–naphthol to stain for cobalt and Prussian blue stain for iron. Column 1, 
CPMVwt; 2, SuccinamateCPMV; 3, mineralized–CPMV. 
 
Dynamic light scattering (DLS) and zeta potential measurements are collected in Table 
4.1, Figure 4.7 and Figure 4.8. The average hydrodynamic diameter, from DLS, of the 
mineralized particles indicates a mineral coating of approximately 2 nm in each case, and the 
polydispersity shows that the particles are monodisperse. The particle size from DLS is in 
agreement with the observed TEM images.  
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Figure 4.7– DLS and correlation plot for CPMVwt, Co–CPMV and iron oxide–CPMV particles. 
 
The zeta potential for the mineralized particles suspended in buffer is considerably more 
negative than CPMVwt; by this criterion, the mineralized particles have good colloidal stability. 
ZP was a useful tool in monitoring the changes in the surface charge as a consequence of virus 
surface modification.  
 
Figure 4.8– Zeta potential measurements of CPMVwt, SuccinamateCPMV, Co–CPMV and iron oxide–
CPMV suspended in buffer at pH 7.2. 
 
Although the conditions used for the formation of the iron oxide coating were chosen to 
favour mineralization with magnetite (Qu et al, 1999; Wu et al, 2009) as shown in equation 1, 
the presence of hematite (α–Fe2O3) or maghemite (γ–Fe2O3) cannot be discounted. 
 
In an attempt to establish the form of iron oxide coating the surface of CPMV, 
Mössbauer spectra were recorded of samples of
 57
Fe–enriched iron oxide–CPMV (Experiments 
were conducted by Prof. Dave Evans and Mrs Elaine Barclay). At 80 K, in frozen solution, a 
single quadrupole split doublet was observed with isomer shift (i.s.) of 0.49 mms
–1
 and 
quadrupole splitting (q.s.) of 0.64 mms
–1
,
 
Figure 4.9. These values are very similar to those 
recorded in the solid state (Figure 4.10) at 80 K, 0.48 and 0.61 mms
–1
, respectively. At 298 K in 
the solid state, the i.s. was 0.37 mms
–1
, as expected when changing the temperature by this 
amount, and the q.s., 0.61 mms
–1
, was found to be invariant with temperature. The values of i.s. 
2FeCl3 + FeCl2 + 8NaOH → Fe3O4 + 8NaCl + 4H2O…………………..(1) 
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and q.s. are fully consistent with the iron oxide being present on the surface of the virus as 
superparamagnetic magnetite nanoparticles; at room temperature i.s. values have been reported 
to range from 0.30 – 0.36 mms–1 and q.s. values from 0.60 – 0.65 mms–1 (Ambashta et al, 2005; 
Marques et al, 2008; Wang & Jiang, 2009). However, Mössbauer spectroscopy does not easily 
differentiate between magnetite and hematite nanoparticles, as the latter, when the particles are 
less than 10 nm in size, gave parameters in the range of i.s. 0.40 – 0.49 mms–1 and q.s. of 0.45 – 
0.60 mms
–1 
(Camargo et al, 2004; Greenwood & Gibb, 1971). 
 
 
Figure 4.9– Frozen solution Mössbauer spectrum at 80 K of iron oxide–CPMV. 
 
 
Figure 4.10– Mössbauer spectrum of iron oxide–CPMV in the solid state (A) At 80 K, there is a 
very small contribution from an underlying six–line spectrum. (B) At 298 K. 
 
The single quadrupole split doublet for the superparamagnetic nanoparticles should be 
contrasted with the two, partially resolved, overlapping, hyperfine split, six–line spectra 
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observed for bulk magnetite Figure 4.11 and the single six–line spectrum observed for bulk 
hematite (Greenwood & Gibb, 1971). 
 
Figure 4.11– Mössbauer spectrum of bulk magnetite in the solid state at 80 K. 
 
If the reaction time for the alkaline hydrolysis was too short a Mössbauer spectrum was 
obtained that showed two overlapping quadrupole split doublets (Figure 4.12). The minor 
doublet had parameters similar to those observed above for superparamagnetic magnetite 
nanoparticles and the major doublet had parameters (i.s. = 1.32 and q.s. = 3.09 mms
–1
) that 
correspond to Fe(OH)2 (Greenwood & Gibb, 1971); the alkaline hydrolysis and consequent 
formation of iron oxide was not complete. 
 
Figure 4.12– Frozen solution Mössbauer spectrum at 80 K of reaction intermediate. Major doublet 
corresponds to Fe(OH)2 and minor doublet to nanoparticulate superparamagnetic iron oxide. 
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Vibrating sample magnetometry data, conducted by Dr Sarah Staniland and Dr Oscar 
Céspedes, of iron oxide–CPMV is also fully consistent with the particles exhibiting 
superparamagnetic behaviour with a blocking temperature (TB) of around 60 K. The zero field 
cooled (ZFC) and field cooled (FC) magnetization curves (Figure 4.13) are typical 
magnetization curves for magnetic nanoparticles. Under FC conditions, there is no sharp change 
in the magnetization value from 380 K to 10 K. The ZFC curve shows a broad maximum at the 
temperature corresponding to TB, below which there is a sharp decrease in magnetization. The 
Verway transition was not visible but this is normal for this size of particles. Variations of the 
magnetization of the sample as a function of applied field, hysteresis loops (Figure 4.13), are 
clearly superparamagnetic at temperatures above TB and ferromagnetic below. 
 
 
Figure 4.13– Zero field cooled (ZFC) and field cooled (FC) magnetization curves (left) and 
hysteresis loops (right) above (200 K) and below (5 K) the blocking temperature (60 K). 
 
4.3.2 Iron oxide–CPMV functionalisation 
Iron oxide–CPMV particles were functionalised with a thiolated oligosaccharide (1–
thio–β–D–maltoheptaose), as proof–of–principle that the surface can be further modified, and 
characterized by mass spectrometry. After rigorous purification (as described in section 2.17) of 
the 
Oligosaccharide
iron oxide–CPMV particles (as described in section 2.17), MALDI–TOF mass 
spectrometry (Figure 4.14) shows the presence of peaks with m/z of 1191.571 [M+Na]
+
, 
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1207.551  [M+K]
+
 and 2373.843 [M2+K]
+
, consistent with functionalisation of the iron oxide 
surface with the thiolated oligosaccharide. Although the thiolated oligosaccharide may bind 
directly to the iron within the iron oxide coating, it is also likely that the thiol group interacts 
with hydroxyl–groups generated on the surface by partial hydrolysis in aqueous media (Boyer et 
al, 2009a; Boyer et al, 2009b). The ease by which the surface iron oxide can be addressed with 
thiolated molecules demonstrates the potential for the modification of the nanoparticle surface 
with a range of chemical moieties. 
 
Figure 4.14– Mass spectrum of Oligosaccharideiron oxide–CPMV showing the corresponding peaks, 
[M+Na]+= 1191.571, [M+K]+ = 1207.551 and [M2+K]+= 2373.843. The upper panel is for iron 
oxide–CPMV and the lower panel is for Oligosaccharide iron oxide–CPMV.  
 
4.4 CPMV–polyelectrolyte–templated gold nanoparticles 
Gold nanoparticles have attracted significant interest because of their great potential in 
photothermal therapy, drug delivery and diagnostics (Ghosh et al, 2008), and for applications as 
plasmonic nanostructures for the optical sensing of biological and chemical analytes (Evans, 
2008; Evans, 2009; Evans, 2010; Steinmetz & Evans, 2007). Access to a wide range of 
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derivatives and functional moieties adds to the versatility of gold nanoparticles for innumerable 
applications in the fields of biomedicine and nanotechnology.  
The value of gold nanoparticles arises from a variety of desirable structural attributes. 
Additionally, the interaction of biological systems with gold nanoparticles has attracted 
considerable attention. For example, a living fungus can ‘actively’ assemble gold nanoparticles 
over its hyphae to give conducting microstructures (Sugunan et al, 2007). The bacterium 
Escherichia coli has been converted into a biocompatible bacteria–gold nanocomposite for 
photothermal anti–cancer therapy (Kuo et al, 2008) and Chilo iridescent virus (CIV) has been 
shown to be a useful core substrate for the fabrication of metallodielectric plasmonic 
nanostructures (Radloff et al, 2005a).  
Genetically modified CPMV, with cysteine residues introduced onto its external 
surface, has been shown to bind to preformed nanogold (Blum et al, 2004; Wang et al, 2002a; 
Wang et al, 2002d). On the contrary, the approach presented in here is template synthesis of 
gold–coated CPMV particles. 
Herein, a cationic polyelectrolyte, poly(allylamine) hydrochloride (PAH), was 
electrostatically adsorbed onto the external surface of the virus capsid. The polyelectrolyte 
(polymer whose repeating units bear an electrolyte group. These groups will dissociate in 
aqueous solutions, making the polymers charged) promotes the adsorption of anionic gold 
complexes, which were then easily reduced, under mild conditions, to form a metallic gold 
layer. The approach is depicted in Figure 4.15. The process is simple and environmentally 
friendly, as only aqueous solvent and ambient temperature and pressure are required. In 
addition, this route offers a way to produce Au–CPMV with a narrow size distribution. As 
expected, the gold surface can be further modified with thiol reagents. In contrast, reaction of 
polyelectrolyte–modified CPMV (PACPMV) with pre–formed gold nanoparticles resulted in the 
self–assembly of large, hexagonally packed, tessellated–spheres. 
 
CHAPTER 4 
 
95 
 
 
Figure 4.15– Schematic representation of the polyelectrolyte adsorption onto the CPMV capsid 
followed by the subsequent incubation with the gold solution to generate Au–CPMV. 
 
4.4.1 Polyelectrolyte adsorption onto CPMV surface 
As stated in section 4.3.1, CPMV can be considered as an anionic macromolecule at 
neutral pH with an isoelectric point (pI) of 4.3± 0.1 (Kewalramani et al, 2011). At physiological 
pH (pH 7.4), aspartic and glutamic acid residues situated on the virus capsid surface are 
deprotonated, so the surface presents an overall negative charge. Incubation of CPMV with 
PAH led to electrostatic adsorption of a thin layer of cationic polyelectrolyte onto the capsid 
surface as confirmed by zeta potential measurements. The negatively charged CPMVwt 
particles, in 10 mM sodium phosphate buffer pH 7.4, have a zeta potential of ca. –12.3 ± 1.76 
mV (Aljabali et al, 2010b; Aljabali et al, 2011). After deposition of the polyelectrolyte, 
PA
CPMV exhibits a zeta potential of +67.8 ± 2.35 mV; the sign of the potential is reversed, 
consistent with the surface charge changing from negative to positive.   
Further confirmation of polyelectrolyte adsorption onto the surface of CPMV was 
obtained by the use of fluorescently labelled polyelectrolyte; fluorescein isothiocyanate–labelled 
poly(allylamine hydrochloride) (FITC–PAH). The UV–vis spectrum of FITC–PACPMV showed 
the presence of a new peak at 500 nm arising from the fluorescent label and confirming 
successful surface modification with 
FITC–PAH
CPMV (Figure 4.16).  
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Figure 4.16– UV–vis absorption spectrum of CPMVwt (blue line) and FITC–PACPMV (red line). 
 
Comparison of native agarose gel electrophoresis of CPMVwt, 
PA
CPMV and 
FITC–PA 
CPMV
 
showed that: (a) both CPMVwt and 
PA
CPMV were not visible without staining; (b) both 
PA
CPMV and 
FITC–PA
CPMV resided in the sample well and did not migrate under the electric 
field conditions employed (Figure 4.17). The lack of migration from the well is probably a 
consequence of the presence of electrostatically bound polyelectrolyte on the virus surface and 
not of particle aggregation. DLS of 
PA
CPMV (Figure 4.18) gave a hydrodynamic diameter of 32 
nm for the polyelectrolyte–coated particles and a polydispersity value of 9.3% that confirmed 
narrow distribution and no aggregation. 
 
Figure 4.17– Agarose gel electrophoresis (1.2%). (A) unstained, (B) ethidium bromide stained and 
(C) coomassie blue stained. Lane 1, CPMVwt, Lane 2, PACPMV and Lane 3, FITC–PACPMV. 
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Figure 4.18– DLS of PACPMV showing narrow size range (hydrodynamic diameter 32 nm) and no 
aggregation (narrow size distribution in B). 
 
PA
CPMV particle integrity was confirmed by negative staining TEM (Figure 4.19–A), 
the particles show a similar morphology to CPMVwt. No aggregation was observed in any of 
the TEM samples. 
 
 
Figure 4.19– TEM images of (A) uranyl acetate stained PACPMV, (B) unstained Au–CPMV, inset is 
high magnification TEM image of unstained Au–CPMV. 
 
4.4.1.1 Gold coated CPMV particles  
An aqueous gold hydroxide solution was prepared by a published procedure (Graf & van 
Blaaderen, 2002; Kuo et al, 2008) from gold(III) chloride and potassium carbonate (Equation 2). 
Treatment of 
PA
CPMV with this solution for two hours, followed by hydroxylamine 
hydrochloride reduction for 20 minutes, and then rigorous purification (as described in section 
2.17), produced gold coated CPMV nanoparticles as shown in Figure 4.19–B.  
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Initially, anionic gold(III) hydroxyl complex was electrostatically adsorbed onto the 
cationic surface of 
PA
CPMV particles, and then this was reduced under mild conditions to give 
metallic gold at the surface. The reaction was accompanied by a colour change from colourless 
to light purple as seen in Figure 4.20–C and the UV–vis spectrum exhibited a surface plasmon 
resonance band at ca. 630 nm as seen in Figure 4.21. Additionally, both experiment controls 
(vial A and B in Figure 4.20) were investigated by TEM, unstained images shown in Figure 
4.22 revealed a different morphology to that observed for the Au–CPMV particles (Figure 4.19-
B).  
 
Figure 4.20– Photographic images of gold coating reaction. (A) in the absence of PACPMV, (B) in 
the presence of CPMVwt and (C) with PACPMV forming Au–CPMV. Image was taken by Andrew 
Davis, Bio–imaging facilities at JIC. 
 
K2CO3 + 2H2O → H2CO3
 
+ 2KOH 
HCO3
– 
+ HAuCl4 → [AuCl4]
– 
+ H2CO3 
[AuCl4]
– 
+ xOH
–
 → Au(OH)xCly
–
 (x + y = 4) + (4–y)Cl– …………….(2) 
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Figure 4.21– UV–vis absorption spectrum of Au–CPMV showing plasmon resonance peak 
at ca. 630 nm for 67 nm diameter Au–CPMV. 
 
 
Unstained TEM images of Au–CPMV particles (Figure 4.19–B) confirmed that gold 
had been deposited on the surface and agreed with the DLS measurements. Unstained 
PA
CPMV 
was not visible by TEM. The gold coating on the virus capsid was rough with an irregular 
surface (Figure 4.19–inset) and the mineralization of the surface probably occurred by an 
Ostwald ripening process (McNaught & Wilkinson, 1997). The structural appearance of the Au–
CPMV particles is reminiscent of the morphological forms obtained when gold is electrolessly 
deposited onto the surface of gold nanoparticle seeded Chilo iridescent virus (Radloff et al, 
2005a). Control experiments, keeping all other reaction conditions the same, where either 
PA
CPMV was omitted (no virus) or CPMVwt was used, resulted in the immediate formation of a 
black precipitate of gold aggregates with a wide size distribution and irregular shapes as shown 
by TEM in (Figure 4.22). 
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Figure 4.22– Unstained TEM images of products from (A) all reagents for Au–CPMV synthesis 
except PACPMV (i.e. no virus) and (B) all reagents for Au–CPMV synthesis except that PACPMV 
was substituted by CPMVwt. In both cases, large aggregates and irregular shaped particles were 
observed. In (B) a different morphology to templated Au–CPMV was observed, as the aggregates 
are comprised of multiple small gold nanoparticles; examples of unmineralized CPMV are shown in 
the red circles. 
 
Au–CPMV particles suspended in buffer have a zeta potential of –46.9 ± 1.39 mV, of 
opposite sign to cationic 
PA
CPMV and significantly more negative than CPMVwt. The higher 
negative values for the mineralized particles may be a consequence of the presence of phosphate 
in the buffer passivating the metal surface and generating a greater apparent negative charge 
under the conditions of measurement. Zeta potential is also an indication that the colloids have 
good stability and no propensity to aggregate in buffer solution.  
The Au–CPMV particle size in buffer, as measured by DLS (Figure 4.23), shows an 
average hydrodynamic diameter of ca. 67 nm suggesting that the gold coating has a thickness of 
approximately 20 nm. The DLS polydispersity indicates that the particles are narrowly 
dispersed, in agreement with the observed TEM images, and that the coated CPMV particles are 
mineralized on their outer surfaces. The thickness of the gold coating can be controlled. 
Treatment of 
PA
CPMV under the standard conditions as described in the experimental section 
(4.2.12) gave a particle size of ca. 67±5 nm. Keeping all other conditions the same but reducing 
the volume of the gold solution aliquot by half gave particles of ca. 40 nm diameter, whereas 
doubling the gold solution aliquot gave much larger particles of ca. 300 nm diameter. 
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Figure 4.23– Dynamic light scattering (DLS) comparing CPMVwt and Au–CPMV. (A) 
hydrodynamic radius and (B) correlation plot. 
 
Energy dispersive X–ray spectroscopy (EDXS) and DLS confirmed the presence of 
gold on the external surface of Au–CPMV as shown in Figure 4.24. In addition, nanoparticle–
tracking analysis, based on laser light scattering microscopy, was also consistent with gold 
deposition (Figure 4.25). There was a significant increase in the relative refractive index of Au–
CPMV compared to CPMVwt and 
PA
CPMV. This analysis is also consistent with the 
mineralized particles being monodisperse as indicated by the particle size distribution; although 
there was a little non–specific aggregation under the measurement conditions employed. 
 
 
Figure 4.24– Energy dispersive X–ray spectroscopy of Au–CPMV particles. The arrow indicates the 
major gold peak. 
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Figure 4.25– Negative image of a freeze–frame from nanoparticle tracking analysis of Au–CPMV 
nanoparticles. The particles appear individually as point scatterers under Brownian motion with a 
high refractive index. 
 
Further, the CPMV coat protein of Au–CPMV was not detected immunologically 
(Figure 4.26). CPMVwt, 
PA
CPMV and Au–CPMV were spotted onto a nitrocellulose 
membrane, which, after blocking, was probed with polyclonal antibodies raised in rabbits 
against CPMV particles. In the case of CPMVwt and 
PA
CPMV a signal was obtained, 
confirming the presence of CPMV coat protein; for the Au–CPMV particles the coat protein 
was not accessible to the antibody presumably due to the metal coating. 
 
 
Figure 4.26– Immunological detection of coat protein for CPMVwt, PACPMV and Au–CPMV 
intact particles. In the latter case, coat protein is inaccessible due to the gold coating. 
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4.4.1.2 Au–CPMV functionalisation 
Au–CPMV particles were functionalised with a thiolated–oligosaccharide (1–thio–β–
D–maltoheptaose), as proof–of–principle that the surface can be further modified and 
characterised by mass spectrometry. After rigorous purification of the 
Oligosaccharide
Au–CPMV 
particles, MALDI–TOF mass spectrometry (Figure 4.27) showed the presence of peaks with 
m/z of 1191.453 [M+Na]
+
, 1207.430  [M+K]
+
 and 2373.803 [M2+K]
+
, consistent with 
functionalisation of the gold surface with the thiolated–oligosaccharide. In addition, Au–CPMV 
particles can be functionalised with cysteamine. The thiol group of the cysteamine binds to the 
gold surface; the amine group of the conjugated–cysteamine can then be reacted with an amine–
specific fluorescent dye confirming that the gold surface has been modified (Figure 4.28). The 
ease by which the surface gold can be addressed with thiolated molecules demonstrates the 
potential for the modification of the nanoparticle surface with a range of chemical moieties. 
Such modified particles have the potential for development in applications such as photothermal 
therapeutics and in biosensory devices. 
 
Figure 4.27– Mass spectrum of (top) negative control, i.e. Au–CPMV, and (bottom) OligosaccharideAu–
CPMV showing peaks 1191.453 [M+Na]+, 1207.430 [M+K]+ and 2373.803[M2+K]+. 
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Figure 4.28– UV–vis absorption spectrum of Au–CPMV (A) and CysteamineCPMV after reaction with 
amine–specific dye, DyLight–594–CysteamineAu–CPMV, (B). Right panel shows the corresponding 
photographic image confirming functionalisation of the gold surface with DyLight–594. 
 
4.4.1.3 PACPMV and pre–formed AuNP 
In order to establish whether pre–formed gold nanoparticles could interact with 
PA
CPMV, the polyelectrolyte–modified virus was incubated with citrate–capped gold 
nanoparticles (AuNP). The UV–vis spectrum presented in Figure 4.29 indicates that the 
interparticle distances in the tessellated–sphere are obviously less than the average particle 
diameter. This was further confirmed by the stained TEM images showed that large, 
hexagonally packed, tessellated–spheres had assembled that incorporated both virus and gold 
nanoparticles (Figure 4.30–B & C). These remarkable, spherical structures had diameters of up 
to several hundred nanometres. On mixing 
PA
CPMV with AuNP there was an immediate colour 
change from red to pale purple as shown in Figure 4.30–A. The colour of the solution of such 
aggregates depends on the nanoparticle spacing and on the size of gold nanoparticles. 
Nanoparticle aggregates of gold with interparticle distances substantially greater than the 
average particle diameter appear red with λmax ~ 520 nm, but as the interparticle distance in the 
aggregates decrease to less than approximately the average particle diameter, the colour 
becomes blue (Hainfeld & Powell, 2000; Nam et al, 2002). The 3–dimensional spherical shape 
was confirmed by scanning electron microscopy of sputter–coated particles (Figure 4.31).  
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Figure 4.29– UV–visible spectrum of the tessellated–spheres. Spectrum (1) CPMVwt (2) gold 
nanoparticles with absorbance max at 520 nm, (3) the incubation of PACPMV with AuNP after 2 
minutes and (4) after 24 hours incubation. 
 
 
Figure 4.30– Tessellated–spheres formation. (A) photographic image of (a) AuNP and (b) PACPMV 
mixed with AuNP. The colour change was immediate and corresponds to the self–assembly of 
tessellated–spheres. (B) Stained TEM image of a single tessellated–sphere showing the CPMV 
particles as hexagonally–packed mosaic pieces in a spherical arrangement together with gold 
nanoparticles and (C) tessellated–spheres of a range of sizes. The black spheres within the 
tessellated–sphere are gold nanoparticles. 
 
 
Figure 4.31– Scanning electron microscope and DLS analysis of the tessellated–spheres. (A) single 
sputter–coated tessellated–sphere on a mica surface and (B) DLS analysis of tessellated–spheres 
showing 5% of the sample is the size of CPMVwt and the tessellated–spheres have an 
hydrodynamic radius of 115–120 nm. 
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The colour of the tessellated–spheres–containing solution in this case indicates that the 
interparticle distances in the tessellated–sphere are obviously less than the average particle 
diameter, which is also evident from the TEM studies. However, control experiments (Figure 
4.32) showed that it was essential for both pre–formed PACPMV and AuNP to be present for 
self–assembly. Reaction of either: (a) citrate with PACPMV; (b) CPMVwt with both citrate and 
AuNP; or (c) PAH, citrate, CPMVwt and AuNP, resulted in no colour change and only gave, in 
each case, normal looking, non–self–assembled, virus particles as shown by TEM. Others have 
shown that CPMV (Li et al, 2008)
 
and turnip yellow mosaic virus (Li et al, 2009)
 
can be used to 
synthesise bio–colloidal composites based upon non–covalent interactions of the icosahedral 
plant viruses with poly(4–vinylpyridine). However, in these systems, in contrast to that reported 
here, the virus particles assemble on the surface of poly(4–vinylpyridine) polymer balls with 
hexagon–like packing to form “raspberry–like” structures. Recently, the electrostatic self–
assembly of virus–polymer complexes of Cowpea chlorotic mottle virus and cationic amine 
functionalised linear polymers, dendrons and dendrimers has been described, and the effect of 
polymer size and ionic strength has been reported (Kostiainen et al, 2011).
 
Hexagonal packing 
was observed within the virus–polymer structures but the structures were less symmetrical than 
those we observed. The mechanism of formation also must be different, as for 
PA
CPMV to form 
self–assembled structures; it was a requirement that AuNP were present. 
 
 
Figure 4.32– Uranyl acetate stained TEM images for PACPMV/AuNP control experiments. (A) 
citrate with PACPMV (no AuNP), (B) CPMVwt with both citrate and AuNP, (C) PAH, citrate, 
CPMVwt and AuNP. 
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4.4.2 Conclusion 
It has been shown that by increasing the surface negative charge of CPMV by chemical 
modification of lysines with succinamate was sufficient to promote surface mineralization under 
mild conditions. The CPMV–templated cobalt and iron oxide nanoparticles that were produced 
are monodisperse with a diameter of ca. 32 nm. Further, the iron oxide–CPMV surface can be 
readily modified by reaction with thiol–containing molecules. The magnetic properties for iron 
oxide–CPMV particles were established.  
A new approach has been described for the CPMV–templated synthesis of 
monodisperse gold nanoparticles. Cationic polyelectrolyte, poly(allylamine) hydrochloride, was 
electrostatically bound to the external surface of the virus capsid. The CPMV–polyelectrolyte 
conjugate, 
PA
CPMV, has an increased surface positive charge compared to wild–type and 
readily attracts anionic gold complexes to the surface. Gold(III) ions were then easily reduced, 
under mild conditions, to form a metallic gold layer on the external surface of the virus capsid. 
By varying reaction conditions there was some control over the thickness of the gold coating. 
Au–CPMV particles might be developed in the future for possible photothermal cancer 
treatment. The gold surface can be further modified with thiol reagents; here a thiolated–
oligosaccharide or cysteamine was used. In contrast, reaction of 
PA
CPMV with pre–formed gold 
nanoparticles of 10–18 nm diameter resulted in the self–assembly of beautiful, large, 
hexagonally packed, tessellated–spheres. The tessellated–spheres are yet to be explored for 
possible future applications. 
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5 Electroless metal deposition on CPMV 
5.1 Introduction   
Metallic nanoparticles have attracted much interest because of their size–dependent 
magnetic, optical and electrical properties that give them significant potential for applications 
such as data storage, catalysts and nanomagnets (Feldheim & Foss, 2002). Further, hollow 
metallic nanoparticles may offer enhanced properties, which may be useful in catalysis and as 
drug delivery vehicles (Kim et al, 2002; Liang et al, 2004; Lu et al, 2009). Such nanoparticles 
consume less material in their preparation and may be cheaper to produce than solid 
nanoparticles.
 
Examples of the use of biological entities in the synthesis of nanomaterials by 
deposition of metals from solution by direct reduction of the metal onto the biological template 
include: modification of the surface of Tobacco mosaic virus (Dujardin et al, 2003b; Knez et al, 
2006; Knez et al, 2003b; Schlick et al, 2005b); gold templated onto Chilo iridescent virus 
(Radloff et al, 2005b); templated synthesis of metallic coatings on genetically modified 
bacteriophage M13 (Flynn et al, 2003b).  
This chapter will describe the extension of the use of CPMV as a template for 
fabricating metallic nanoparticles without any prior genetic or chemical modification to the 
virus capsid and, importantly, without the need of peptides to act as nucleation sites as been 
previously discussed in chapter 3. Electroless deposition (ELD) is an autocatalytic redox 
process in which metal ions are chemically reduced to metal in the absence of an external 
current. ELD has become a commonly used process and allows the production of thin layers of 
metals and alloys with uniform thickness and composition (Mallory & Hajdu, 1996).
 
The 
metallization of CPMV by pre–activation of the capsid surface with palladium(II) followed by 
ELD of cobalt, nickel, iron, platinum, cobalt–platinum and nickel–iron at room temperature, 
resulted in monodisperse metallic nanoparticles by a method that is environmentally friendly, 
simple and quick.  
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5.2 Experimental  
5.2.1 Materials  
Sodium tetrachloropalladate, cobalt(II)chloride, nickel(II)chloride hexahydrate, 
chloroplatinic acid hexahydrate, dimethylaminoborane, sodium hypophosphite, maleic acid and 
boric acid were purchased form Sigma–Aldrich; ammonium chloride and iron(II) sulfate from 
BDH; nickel sulfate from Fisher Scientific; and trisodium citrate dihydrate from Riedel–de 
Häen. All were used as supplied without further purification. 
5.2.2 Pre–activation of CPMV with palladium  
CPMV particles (4 mg ml
–1
, 400 µl) suspended in 10 mM sodium phosphate buffer pH 
7.0, were incubated with 400 µl of 3 mM sodium tetrachloropalladate freshly prepared in Milli–
Q water. To prevent hydrolysis of palladate, the reaction pH was adjusted to 3.8, by dropwise 
addition of 1mM HCl, and 400 µl of aqueous 1 M NaCl was added. The reaction solution was 
incubated at ambient temperature with gentle stirring for 30 minutes. The 
Pd2+
CPMV particles 
produced were purified on PD–10 columns (GE Healthcare) equilibrated with saline solution 
(500 mM NaCl in Milli–Q water, pH 5.0), the eluted sample was dialysed on 100 kDa  
molecular weight cut–off membranes (Spectrum Labs) against saline solution for 4 hours. The 
Pd2+
CPMV particle integrity was established by TEM after uranyl acetate staining. Before the 
electroless deposition of the desired metals, 
Pd2+
CPMV had first to be reduced with 5 mM of 
either dimethylaminoborane (DMAB) or sodium hypophosphite, NaH2PO2. The reaction was 
allowed to proceed at ambient temperature for 30 minutes to generate Pd
0 
clusters at the surface, 
which in turn act as nucleation sites for metal deposition. Pd
0–CPMV was washed 3–5 times on 
100 kDa cut–off columns (Millipore). The Pd0–CPMV particle integrity was ascertained by 
TEM, EDXS, agarose gel electrophoresis and zeta potential measurements. 
5.2.3 ELD of metal coating 
Equal volumes of pre–activated Pd0–CPMV (2–5 mg ml–1) in saline solution (500 mM), 
aqueous sodium chloride solution (1M) and plating solution (containing metal salt, reducing 
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agent, ammonium chloride and trisodium citrate) were stirred for 2–3 minutes at ambient 
temperature. CPMV concentrations and reaction conditions are summarised in Table 5.1. All 
plating solutions were used within four days of their preparation. Metallized–CPMV particles 
were purified as described below.  
 
Metal Pd
0–CPMV 
(mg ml
–1
) 
Metal Salt 
(100 mM) 
Reductant 
(500 mM) 
NH4Cl Na3Citrate pH 
Co 3.2 CoCl2 DMAB 900 mM 170 mM 8.0 
Fe 4.5 FeSO4 NaH2PO2 900 mM 180 mM 8.1 
Ni 4.0 NiCl2 DMAB 900 mM 170 mM 8.0 
Pt 2.3 H2PtCl4 NaH2PO2 900 mM 170 mM 6.0 
Table 5.1– Pd0–CPMV concentration and plating solution composition. 
 
5.2.4 ELD of mixed metal coating 
5.2.4.1 CoPt–CPMV  
Pre–activated Pd0–CPMV (400 µl of 4.5 mg ml–1, 1 ml), suspended in 500 mM saline 
solution pH 5.0, was stirred at ambient temperature with 400 µl of aqueous sodium chloride 
solution (1M) and a mixture of 200 µl each of cobalt and platinum plating solutions at pH 8.0 
for 2–4 minutes. 
5.2.4.2 NiFe–CPMV 
A 1:1:1 (v/v/v) mixture of pre–activated Pd0–CPMV (3.5 mg ml–1, 1 ml), suspended in 
500 mM  saline solution pH 5.0, aqueous sodium chloride solution (1M) and a NiFe plating 
solution, prepared by adaptation of a published procedure (Yi et al, 2010), [comprising nickel 
sulfate (100 mM), ferrous sulfate (100 mM), sodium hypophosphite (100 mM), trisodium citrate 
(200 mM), maleic acid (50 mM) and boric acid  (200 mM)] at pH 6 was gently stirred, at 
ambient temperature, for 2–4 minutes. 
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5.2.5 Purification of metallized particles 
After reaction, solutions were spun at 14000 rpm (bench top, Eppendorf) for 20 minutes 
to remove any large aggregates, the supernatant was collected and purified on PD–10 columns, 
and eluted samples were concentrated on 100 kDa cut–off columns before being layered onto 5 
ml 10%–50% sucrose gradients as described in section 2.17.1. After further concentration on 
100 kDa cut–off columns, the concentration of metallized–CPMV was determined 
photometrically at 260 nm. Recovery of metallized–CPMV was approximately 50–70% based 
on the initial virus concentration.  
5.3 Results and Discussion  
5.3.1 Pd2+CPMV activation  
It has been previously reported that amine–functionalised surfaces pre–activated with 
Pd
0
 clusters promote the ELD of metals (Dressick et al, 1994; Falkner et al, 2005; Kind et al, 
1998).
 
Incubation of CPMV particles with a sodium tetrachloropalladate solution, followed by 
chemical reduction with DMAB or NaH2PO2, at pH 3.8, is expected to produce islands of 
palladium clusters on the virus capsid surface. These then act as nucleation sites for the 
subsequent ELD of metal. Only metallic Pd
0
 can act as the catalyst for the metallization but not 
Pd
2+
. 
 
   
  
The virus particles were very stable under the reaction conditions employed; neither 
reducing agents nor ELD solutions disrupted the virus capsid structure. The integrity of the 
initially isolated 
Pd2+
CPMV particles was confirmed by uranyl acetate negatively stained TEM 
(Figure 5.1–A). The zeta potential of –10.6 ± 1.5 mV was similar to that of wild–type (~ –12 
mV). 
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On reduction of 
Pd2+
CPMV, islands of Pd
0
 clusters distributed over the capsid surface 
were formed but these did not fully coat the virus. The unstained TEM image for Pd
0–CPMV 
revealed dark clusters scattered on the virion surface (Figure 5.1–B). Note that only on 
reduction are the particles visible in the unstained image. On reduction of 
Pd2+
CPMV to Pd
0–
CPMV
 
there was no significant change in the particle size (Figure 5.2). Furthermore, EDXS 
confirmed that palladium is present on the external surfaces of the particles (Figure 5.3–B). The 
zeta potential for Pd
0–CPMV particles were considerably more negative than those for wild–
type and 
Pd2+
CPMV particles (Figure 5.4) and the scan consists of two peaks, this might be 
because two different surfaces are present on the particles (protein & Pd
0
); the suspension of 
Pd
0–CPMV particles in buffer is a stable colloid. Further, agarose gel electrophoresis of Pd0–
CPMV stained with ethidium bromide showed some fluorescent intensity from a band of 
different mobility to wild–type, suggesting that the Pd0–CPMV surface has some porosity 
sufficient to allow intercalation of ethidium bromide with the encapsidated RNA (Figure 5.5). 
This is consistent with incomplete coverage of the capsid surface with palladium clusters. When 
the gel was stained with Coomassie blue, colouration was observed for each of the Pd
0–CPMV 
and the wild–type particles, again consistent with the virus protein surface not being fully 
coated with palladium.   
 
Figure 5.1– TEM image of (A) Pd2+CPMV stained with 2 % uranyl acetate solution; (B) unstained 
Pd0–CPMV particles. 
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Figure 5.2– DLS comparing wild–type CPMV and Pd0–CPMV particles. 
 
 
 
Figure 5.3– EDX spectrum of Pd0–CPMV metallized particles. (A) CPMVwt and (B) Pd0–CPMV. 
Major palladium peak indicated by arrow. 
 
 
 
Figure 5.4– Zeta potential measurement of ( A) Pd2+CPMV particles , (B) Pd0–CPMV particles 
suspended in buffer at pH 7.0. 
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Figure 5.5– Agarose gel (1.2%) of CPMV particles visualised by (A) ethidium bromide staining, (B) 
Coomassie staining. Lane 1, CPMVwt; 2, Pd0–CPMV. 
 
5.3.2 Metallization of CPMV  
For the metallization process, the pre–activated Pd0–CPMV particles were dispersed in 
ELD solutions (Table 5.1). The reaction time was generally restricted to two minutes and 
deposition was stopped by washing the particles thoroughly with Milli–Q water. The 
metallization of CPMV particles was confirmed by TEM (Figure 5.6); unstained images reveal 
dense, monodisperse, metallized nanoparticles of ca. 31–34 nm. CPMVwt cannot be visualised 
in an unstained TEM image. Control experiments performed under identical conditions, with 
wild–type CPMV, without CPMV, and without Pd0–CPMV particles, all gave non–specific, 
visible bulk precipitation of metal with a wide size distribution as observed by TEM (data not 
shown). Thus, pre–activation of CPMV is essential for the controlled nanoshell formation. 
EDXS confirmed that cobalt, iron, nickel, and platinum coated the external surfaces of the 
respective Co–, Fe–, Ni–, Pt–, CoPt and NiFe–CPMV nanoparticles (Figure 5.7). The DLS of 
the particles in buffer confirmed the change in the particle size implying that the coating on each 
particle is approximately 2–3 nm (Table 5.2). The DLS polydispersity shows that the particles 
are monodisperse and that the particles are uniformly metallized on their outer surfaces, in 
agreement with the observed TEM images.  
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  CPMVwt 
diameter 
(nm) 
Polydispersity 
(%) 
Metallized 
particles 
(nm) 
Polydispersity 
(%) 
Zeta 
potential 
(mV) 
Ni–CPMV  27.4 ± 0.4 14.1 32.4 ± 0.4 20.9 –44.0 ± 2.0 
Co–CPMV  26.8 ± 0.5 14.3 32.0 ± 0.5 13.3 –41.2 ± 2.5 
Pt–CPMV  27.2 ± 0.5 14.0 32.6 ± 0.5 16.3 –33.2 ± 2.5 
Fe–CPMV  27.6 ± 0.3 9.0 31.0 ± 0.3 14.0 –39.7 ± 1.8 
NiFe–
CPMV 
 27.9 ± 0.5 10.0 31.4 ± 0.5 24.6 –66.3 ± 2.4 
CoPt–
CPMV 
 28.6 ± 0.3 12.2 34.4 ± 0.3 13.6 –61.7 ± 2.2 
Pd0–CPMV  29.6 ± 0.3 13.5 30.2 ± 0.1 14.7 –19.0 ± 0.5 
Table 5.2– Diameter and polydispersity measured by dynamic light scattering of wild–type CPMV 
and metallized–CPMV, and zeta potential of metallized–CPMV nanoparticles. 
 
 
Figure 5.6– Unstained TEM images of metallized CPMV particles (A) Co–CPMV, (B) Fe–CPMV, 
(C) Ni–CPMV, (D) Pt–CPMV, (E) CoPt–CPMV, and (F) NiFe–CPMV. 
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Figure 5.7– EDX spectrum of metallized CPMV particles (A) Co–CPMV, (B) Fe–CPMV, (C) Ni–
CPMV, (D) Pt–CPMV, (E) NiFe–CPMV and (F) CoPt–CPMV metallized particles. Major metal 
peaks indicated by arrows. 
 
The zeta potential for suspensions of the metallized particles in buffer are considerably 
more negative than that for CPMVwt, and show that the colloids have good stability (Table 
5.3). In addition, the CPMV coat protein of Co–CPMV, Fe–CPMV, Ni–CPMV, Pt–CPMV, 
CoPt–CPMV and NiFe–CPMV was not detected immunologically implying that the coat 
protein was not accessible to the antibody as it is coated with metal (Figure 5.8). In addition, 
when each of the metallized particles was observed by agarose gel electrophoresis with 
coomassie blue staining, no protein bands were observed, this is consistent with the virus 
protein surface not being accessible to the stain as it is coated with metal (Figure 5.9). However, 
when the electrophoretic gel was stained with ethidium bromide, slight fluorescent intensity was 
observed, in some cases, suggesting that the metal shell may have limited porosity sufficient to 
allow intercalation of ethidium bromide with the encapsidated RNA. 
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Figure 5.8– Immunological detection of CPMV coat protein of metallized particles spotted on a 
nitrocellulose membrane probed with polyclonal antibodies raised against CPMV. Only CPMVwt 
was detected. 
 
 
 
 
 
Figure 5.9– Agarose gel (1.2%) of CPMV particles visualised by ethidium bromide staining (A) and 
Coomassie blue staining (B). Lane 1, wild–type CPMV; 2, Co–CPMV; 3, Fe–CPMV; 4, Ni–CPMV; 
5, Pt–CPMV; 6, CoPt–CPMV; and 7, NiFe–CPMV. 
 
Nanoparticle tracking analysis (NTA) was also consistent with metallization of the virus 
(Figure 5.10). There was a significant increase in the relative refractive index compared to wild–
type particles. The analysis is also consistent with the metallized particles being monodisperse 
as indicated by the particle size distribution. For Ni–CPMV particles, atomic force microscopy 
(AFM) images confirmed the uniformity of the metallized particles (Figure 5.11). 
CHAPTER 5 
 
121 
 
  
 
Figure 5.10– Negative image of a freeze–frame from nanoparticle tracking analysis for metallized–
CPMV nanoparticles showing that the particles appear individually as point scatterers under 
Brownian motion with a high refractive index. (A) Co–CPMV; (B) Ni–CPMV; (C) CoPt–CPMV. 
 
 
 
Figure 5.11– AFM image for Ni–CPMV dried on a glass slide and its corresponding 3D image. 
 
It has been reported that the use of different reductants, DMAB or hypophosphite, can 
result in different sized palladium clusters forming on a surface (Knez et al, 2003a).
 
However, it 
was observed that there was no significant change in the size of the Pd
0–CPMV particles on 
varying the reductant. However, in the case of metallization with cobalt, for example, the 
thickness of the metallic coating was dependent on the incubation time with ELD solution, 
growing from about 2 nm after two minutes incubation to 9 nm after 10 minutes (Table 5.3); 
hence providing some control over the nanoparticle shell thickness. 
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Particle  Diameter (nm) Polydispersity (%) 
CPMVwt  27.6 ± 0.2 9.0 
Pd
0–CPMV  30.2 ± .02 13.9 
Co–CPMV (2 minutes)  32.0 ± 0.5 13.3 
Co–CPMV (3 minutes)  37.6 ± 0.2 25.1 
Co–CPMV (5 minutes)  39.2 ± 0.3 18.5 
Co–CPMV (10 minutes)  46.4 ± 0.5 13.3 
Table 5.3– Diameter and polydispersity measured by dynamic light scattering of wild–type CPMV 
and Co–CPMV nanoparticles on variation of incubation time with the ELD solution. 
 
5.4 Conclusions 
The work described in this chapter has extended the utilisation of the CPMV capsid for 
templated nanoparticle fabrication. ELD of Co, Ni, Fe, Pt, CoPt and NiFe on Pd
0–pre–activated 
CPMV resulted in the formation of monodisperse, metallic–shells fully coating the virus capsid 
external surface. The metallization process is simple, quick and efficient and can be performed 
under conditions that are environmentally friendly. The particles may have some applications as 
catalysts, for example, Pt–CPMV particles might be useful as catalyst of H2 production. The 
particles syntheses require less material than their synthetic particles and they have larger 
surface area. 
 
 
 
  
CHAPTER 5 
 
123 
 
5.5 References  
Aljabali AAA, Barclay JE, Lomonossoff GP, Evans DJ (2010) Virus templated metallic 
nanoparticles. Nanoscale 2: 2596–2600 
 
Aljabali AAA, Shah SN, Evans–Gowing R, Lomonossoff GP, Evans DJ (2011) Chemically–
coupled–peptide–promoted virus nanoparticle templated mineralization. Integrative Biology 3: 
119–125 
 
Dickerson MB, Sandhage KH, Naik RR (2008) Protein– and Peptide–Directed Syntheses of 
Inorganic Materials. Chemical Reviews 108: 4935–4978 
 
Dressick WJ, Dulcey CS, Georger JH, Calabrese GS, Calvert JM (1994) Covalent Binding of 
Pd Catalysts to Ligating Self–Assembled Monolayer Films for Selective Electroless Metal–
Deposition. J Electrochem Soc 141: 210–220 
 
Dujardin E, Peet C, Stubbs G, Culver JN, Mann S (2003) Organization of Metallic 
Nanoparticles Using Tobacco Mosaic Virus Templates. Nano Letters 3: 413–417 
 
Evans DJ (2008) The bionanoscience of plant viruses: templates and synthons for new 
materials. Journal of Materials Chemistry 18: 3746–3754 
 
Falkner JC, Turner ME, Bosworth JK, Trentler TJ, Johnson JE, Lin T, Colvin VL (2005) Virus 
Crystals as Nanocomposite Scaffolds. Journal of the American Chemical Society 127: 5274–
5275 
 
Feldheim DL, Foss CA (2002) Metal nanoparticles: synthesis, characterization, and 
applications,  New York: Marcel Dekker. 
 
Flynn CE, Lee SW, Peelle BR, Belcher AM (2003) Viruses as vehicles for growth, organization 
and assembly of materials. Acta Mater 51: 5867–5880 
 
Kim SW, Kim M, Lee WY, Hyeon T (2002) Fabrication of hollow palladium spheres and their 
successful application to the recyclable heterogeneous catalyst for Suzuki coupling reactions. 
Journal of the American Chemical Society 124: 7642–7643 
 
Kind H, Bittner AM, Cavalleri O, Kern K, Greber T (1998) Electroless deposition of metal 
nanoislands on aminothiolate–functionalized Au(111) electrodes. J Phys Chem B 102: 7582–
7589 
 
Knez M, Bittner AM, Boes F, Wege C, Jeske H, Maiss E, Kern K (2003a) Biotemplate 
synthesis of 3–nm nickel and cobalt nanowires. Nano Letters 3: 1079–1082 
 
Knez M, Kadri A, Wege C, Gosele U, Jeske H, Nielsch K (2006) Atomic layer deposition on 
biological macromolecules: Metal oxide coating of tobacco mosaic virus and ferritin. Nano 
Letters 6: 1172–1177 
 
Knez M, Sumser MP, Bittner AM, Wege C, Jeske H, Hoffmann DMP, Kuhnke K, Kern K 
(2003b) Binding the Tobacco Mosaic Virus to Inorganic Surfaces. Langmuir 20: 441–447 
 
Liang HP, Zhang HM, Hu JS, Guo YG, Wan LJ, Bai CL (2004) Pt hollow nanospheres: Facile 
synthesis and enhanced electrocatalysts. Angew Chem–Int Edit 43: 1540–1543 
 
CHAPTER 5 
 
124 
 
Lu W, Xiong C, Zhang G, Huang Q, Zhang R, Zhang JZ, Li C (2009) Targeted photothermal 
ablation of murine melanomas with melanocyte–stimulating hormone analog–conjugated 
hollow gold nanospheres. Clin Cancer Res 15: 876–886 
 
Mallory GO, Hajdu JB (eds) (1996) Electroless Plating: Fundamentals and Applications. 
Norwich, New York: Noyes Publications/ William Andrew Publishing, LLC 
 
Radloff C, Vaia RA, Brunton J, Bouwer GT, Ward VK (2005) Metal nanoshell assembly on a 
virus bioscaffold. Nano Letters 5: 1187–1191 
 
Rosi NL, Chen CL (2010) Peptide–Based Methods for the Preparation of Nanostructured 
Inorganic Materials. Angew Chem–Int Edit 49: 1924–1942 
 
Schlick TL, Ding ZB, Kovacs EW, Francis MB (2005) Dual–surface modification of the 
tobacco mosaic virus. Journal of the American Chemical Society 127: 3718–3723 
 
Shah SN, Steinmetz NF, Aljabali AA, Lomonossoff GP, Evans DJ (2009) Environmentally 
benign synthesis of virus–templated, monodisperse, iron–platinum nanoparticles. Dalton 
Transactions: 8479–8480 
 
Yi J, Lee S, Kim J, Lee S (2010) Fabrication of ultrafine hollow Ni and Ni/Fe fibers and their 
dispersion characteristics in the epoxy matrix. Surface and Coatings Technology 204: 1419–
1425 
 
 
 
CHAPTER 6 
 
125 
 
6 Empty Virus–like particles (eVLPs) 
6.1 Introduction  
Virus–like particles (VLPs) are a subclass of virus nanoparticles; their external 
structures are identical to native viruses, but they are devoid of genetic material and thus cannot 
replicate. VLPs are often spontaneously formed when virus structural proteins are produced in 
heterologous expression systems (E. coli, yeast, baculoviruses and plant based expression 
system) (Mason et al, 2006). VLPs hold great potential in vaccine development, drug 
encapsulation and drug delivery (Ren et al, 2006a). For example, Tomato bushy stunt virus 
(TBSV) has been genetically engineered to display antigenic peptide sequences from Human 
immunodeficiency virus–1 (HIV–1) and induces an immune response (Joelson et al, 1997; 
Ludwig & Wagner, 2007; Plummer & Manchester, 2010). Such molecules will retain the 
desirable features of native virus but without their infectivity.  
The encapsulation of small molecules within host particles is of great potential in the 
field of nanotechnology. The formed nanoparticles are highly monodisperse as they are 
constrained by the host size and shape. There are many kinds of potential hosts including 
protein cages, viral capsids, lipid coats, polymers, and synthesized organic capsid–like 
structures (discussed in more detail in the Introduction). The internal environment of protein 
cages is separated from the outside by a porous protein shell that restricts the types of 
encapsulated molecules that can enter. Self–assembled empty virus–like particles (eVLPs) can 
be used as constrained environments for the preparation of nanomaterials and encapsulation of 
foreign materials (cargo) and have potential applications in drug delivery (Conn & Rebek, 
1997).  
The possibility to synthesize nanoparticles within the empty capsids of eVLPs is 
advantageous as the capsid constrains the size of the cargo within; eVLPs have been used to 
encapsulate foreign molecules in vitro (Douglas & Young, 1999). However, there is to date no 
in vitro study on material loading of CPMV eVLPs. This chapter will focus on the synthesis and 
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characterisation of cobalt and iron oxide nanoparticles produced within highly monodisperse 
size–constraining CPMV eVLPs. In addition, the internal chemistry of eVLPs and drug loading 
within the cavity will be explored. The coat protein of CPMV eVLPs has an inner diameter of 
~25–27 nm and act as size–limiting vessels for metallic core nanoparticle formation. The 
monodispersity of the particles, along with their nano–sized dimensions, are attractive features 
for material synthesis and drug delivery applications, which will be explored in this chapter.  
6.1.1 CPMV eVLPs  
The recent development of a method for the production of large quantities of CPMV 
eVLPs in plants (Saunders et al, 2009) was the motivation behind the research described in this 
chapter. The mature large (L) and small (S) proteins are produced by the cleavage of the 
precursor (VP60) by the action of a virus–encoded proteinase (24K proteinase). CPMV eVLP 
production takes advantage of the highly efficient plant transient expression system, pEAQ–HT 
(Sainsbury & Lomonossoff, 2008; Sainsbury et al, 2009). The pEAQ–HT system is used to 
simultaneously express the VP60 coat protein precursor and the 24K proteinase in plants via 
agro–infiltration. Efficient processing of VP60 to the L and S proteins occurs, leading to the 
formation of eVLPs (Montague et al, 2011; Saunders et al, 2009). The simplified process is 
depicted in Figure 6.1. CPMV eVLPs possess the same structure as CPMVwt but they lack the 
genetic material within the capsid as shown in Figure 6.2.  
 
Figure 6.1– Schematic representation of the production of eVLP using pEAQ–HT system. 
Adapted from (Saunders et al, 2009). 
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Figure 6.2– Cryo–EM reconstruction of CPMV particles. Purified particles were flash–frozen in 
vitreous ice, and then subjected to cryo–electron microscopy. (A) reconstruction of CPMVwt 
exterior, (B) reconstruction of CPMV eVLPs, (C) internal view of CPMV eVLPs showing empty 
capsid and (D) average reconstruction of CPMVwt. Kyle Dent and Neil Ranson, University of 
Leeds performed cryo–EM and computational analysis.  
 
6.2 Experimental  
Throughout this chapter, superscript following the virus name denotes molecules 
attached to the external surface and subscript denotes molecules within or attached to the 
interior of the capsid 
6.2.1 CPMV eVLP production 
CPMV eVLPs were produced using the pEAQ–HT system to simultaneously express 
the VP60 coat protein precursor and the 24K proteinase in plants via agro–infiltration. CPMV 
eVLPs were isolated from plants and purified by methods similar to those used for wild–type 
CPMV (J. Wellink, 1998) but omitting the chloroform step. The agroinoculation and eVLPs 
extraction was done in collaboration with Miss Pooja Saxena and Mrs Elaine Barclay, 
Biological Chemistry, John Innes Centre, UK). 
Particle integrity was confirmed by TEM, gel electrophoresis and DLS. The eVLPs 
were stored in 10 mM sodium phosphate buffer pH 7.0 at 4 ºC. The concentration of the eVLPs 
can be calculated from their UV–vis absorbance at 280 nm (Figure 6.3) using an extinction 
coefficient ε of CPMV eVLPs at λ280 = 1.28 ml mg
–1
cm
–1
. The eVLPs were purified further after 
the final ultracentrifuge step using a combination of dialysis and gel filtration. The 
concentration was determined using UV–Vis (see section 2.9). 
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Figure 6.3– UV–vis spectrum of CPMV eVLPs (red), with a maximum at 280 nm from protein and 
wild–type CPMV (blue) with a maximum at 260 nm arising from internal RNA. 
 
6.2.2 Encapsulation of cobalt within CPMV eVLPs (VLPscobalt) 
CPMV eVLPs (1 mg, 0.5 ml) suspended in 10 mM sodium phosphate buffer pH 7.0 
were incubated with a final concentration of aqueous cobalt chloride solution of 10 mM at 
ambient temperature while gently stirring. After 30–40 minutes, the sample was purified on 
PD–10 desalting columns (GE Healthcare). The eluted sample was washed twice with MilliQ 
water (3 ml each) and concentrated in 10 mM sodium phosphate buffer by centrifugal 
ultrafiltration. The sample was then incubated with a freshly prepared aqueous solution of 
sodium borohydride to a final concentration of 5 mM for a further 30 minutes at ambient 
temperature. The cobalt–loaded particles (VLPscobalt) were dialyzed overnight using 100 kDa 
molecular–weight cutoff membranes (Float–A–LyzerG2, Spectrum Laboratories) against 10 
mM sodium phosphate buffer pH 7.0 or layered onto sucrose gradient (section 2.17.1). The 
VLPscobalt were concentrated by centrifugal ultrafiltration using 100 kDa molecular–weight 
cutoff columns (Millipore). The yield of VLPscobalt was 70% relative to the initial eVLP 
concentration as determined by UV–vis spectrophotometry. A control experiment, under 
identical conditions but using RNA–1 containing particles (Bottom component), gave visible 
bulk precipitation with a wide size distribution of particles as confirmed by DLS and TEM. 
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6.2.3 Encapsulation of iron oxide within CPMV eVLPs (VLPiron oxide) 
CPMV eVLPs (1 mg, 3 ml) suspended in 10 mM sodium phosphate buffer pH 7.0 were 
treated with a solution of ferric and ferrous sulfate in a molar ratio of 2:1 (10 mM: 5 mM), 
which favours the formation of Fe3O4; the pH after the addition was 3.5–3.8. The mixture was 
incubated overnight (~15 hours) while gently stirring at 4 °C. The particles were then washed 
twice with MilliQ water on 100 kDa cutoff columns (Millipore). The pH was raised to 10.1 by 
the gradual addition of 1 mM sodium hydroxide, and the particles were kept at this pH for 60–
70 minutes. A combination of dialysis (100 kDa membrane) and sucrose gradient was used to 
purify the particles (see section 2.17.1). 175 μl fractions containing mineralized particles were 
collected and dialysed against 10 mM sodium phosphate buffer using 100 kDa (molecular–
weight cut–off membranes) (Float–A–Lyzer G2, Spectrum Laboratories). The yield of VLPiron 
oxide was 30–40% relative to the initial eVLP concentration as determined by UV–vis 
spectrophotometry. A control experiment, with the same concentration of ferric/ferrous ions at 
the same pH but without the eVLPs (no virus particles), was performed under the same reaction 
conditions. An orange colour was observed and DLS indicated aggregation of iron oxide 
particles with a wide range of particle size distribution. 
6.2.4 Mössbauer analysis of VLPiron oxide 
Prof. Dave Evans and Mrs Elaine Barclay conducted Mössbauer experiments. The 
particles were analysed as described in section 2.13. 
6.2.5 Vibrating sample magnetometer (VSM) measurements of VLPiron oxide  
The particles were analysed as described in section 2.14. (The magnetic measurements 
were conducted as a collaborative project with Drs. Oscar Céspedes and Sarah Staniland, 
School of Physics and Astronomy, University of Leeds, United Kingdom). 
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6.2.6 Staining for cobalt and iron within eVLPs 
VLPcobalt and VLPiron oxide particles were probed for cobalt and iron using the appropriate 
stain as described in section 2.17, for immunological detection of the coat protein see section 
2.13.3.  
6.2.7 Biotinylation of eVLPs (BiotinVLPs) 
CPMV eVLPs and VLPcobalt particles were biotinylated using an adaptation of a 
standard procedure (Steinmetz et al, 2006a). In brief, particles suspended in 10 mM sodium 
phosphate buffer pH 7.0 were reacted with a 2000 molar excess of biotin–N–
hydroxysuccinimide ester (Aldrich) dissolved in dimethylformamide (DMF); the final 
concentration of DMF: water was adjusted to 10% (v/v). The reaction was left overnight at 4 
°C, and then the 
Biotin
VLPs and 
Biotin
VLPscobalt were dialyzed using 100 kDa molecular–weight 
cut–off membranes (Float–A–Lyzer G2, Spectrum Laboratories) against 10 mM sodium 
phosphate buffer for 2 days. The sample was concentrated and the concentration of eVLPs 
determined from absorption at 280 nm. The binding of each 
Biotin
VLPscobalt or 
Biotin
VLPs to a 
streptavidin–modified chip was monitored by surface plasmon resonance (SPR). 
6.2.8 Surface plasmon resonance (SPR) 
Biotin
VLPs samples were spotted onto a series S Sensor Chip SA (Biacore); the chip has 
a carboxymethylated dextran matrix pre–immobilized with streptavidin. Binding was measured 
in response units (RU). The instrument is a four–flow cell system (each flow cell volume is 0.06 
ml) equipped with a temperature control unit and an optical system to measure the molecular 
interaction occurring on the sensor chip in real–time. The instrument was used in manual run 
mode with a flow rate of 10 μl/min, at ambient temperature, with PBS pH 7.4 as running buffer. 
Flow cell 1 was a negative control with biotin–N–hydroxysuccinimide ester, flow cell 2 a 
positive control with multi–injection steps using BiotinVLPs with a contact time of 1 minute until 
each run reached saturation (the overall time for chip saturation was 360 seconds). Flow cell 3 
and 4 showed the sensogram presented in Figure 6.9 during association and dissociation 
CHAPTER 6 
 
131 
 
measurements of 
Biotin
VLPs and 
Biotin
VLPcobalt
 
on a streptavidin–modified chip. The association is 
measured at approximately the same concentration as determined by UV–vis 
spectrophotometry. 
6.2.9 Infusion of rhodamine or doxorubicin into CPMV eVLPs  
1–2 mg ml–1 CPMV eVLPs were incubated with a 2000:1 molar ratio of rhodamine 
hydrochloride or doxorubicin hydrochloride dissolved in DMSO. The DMSO level was adjusted 
to 10–20 % (v/v), and the reaction was left to proceed at 4 ºC overnight (12–16 hours). The 
samples (VLPsrhodamine or VLPsdox) were then purified on PD–10 gel filtration columns pre–
equilibrated with 10 mM sodium phosphate buffer pH 7.0. The eluted fractions were collected 
and dialysed for 2 days at ambient temperature against 10 mM sodium phosphate buffer pH 7.0. 
The rhodamine or doxorubicin was quantified by fluorescence measurement. VLPsrhodamine were 
measured at an excitation wavelength of λ500 nm and extinction coefficient of 80000 M
–1 
cm
–1
. 
For VLPsdox the extinction coefficient ε484 is 13500 M
–1
 cm
–1
. 
As a control experiment, the bottom component (which contains RNA–1) was treated as 
described above. 
6.2.10 Gemcitabine and cisplatin loading 
CPMV eVLPs (1 mg ml
–1
) suspended in Milli–Q water just prior to the experiment 
were incubated with an aqueous solution of 0.5 mg of gemcitabine or cisplatin in 0.2 ml Milli–
Q water and kept in a shaker at 4 °C. After overnight incubation, the VLPsdrug
 
were washed once 
with Milli–Q water using 100–kDa cutoff membranes, the recovered particles were then used 
for the LBL experiment as described below. As wild–type CPMV particles contain ~10% 
eVLPs, bottom component particles (containing RNA–1) were used as a negative control. 
6.2.11 LBL formation onto eVLPsdrug 
Layer–by–layer (LBL) assembly was used to prepare polyelectrolyte multilayer–coated 
CPMV eVLPs. A solution of the cationic polyelectrolyte (PAH) (1 mg) dissolved in 1 ml of 
aqueous 0.25 M NaCl was prepared and added to 2 mg ml
–1
 CPMV eVLPsgemcitabine suspended in 
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Milli–Q water just prior to the reaction. The cationic polyelectrolyte was allowed to adsorb onto 
the virus capsid for 15–20 minutes while stirring at 2000 rpm at ambient temperature. The 
PAH
VLPsgemcitabine were washed 4 times with Milli–Q water using 300 kDa cut–off membranes 
(Sartorius Stedim Biotech). 
PAH
VLPsgemcitabine were re–dispersed in Milli–Q water by vortexing. 
Before the next polyelectrolyte coating step, the washing process was repeated twice to remove 
any non–adsorbed cationic polyelectrolyte. Deposition of anionic polyelectrolyte (PSS; 1mg ml–
1
 solution containing 0.25 M NaCl) was carried out using the same approach as for the first 
layer. The layer deposition was repeated as in the first cycle on the recovered 
(PAH/PSS)1
VLPsgemcitabine
 
to generate thicker multi–polyelectrolyte coatings denoted 
(PAH/PSS)2
VLPsgemcitabine. Particle integrity was investigated and recorded (see result section). 
6.2.12 In vitro gemcitabine release and quantification  
The 
(PAH/PSS)1 or 2
VLPsgemcitabine was investigated under simulated physiological conditions 
at pH 7.4 and in an acidic environment (sodium acetate buffer, pH 5.3 as prepared in section 
2.5) at 37 °C to assess the feasibility of drug release from CPMV eVLPs.  
As gemcitabine is easily tracked due to its fluorescence, it was selected to demonstrate 
proof–of–principle in vitro gemcitabine release. The (PAH/PSS)2VLPsgemcitabine
 
 were re–suspended 
in 5 ml of 0.15 M sodium phosphate buffer pH 7.4 and transferred into a dialysis cassette (MW 
cut–off 100 kDa). The cassette was placed in 50 ml of 0.150 M sodium phosphate buffer pH 7.4 
or in sodium acetate buffer at pH 5.3. The release study was performed at 37 °C in a Thermo 
Micromixer (FINEPCR) incubator shaker. 10 µl of 
(PAH/PSS)2
eVLPsgemcitabine (inside the dialysis 
membrane) was removed at set time points and analysed by agarose gel electrophoresis to 
monitor the electrolyte break down. After 24 hours incubation, the native intact form of eVLPs 
was observed by agarose gel electrophoresis (see results section). The gemcitabine was 
quantified from the accumulated dialysis solution using a molar extinction coefficient of ε299= 
5710 M
–1
 cm
–1
 (Lammers et al, 2009). 
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6.2.13 Internal chemistry (modifying internal cysteines) 
CPMV eVLPs (1–1.5 mg, 1 ml) suspended in 0.1M sodium phosphate buffer pH 7.0 
were incubated with a 2000 molar excess of DyLight–488 maleimide (Thermo Scientific) in 
DMSO. The final concentration of DMSO was adjusted to 10% (v/v). The reaction was left to 
proceed for 8 hours or overnight (~15 hours) while gently stirring at 4 °C. A combination of 
dialysis (100 kDa membrane), PD–10 gel filtration columns and sucrose gradient was used (2.1 
ml 10%–50% sucrose gradients centrifuged at 137000 g for 1.5 hours at 4 ºC; 175 μl fractions 
containing VLPDyLight–488 were collected and dialysed against 10 mM sodium phosphate buffer 
for 48 hours using 100 kDa molecular–weight cut–off membranes (Float–A–Lyzer G2, 
Spectrum Laboratories)). The yield of VLPDyLight–488 was 60% relative to the initial eVLP 
concentration as determined by UV–vis spectrophotometry. 
Reducing conditions: the crystal structure of CPMVwt revealed Cys–187 and Cys–355 
formed disulfide bonds. Therefore, the same approach described above was repeated with the 
addition of a final concentration of 10 mM tris(2–carboxyethyl)phosphine (TCEP) to cleave the 
disulfide bond and make more cysteine thiol groups available for chemical modification. 
6.2.14 A20FMDV2VLPs   
Two approaches have been adopted to either couple the peptide (A20FMDV2) to the 
eVLPs surface, using SPDP as described in section 2.16 or alternatively for simplicity, as 
described here, a one–step reaction to form a thioester bond, section 2.14. Carboxylate groups 
on the external surface of CPMV particles were derivatised through the formation of an active 
ester intermediate using EDC (Hermanson, 2008). EDC and A20FMDV2 peptide in 10 mM 
sodium phosphate buffer pH 7.0, both in 2000 molar excess, were added to CPMV eVLPs. The 
reaction was stirred overnight at 4 °C and the 
A20FMDV2
eVLPs particles were purified and 
concentrated as described in the general methods section. The yield of the conjugated particle 
was between 80–90% based on the initial virus concentration.  Modified particles were 
characterised by agarose gel electrophoresis and their integrity was confirmed by TEM. 
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6.2.15 A20FMDV2VLPs peptide quantification 
The number of peptides per particle was determined for 
A20FMDV2
VLPs as follows. 
A20FMDV2
VLPs in 10 mM sodium phosphate buffer pH 7.0 was reacted with a 1000:4000 molar 
ratio of EDC and Sulfo–NHS in aqueous solution, as described in section 2.15. A 2000 molar 
excess of freshly prepared cascade blue ethylenediamine dye (Invitrogen), dissolved in 10 mM 
sodium phosphate buffer, was added. The reaction scheme is depicted in Figure 6.4. The 
reaction was left to proceed at 4 °C overnight while gently stirring. The doubly–functionalised 
particles 
A20FMDV2
VLPs
cascade blue dye 
were purified on a PD–10 column equilibrated with 10 mM 
sodium phosphate buffer pH 7.0, and eluted fractions were concentrated on 100 kDa cut–off 
columns before being layered onto 5 ml 10%–50% sucrose gradients. The gradients were 
centrifuged at 137000g for 1 to 1.5 hours at 4 °C; 300 µL fractions were collected and dialysed 
against 10 mM sodium phosphate buffer pH 7.0 for 2 days, changing the buffer every 12 hours. 
After further concentration on 100 kDa cut–off columns, the number of remaining reactive 
carboxylates was calculated, from the absorbance of the dye at λ399 and ε = 27000 M
–1
 cm
–1
, to 
be ~100–110 ± 8 per virion. This equates to approximately 45–50 peptides being bound to each 
eVLP. Moreover, a control experiment was conducted with unmodified eVLPs and the cascade 
blue dye and the number of dyes was found to be ~145–150 dye per virus, this is almost full 
coverage of all surface accessible carboxylates.  
 
 
Figure 6.4– The side–chain primary amine group of cascade blue ethylenediamine was coupled to 
the remaining carboxylate groups on the virus capsid using the carbodiimide reaction, R1 represents 
the virus. 
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6.3 Results and discussion 
6.3.1 Internal mineralization of CPMV eVLPs 
Internal mineralization of CPMV eVLPs with cobalt and iron oxide have been achieved 
for the first time. Incubation of CPMV eVLPs, suspended in 10 mM sodium phosphate buffer 
pH 7.0, with cobalt chloride solution, followed by washing, then subsequent reduction with 
sodium borohydride gave cobalt–loaded VLPs (VLPscobalt) in which cobalt is encapsulated 
within the capsid core while preserving the external capsid surface for further modifications. 
The general method is depicted in Figure 6.5. Recovery of VLPscobalt was approximately 70% 
based on initial CPMV eVLP concentration.  
 
Figure 6.5– Schematic representation of loading eVLPs with metal ions. The subsequent reduction 
of the metal ions (Mn+) resulted in the formation of metallic cores within the eVLPs. In addition, 
the capsid was preserved and can be biotinylated. Reproduced from Aljabali et al 2010. 
 
A similar approach can be employed to generate internalized iron oxide. A suspension 
of CPMV eVLPs was treated with a mixture of ferric and ferrous sulfate solutions in a molar 
ratio of 2:1, under alkaline hydrolysis conditions that favour the formation of Fe3O4, magnetite, 
as depicted in the equation below. However, the presence of hematite (α–Fe2O3) or maghemite 
(γ–Fe2O3) cannot be discounted.  
  2FeCl3 + FeCl2 + 8NaOH → Fe3O4 + 8NaCl + 4H2O 
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After mixing overnight at pH 3.7–4.2, the particles were washed on 100 kDa cut–off 
columns before the pH was raised to 10.1. The resultant iron oxide–VLPs (VLPsiron oxide) were 
purified and obtained in 40–45% yield based on initial CPMV eVLP concentration. 
An unstained TEM image clearly shows electron–dense material, cobalt or iron oxide, 
was formed within eVLPs, and that sucrose density centrifugation eliminates almost all of the 
reaction impurities, Figure 6.6. CPMV eVLPs, prior to the reaction, were not visible by TEM 
without staining.  Based on the results from TEM, the average size of internally mineralized 
eVLPs was 31.5 ± 2 nm, which agrees with the unmodified particle size. Further, the metallic 
core within VLPs of ~ 25 nm is in agreement with the internal diameter of eVLPs. 
 
 
Figure 6.6– Unstained TEM images of internally mineralized CPMV eVLPs. A) VLPscobalt and B) 
VLPsiron oxide.  
 
 
A negative stain of the modified particles with either 2% UA or 1% phosphotungstic 
acid (PTA) showed the presence of the complete protein shell encapsulating ~25 nm metallic 
cores, Figure 6.7. Two morphologies were observed with UA staining as is also seen for eVLPs 
(unmodified particles) this might be because of partial loading or it is a stain property Figure 
6.7. When staining with 1% PTA only one morphology was observed. The bright ring around 
the solid core in Figure 6.7 panel C represents the intact coat protein surrounding the metallic 
core.  
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Figure 6.7– Negatively stained internally mineralized CPMV eVLPs. Panel (A) VLPscobalt, (B) 
VLPsiron oxide both stained with 2% uranyl acetate, and (C) VLPsiron oxide stained with 1% PTA. The 
white ring is the coat protein surrounding solid metallic cores. 
 
Furthermore, the metallic cores could be extracted by disruption of the coat protein of 
the modified particles. Particles were heated for 10 minutes at 80–90 °C with 20 % (w/v) SDS. 
Unstained TEM reveals 10% of the metallic cores were approximately 25–28 (± 2) nm in 
diameter (Figure 6.8–A), the rest of the sample forming large aggregates. Staining the cobalt 
metallic cores with UA or PTA did not result in the same morphologies and the white ring of 
the coat protein was absent. In addition, DLS analysis confirmed the presence of a peak 
corresponding to the internal cavity size of ~ 25 nm with most of the sample being aggregated 
(Figure 6.8–B). This is direct confirmation that the capsid is important in preventing 
aggregation. The high percentage aggregation is possibly due to the metallic cores not being 
produced from single domain crystals and therefore upon capsid dissociation, the metallic 
multi–domains fall apart and aggregates formed. 
The DLS data of the mineralized particles in 10 mM sodium phosphate buffer pH 7.0 
(Figure 6.9), confirms that the external diameter of the VLPs of 31.9 (± 2.0) nm compared to 
32.0 (± 2.0) nm for CPMV eVLP does not change significantly on internalization of cobalt or 
iron oxide and that the particles remain monodisperse. The data is in full agreement with the 
observed TEM images. 
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Figure 6.8– Metallic core analysis post protein capsid disruption. (A) Unstained TEM image of one 
of the cobalt cores resulting from disruption of the capsids. The cobalt particle size of ca. 26 nm is 
as expected if the interior cavity of the VLP is fully filled and (B) corresponding DLS measurement, 
the arrow indicates the particles size within the VLPs. 
 
 
 
Figure 6.9– DLS data of VLPscobalt, and VLPsiron oxide: (A) comparison between hydrodynamic radius 
of VLPscobalt, and VLPsiron oxide; (B) correlation plot for VLPscobalt, and eVLPs; (C) regularization 
graph of DLS of purified VLPsiron oxide; (D) correlation plot for VLPsiron oxide. All readings were 
recorded at 21°C in triplicate. 
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Energy dispersive X–ray spectroscopy (EDXS) confirms the presence of cobalt, and 
iron and oxygen, data is represented in Figure 6.10. In addition, there was an insignificant 
amount of oxygen in VLPscobalt and thus no evidence for cobalt oxide formation. The zeta 
potentials, as shown in Figure 6.11, for suspensions of eVLPs (–32.0 ± 2.3 mV), VLPscobalt (–
32.9 ± 1.8 mV) and VLPsiron oxide (–32.1 ± 2.4 mV) indicate that the colloids have good stability 
and show little propensity to aggregate, as was confirmed by TEM, Figure 6.6. In each case, 
control experiments were performed under identical conditions except for the absence of eVLPs 
or by using "B component” in which both gave non–specific bulk precipitation with a wide size 
distribution of nanoparticles as observed by TEM and DLS; thus, the eVLPs are essential for 
controlled nanoparticle growth. 
 
 
Figure 6.10– Elemental energy–dispersive X–ray spectroscopy analysis. (A) VLPscobalt showing the 
presence of cobalt, indicated by red arrows, and (B) of VLPsiron oxide showing the presence of iron, 
indicated by red arrows. Aluminium signal is from the sample holder. 
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Figure 6.11– Examples of zeta potential results for (A) CPMV eVLPs, (B) VLPscobalt and (C) 
VLPsiron oxide. Data show no significant change of the particle outer–surface confirming the 
mineralization is internal. 
 
Previously, it has been found that externally mineralized CPMV particles are robust and 
the coat proteins cannot be released even by denaturation under harsh conditions (e.g. 
denaturing with sodium dodecyl sulfate at 100 ºC for 30 min) as demonstrated in chapter 3 
(Aljabali et al, 2011; Steinmetz et al, 2009b). Here, however, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS–PAGE) of the denatured proteins from “top 
component” and wild–type CPMV isolated from infected plants, which consist of naturally 
occurring empty particles from a wild–type infection, CPMV eVLPs, VLPscobalt and VLPsiron oxide 
(Figure 6.12–A) all gave a similar pattern of bands after Coomassie Blue staining consisting of 
the L and S capsid proteins. The difference in the size of the S proteins isolated from wild–type 
virus and the eVLP samples is due to the differing degrees of C–terminal processing. These 
results indicate that the coat proteins are accessible, indicating that the mineralization is, indeed, 
internal. Further confirmation that the capsid structure is preserved, and that the eVLPs were not 
externally mineralized, was provided by analysis of the intact particles by agarose gel 
electrophoresis (Figure 6.12–B). Coomassie Blue staining revealed that all the VLPs, which 
were devoid of RNA, whether containing internalized metal/metal oxide or not, had the same 
mobility. By contrast, the RNA–containing particles from natural populations of particles gave a 
typical complex pattern.  
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Figure 6.12– Gel electrophoresis analysis for internally mineralized CPMV eVLPs. A) SDS–PAGE 
and B) native 1% agarose gel stained with coomassie blue. Lane 1: CPMVwt; lane 2: CPMVwt ‘‘top 
component’’ (devoid of RNA); lane 3: CPMV eVLPs; lane 4: VLPscobalt; lane 5: and VLPsiron oxide. 
 
Further analysis confirmed that the mineralized VLPs contained both the coat proteins 
and either cobalt or iron, respectively. Samples of each unmineralized eVLP, VLPscobalt and 
VLPsiron oxide were spotted onto a nitrocellulose membrane, which, after blocking, was probed 
with polyclonal antibodies raised in rabbits against CPMV particles. The binding of the 
antibodies was detected using a goat anti–rabbit IgG coupled to horseradish peroxidise and the 
signals were visualised by chemiluminescence. In each case, a dark signal was obtained 
confirming the presence of CPMV coat protein in all the VLP samples (Figure 6.13–A). This is 
in contrast to external mineralization of CPMV where the coat protein is not immunologically 
detected. Similarly, each of eVLP, VLPscobalt and VLPsiron oxide were spotted onto a nitrocellulose 
membrane and probed with either a cobalt–specific stain (1–nitroso–2–naphthol) or Prussian 
blue staining to identify iron. Only the VLPscobalt stained orange (Figure 6.13–B), showing the 
presence of cobalt, and only the VLPsiron oxide stained blue, showing the presence of iron, within 
the VLPs (Figure 6.13–C).  
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Figure 6.13– Images of VLPs spotted on a nitrocellulose membrane probed with: (A) polyclonal 
antibodies raised against CPMV particles – dark spots show intact CPMV coat protein; (B) 1–
nitroso–2–naphthol to stain for cobalt; (C) Prussian blue stain for iron. Column 1, eVLPs; column 
2, VLPscobalt; column 3, VLPsiron oxide. 
 
To demonstrate that the external coat of the metal containing VLPs is still amenable to 
chemical modification, VLPscobalt were functionalised at solvent–exposed lysines with 
succinimide ester activated biotin by an adaptation of a previously published standard procedure 
(Steinmetz et al, 2006a). The binding of both 
Biotin
VLPscobalt and 
Biotin
VLPs to streptavidin–
modified chips was monitored by surface plasmon resonance (SPR). In each case a response 
was observed, Figure 6.14, confirming that chemical modification of the VLP capsid exterior 
had successfully occurred, irrespective of the internal mineralization. This provides the first 
evidence that the external surface of eVLPs and internally mineralized VLPs can be chemically 
modified using the same approach taken for wild–type CPMV. Comparison of normalized 
sensograms recorded at the same VLP concentration (based on protein content as estimated by 
UV–visible spectroscopy) showed a two and a half fold increase in resonance units consistent 
with the increase in mass associated with the loading of cobalt within the VLP. To confirm the 
CHAPTER 6 
 
143 
 
covalent attachment of 
Biotin
VLPscobalt to the modified chip, the chip was examined using AFM 
as shown in Figure 6.15. 
 
 
Figure 6.14– Sensogram showing the evolution of resonance units (RU) versus time during 
association and dissociation measurements of BiotinVLPs (red) and BiotinVLPscobalt (blue) on a 
streptavidin–modified chip. The association is measured at approximately the same concentration 
(as determined by UV–vis spectroscopy) of BiotinVLPs A delay of 100 seconds is applied and the 
association is allowed to occur during 360 seconds before the flow is switched to buffer for the 
dissociation step. 
 
 
 
Figure 6.15– AFM image for BiotinVLPscobalt on a SA–functionalised chip. (A) Chip surface with 
BiotinVLPscobalt, (B) 3–D image of the same surface. 
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In an attempt to establish the nature of the iron oxide formed within the eVLPs, 
Mössbauer spectroscopy analysis for the particles in frozen solution was obtained as shown in 
Figure 6.16. At 80 K, in frozen solution, a single quadrupole split doublet was observed with 
isomer shift (i.s.) of 0.45 mms
–1
 and quadrupole splitting (q.s.) of 0.81 mms
–1
. The values of i.s. 
and q.s. are  consistent with the iron oxide being present within the virus capsid VLPsiron oxide as 
superparamagnetic magnetite nanoparticles; at room temperature i.s. values have been reported 
to range from 0.30 – 0.36 mms–1 and q.s. values from 0.60 – 0.65 mms–1 (Wang & Jiang, 2009). 
 
Figure 6.16– Frozen solution Mössbauer spectrum at 80 K of VLPsiron oxide. 
 
Vibrating sample magnetometry of VLPsiron oxide is also fully consistent with the 
particles exhibiting superparamagnetic behaviour with a blocking temperature (TB) of around 60 
K and ferromagnetic behaviour below the blocking temperature. The zero field cooled (ZFC) 
and field cooled (FC) magnetization curves (Figure 6.17) are typical magnetization curves for 
magnetic nanoparticles. Under FC conditions, there is no sharp change in the magnetization 
value from 300 K to 10 K. The ZFC curve shows a broad maximum at the temperature 
corresponding to TB, below which there is a decrease in magnetization.  
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Figure 6.17– Zero field cooled (ZFC) and field cooled (FC) of VLPsiron oxide particles. (A) 
magnetization curves (B) hysteresis loops at (5 K) and (C)  hysteresis loops above (200 K)  and 
below (5 K) the blocking temperature (60 K). 
 
 
 
The now readily available CPMV eVLPs were used, without further genetic or chemical 
modification, to easily encapsulate cobalt or iron oxide within the capsid interior. Previously, it 
has been shown that CPMVwt particles are permeable to caesium ions and that penetration 
probably occurs via channels at the five–fold axes of the virus particles, where the S subunits 
cluster. These channels are funnel–shaped, with the narrow end at the outer surface of the virus 
particle and the wider end in the interior (Lin & Johnson, 2003). The opening at the narrow end 
is about 7.5 Å in diameter. Further down the five–fold axis, a second constriction can be found 
which occurs as a result of the three N–terminal residues of the S subunits forming a pentameric 
annulus structure. In this structure, the amino group of the N–terminus forms a hydrogen bond 
with the main chain carbonyl oxygen of the neighbouring third residue, the opening at this point 
is ca. 8.5 Å as shown in Figure 6.18. It is proposed that it is through these channels that the 
cobalt and iron ions enter the inside of the eVLP. The fact that the pentameric annulus controls 
access to the interior of the eVLP is supported by the observation that the addition of a 
methionine residue to the N–terminus of the S protein prevents penetration by cobalt ions, 
presumably by occluding the channel with a bulky side chain. In addition, it was confirmed that 
the presence of the 24 amino acids extension on the C–terminus, which are responsible for the 
slow–migrating form (S) upon particle separation by electrophoresis, prevented loading with 
cobalt and iron oxide (Sainsbury F. et al, 2011). Normally, these 24 a.a are trimmed (not 
cleaved) with plant proteinase. Alternatively, the 24-a.a extension can be trimmed with 
chymotrypsin to convert the slow–migrating to the fast–migrating form in vitro (Niblett & 
Semancik, 1969a).  
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The charge on the internal surface of the capsid is negative, arising from glutamic acid 
and aspartic acid residues. The electrostatic interactions between the internal surface and the 
incorporated metal ions entrap them within the capsid. Even six hours dialysis against buffer 
does not remove the electrostatically entrapped metal ions. On further treatment, either 
reduction for cobalt or alkaline hydrolysis for the iron oxide, the metal ions act as nucleation 
sites for metal particle formation or further autocatalytic hydrolysis (Wade et al, 1991) to 
produce iron oxide, respectively. The encapsulation processes occur at ambient temperature, in 
aqueous media, producing little waste, so are environmentally friendly. In addition, amino acid 
residues on the exterior surface of the internally mineralized particles remain amenable for 
chemical modification. The ability to both encapsulate materials (e.g. nanoparticles or drugs) 
within the eVLP and to chemically modify the external surface opens up routes for the further 
development of CPMV–based systems for the targeted delivery of therapeutic agents and for 
other uses in biomedicine. 
 
 
Figure 6.18– Illustration of one of 12 pentamers of CPMV at the five–fold axis. Showing the pore 
with an average opening of 7.5 Ǻ. Images generated with PyMOL–1–2b8eval version. The 
accessible surface profile of CPMV half capsid file is available at http://viperdb.scripps.edu with 
PDB–ID (1NY7). Right panel is reproduced from (Lin & Johnson, 2003).  
 
  
6.3.2 VLPsiron oxide as possible targeted hyperthermia therapeutics 
In recent decades, the major challenge for oncologists has been the understanding of 
biological mechanisms underlying tumour formation, as well as the development of therapies 
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that can reduce or even eliminate these tumours (Ito et al, 2005). One method is hyperthermia 
treatment, which is a therapeutic procedure that promotes the increase of temperature in the 
targeted tissues. Hyperthermia activity is based on the fact that a temperature increase to 
between 41–45 °C can induce tumour death (Gamarra et al, 2010; Harima et al, 2001; Harima & 
Sawada, 2009). Investigating the application of magnetic materials to promote hyperthermia 
began in 1957, in which Gilchrist treated various tissue samples with 20–100 nm particles of γ–
Fe2O3 exposed to a 1.2 MHz magnetic field (Gilchrist et al, 1957). Iron oxide nanoparticles 
exposure to external magnetic field can generate heat through oscillation of their magnetic 
moment therefore generating regional heating. In this temperature range, tumour cells are 
generally found to be more heat–sensitive compared to normal cells because tumour cells are 
poorly oxygenated (Berry & Curtis, 2003), It has been demonstrated that the ideal iron oxide 
nanoparticles are within the size range of 20–25 nm (personal communication, Prof Quentin 
Pankhurst, The Royal Institution of Great Britain). Therefore, CPMV eVLPs offer an ideal 
nanocontainer of internal diameter ~ 25–26 nm to generate highly monodisperse iron oxide 
nanoparticles. The VLPsiron oxide, as has been demonstrated, can be easily functionalised with 
biocompatible reagents or targeting moieties. The proposed mechanism is depicted in Figure 
6.19. 
CPMV eVLPs have been loaded with iron oxide and externally functionalised with 
A20FMDV2 peptide, which binds specifically to the surface integrin present on many tumours 
(for further discussion see chapter 9). The peptide was designed with a biotin group at one end 
to help detection with streptavidin functionalised gold nanoparticles as shown in Figure 6.20. 
A20FMDV2
VLPs particles were reacted with cascade blue dye as described in section 6.2.15 to 
quantify the number of peptides bound to the capsid. The doubly–functionalised particles 
A20FMDV2
VLPs
Cascade blue dye 
were purified rigorously by sucrose gradient followed by dialysis 
against 10 mM sodium phosphate buffer pH 7.0. The number of remaining reactive carboxylates 
was calculated, from the absorbance of the dye at λ399 and ε = 27000 M
–1
 cm
–1
, to be ~100–110 
± 8 per virion. This equates to approximately 45–50 peptides being bound to each eVLP. 
Moreover, a control experiment was conducted with unmodified eVLPs and the cascade blue 
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dye and the number of dyes was found to be ~145–150 dye per virus, this is almost full 
coverage of all surface accessible carboxylates. The next step will be to test these particles for 
thermal properties in collaboration with Prof. Quentin Pankhurst, The Royal Institution of Great 
Britain. 
 
 
Figure 6.19– Schematic illustration of the mechanism of hyperthermia treatment using iron oxide 
loaded CPMV eVLPs. Iron oxide loaded particles are specifically designed to selectively attach to 
the cancer cells without affecting the healthy cells. The localized particle in an external magnetic 
field generates heat destroying the targeted cells. 
 
 
Figure 6.20– TEM images for (A) stained VLPsiron oxide and (B) A20FMDV2VLPsiron oxide detected by 
streptavidin functionalised gold nanoparticles. It has been found that there are 40–50 peptides per 
virus using a carboxylate–specific fluorescent dye. 
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6.4 Internal functionalisation of CPMV eVLPs 
Further to the internal mineralization of CPMV eVLPs, studies on the chemical 
modification of the interior of the capsid will be presented in this section. These studies 
focussed on internal cysteines, which have been identified previously (Wang et al, 2002d; Wang 
et al, 2003b). As there are no accessible cysteines on the exterior of CPMV particles, the 
internal cysteines provide a unique functional amino acid within the virus particles. 
CPMV eVLPs can be viewed as molecular “nano–vessels”. Thus, therapeutic molecules 
can be housed within their interior, anticancer drugs and positively charged molecules can be 
diffused and trapped within the interior of eVLPs. Housing drug molecules within eVLPs may 
restrict their functionality until their release is triggered by host cell acid hydrolase enzymes that 
are contained within the lysosomes. In addition, some protein cages, including CCMV, have 
structural features that allow for the controlled encapsulation and release of material (Douglas & 
Young, 1998a; Speir et al, 1995). Herein, the uses of CPMV eVLPs as a potential drug carrier 
are explored. 
6.4.1 Results and discussion 
6.4.1.1 Diffusion of molecules into CPMV eVLPs 
The results in Sections 6.3.1 and 6.3.2 demonstrated the ability of CPMV eVLPs to 
encapsulate metals and metal oxides within the capsid. The next step was to expand further the 
versatility of CPMV eVLPs to package other smaller molecules. As previously described, the 
pores are essential for material diffusion and for allowing the inner cavity to be accessible. Once 
inside the interior cavity, the diffused materials either can interact with the negatively charged 
interior or can be covalently attached to specific amino acids depending upon the chemistry 
used. Covalent interior modification has been reported in the literature for CPMV, MS2 and 
TMV (Hooker et al, 2007b; Hooker et al, 2004; Schlick et al, 2005b(Rhee et al, 2011)).   
The ability to modify the external surface with moieties for diseased cell targeting, 
along with the packaging capacity, enables CPMV eVLPs to perform as multifunctional 
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nanocontainers. Moreover, the results presented here indicate that the diffusion mechanism is 
charge–related. Therefore, positively charged molecules such as rhodamine, gemcitabine and 
doxorubicin (Figure 6.21) were selected together with cisplatin drug to test the loading 
capabilities of eVLPs. 
 
 
Figure 6.21– Chemical structures for (A) rhodamine hydrochloride, (B) doxorubicin, (C) 
gemcitabine and (D) cisplatin. 
 
6.4.1.2 VLPsrhodamine   
Most of the reported work in the literature using eVLPs as drug carriers requires further 
modifications to the virus particles. For example, MS2 requires genetic engineering to the 
capsid in order to package molecules (Brown et al, 2002). On the contrary, the approach 
described here offers a direct route to packaging molecules without the need for further 
modification of CPMV eVLPs but by using the natural properties of the native particles. The 
loading capacity of rhodamine was determined photometrically to be ~20–30 molecules per 
virus (Figure 6.22). TEM analysis confirmed the integrity of the modified particles and did not 
result in a detectable change in the capsid diameter or morphology, Figure 6.23. The ability to 
diffuse positively charged rhodamine is presumably due to the electrostatic interaction with the 
overall internal anionic surface of the virus capsid and not because of covalent attachment. The 
VLPsrhodamine were monitored by spectrophotometry over 4 days without the loss of the 
fluorescent signal or its intensity, suggesting strong electrostatic interaction within the interior 
of the capsid, which is sufficient to trap the positively charged rhodamine. It is still not clear 
why there are a low number of rhodamine molecules per virus. A control experiment was 
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performed where rhodamine was incubated with bottom component particles (containing RNA–
1), at the same molar ratio, followed by identical protocols for purification and characterisation. 
There was no fluorescent signal detected on unstained agarose gel electrophoresis, Figure 6.24 
lane 2. This is direct evidence that the particles must be empty in order to incorporate 
rhodamine. 
 
Figure 6.22– UV–vis for VLPsrhodamine. Rhodamine was measured with an excitation wavelength at 
500 nm and extinction coefficient of 80000 M–1 cm–1. 
 
 
Figure 6.23– TEM image of VLPsrhodamine stained with 2% UA. 
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Figure 6.24– Wild–type and VLPsrhodamine on a 1.2% agarose gel. (A) Unstained, (B) Coomassie 
stained gels. Lane 1, wild–type CPMV; 2, CPMV “bottom component” (positive control); 3, eVLPs; 
4, VLPsrhodamine. Only VLPsrhodamine were visible in the unstained gel because of rhodamine 
entrapment within eVLPs. 
 
6.4.1.3 VLPsdoxorubicin  
Doxorubicin is commonly used in cancer therapy but has undesirable cytotoxicity and 
side effects. It is also a very popular research tool due to its fluorescence properties (Mohan & 
Rapoport, 2010). To minimize these side effects, an attempt has been made here to encapsulate 
doxorubicin in biodegradable naturally occurring nanoparticles, CPMV eVLPs. Doxorubicin is 
a positively charged chemotherapeutic agent so it might interact with the negatively charged 
interior of the capsid.  
eVLPs were incubated with doxorubicin followed by rigours purification (as described 
in section 2.17) and native gel electrophoresis was employed to verify that doxorubicin was 
present within the eVLPs. Unstained native agarose gel electrophoresis for the rigorously 
purified particles(as describe in section 2.17) revealed a fluorescent band as shown in Figure 
6.25–A, this corresponds to VLPsdox, whereas the free doxorubicin moved in the opposite 
direction. In addition, VLPsdox were visible in solution with a light raspberry colour. This 
suggests that the doxorubicin is present within the eVLPs and it is being kept inside the particles 
by an electrostatic interaction within the interior of the capsid. After staining by Coomassie 
blue, VLPsdox and eVLPs were visible on the same gel (Figure 6.25–C). 
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The spectrophotometric analysis of VLPsdox gave ~8–10 (± 3) molecules per virus 
capsid. The doxorubicin showed no leakage or diffusion through the opened pores over the four 
days that the particles were monitored. A fundamental issue in drug delivery is the ability of the 
drug to reach its target within the nucleus (Topoisomerase–2). In the case of doxorubicin, this 
approach appears very promising, as the drug might slowly diffuse from the particles without 
relying on degradation of the particles. This approach is still under investigation. 
 
 
Figure 6.25– eVLPs and VLPsdox on a 1.2% agarose gel. (A) unstained, (B) ethidium bromide 
stained and (C) Coomassie stained gels. Lane 1, wild–type CPMV; 2, eVLPs; 3, VLPsdox; 4, free 
doxorubicin. Only VLPsdox were visible in the unstained gel because of doxorubicin entrapment 
within eVLPs. 
 
6.4.1.4 Internal chemistry of CPMV eVLPs  
The cysteine side chain is a reactive nucleophile that can react with a large variety of 
molecules (Hermanson, 2008). However, as wild–type CPMV particles contain no cysteines on 
the exterior of the capsid (Wang et al, 2002a) this makes cysteine–labelling specific to within 
the eVLPs. It has been shown that small thiol–selective dyes such as ethylmercury phosphate 
(EMP), fluorescein and thiol–selective stilbene derivatives (Wang et al, 2002e) can be coupled 
to the interior of wild–type CPMV. EMP was found to be coupled to an internal cysteine residue 
on the L subunit, at amino acid position 295, whereas the 5–maleimidofluorescein was attached 
to cysteines on both the S and L subunit, though the exact positions have not been identified yet. 
Internal labelling with nanogold, with a diameter of 1.4 nm, could not be achieved, as the pore 
size is approximately 7.5 Å (Wang et al, 2002d; Wang et al, 2003b). 
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Chemical modification of the interior cysteines within CPMV eVLPs with sulfhydryl–
reactive fluorescent dye (DyLight–488 maleimide) was explored. Incubating DyLight–488 
maleimide with eVLPs, followed by rigorous purification, resulted in an average of 60–70 (± 2) 
dyes per virus covalently attached, presumably to the interior surface, Figure 6.26. Repeating 
this experiment five times resulted in consistent labelling with almost the same numbers of dyes 
per virus. The data suggests one dye per asymmetric unit. Applying the same approach, as a 
control experiment, with the CPMV “bottom component” resulted in no fluorescence detected 
on agarose gel or by UV–vis. 
  
 
Figure 6.26– The double bond of maleimide reacts specifically with sulfhydryl groups to form a 
stable thioether bond. R1 represents the virus and R2 represents the maleimide containing dye. 
 
Examination of the crystal structure of wild–type CPMV, which is similar to CPMV 
eVLPs, from the VIPERDB database suggested that the dye is possibly bound to cysteine 295 of 
the large protein as shown in Figure 6.27. Furthermore, the crystal structure revealed a possible 
disulfide bridge formed between Cys–187 and Cys–355. The distance between Cys–187 and 
Cys–355 is 2.82 Å as shown in Figure 6.27, a distance consistent with the published data for 
disulfide bond formation (Sevier & Kaiser, 2002).  
Based on this knowledge, the second approach involved the addition of 10 mM TCEP 
as a reducing agent together with the DyLight–488 maleimide and CPMV eVLPs. Interestingly, 
the spectroscopic analysis resulted in approximately 120 (± 10) dyes per virus; presumably, the 
reducing agent disrupts the disulfide bond between Cys–187 and Cys–355, making another thiol 
group available. The number of dyes per virus was consistent upon repeating the experiments 
five times. The size of the dye might be blocking the third cysteine side chain thiol. Incubating 
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TCEP with the virus particles followed by purification and then conducting the same reaction, 
resulted in no significant changes in the number of dyes covalently bound to the interior of the 
virus capsid. 
The characterisation of the modified particles with or without the reducing agents 
revealed no morphological changes and the particles remained intact as confirmed by agarose 
gel electrophoresis, Figure 6.28. The intensity of the VLPsDyLight–488 differs between the two 
conditions (with or without reducing agent), this presumably arises from differential 
modification of the L and S coat proteins, and the corresponding UV–vis spectrum is shown in 
Figure 6.29. The difference in the intensity of the modified particles is clear in the presence of 
TCEP and confirmed by the quantitative analysis (Figure 6.29–B). Particle integrity was 
confirmed by TEM. The addition of the reducing agent has no effect on particle stability or 
morphology as shown in Figure 6.30. 
 
Figure 6.27– The CPMV asymmetric unit. (Small subunit in green; large subunit in blue) with 
positions of the possibly accessible cysteines. Cys–295 is the most likely to be accessible while Cys–
187 and Cys–355 form disulfide bonds. Inside view image generated by PyMol free evaluation 
software. 
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Figure 6.28– Wild–type and VLPsDyLight–488 migration on a 1.2% agarose gel. (A) unstained, (B) 
Coomassie stained gels. Lane 1, wild–type CPMV; 2, eVLPs (positive control); 3, VLPsDyLight–488 
(double the amount in order to see the weak band); 4, VLPsDyLight–488 reduced.  
 
 
 
Figure 6.29– UV–visible spectrum for VLPsDyLight–488. Blue line is unmodified eVLPs; green line, 
VLPsDyLight–488 unreduced; red line, VLPsDyLight–488 reduced. The inset is a digital image of A, 
VLPsDyLight–488 unreduced and B, VLPsDyLight–488 reduced. 
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Figure 6.30– TEM image of VLPsDyLight–488 in the presence of TCEP. The particles were purified on 
sucrose gradient and stained with 2% UA. 
 
 
6.4.1.5 Encapsulation of anti-cancer drugs within eVLPs via LBL approach 
The layer–by–layer (LBL) technique is a versatile tool for the controlled fabrication of 
multimaterial surface coatings (Leguen et al, 2007). The degradable–layered structure would be 
advantageous for drug delivery and has the potential to carry targeting agents. The aim of this 
work was to investigate if CPMV eVLPs coated with polyelectrolyte could be used to carry 
anticancer drugs. 
CPMV eVLPs do not appear to have a built–in mechanism for controlled drug 
encapsulation and release as for CCMV (Speir et al, 1995), RCNMV (Loo et al, 2007) and MS2 
(Wu et al, 1995). As an initial attempt to infuse molecules within eVLPs, rhodamine and 
doxorubicin were studied. However, relying on the electrostatic interaction of the positively 
charged molecules within the virus capsid is not sufficient to deliver a high payload of drugs to 
the targeted diseased cells.  
CPMV can be considered as an anionic macromolecule with an isoelectric point (pI) of 
4.3 ± 0.1 at physiological pH (pH 7.4) (Kewalramani et al, 2011). This property is valuable for 
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the electrostatic LBL self–assembly technique. Previously, it was shown to be possible to 
sequentially deposit a thin layer of cationic polyelectrolyte such as poly(allylamine 
hydrochloride) (PAH) onto the wild–type CPMV capsid by electrostatic adsorption of positively 
charged polyelectrolyte, PAH, onto the CPMV capsid. Subsequent treatment with gold 
containing solution followed by reduction, resulted in gold coating the CPMV particles, denoted 
Au–CPMV (see chapter 4). Here, a LBL approach was adopted to trap drug molecules within 
the eVLPs by the sequential deposition of oppositely charged polyelectrolytes on the external 
surface, Figure 6.31. 
 
 
Figure 6.31– Schematic representation of the deposition of polycation/polyanion onto eVLPs. 
Particles were incubated with gemcitabine or cisplatin followed by deposition of PAH and PSS 
electrolytes. Polyanion/polycation coated particles were washed thoroughly between each step of 
the electrolyte deposition with Milli–Q water. TPolyanion/polycation process was repeated for 
either one or two cycles.   
 
 
Gemcitabine or cisplatin were incubated with eVLPs. The subsequent deposition of 
alternating polyelectrolytes was monitored by zeta potential (ZP) measurements. The complete 
reversal of surface charge is a crucial factor for the stepwise growth of the multilayer 
electrolytes. The negatively charged CPMV eVLPs particles (uncoated) have a ZP value of ca. –
31.9 (± 2.5) mV. The presence of PAH on the virus capsid caused a reversal in the ZP to 
approximately +67.8 (± 2.0) mV for 
PAH
VLPsdrug whereas 
(PAH/PSS)1
VLPsdrug have a ZP value of –
55.3 (± 1.7) mV, Figure 6.32. Alternating ZP measurements with the subsequent deposition of 
cationic/anionic electrolytes, confirmed the stepwise formation of the PAH/PSS/PAH layers on 
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the eVLPs capsid. Furthermore, alternating polycation/polyanion to generate thicker electrolyte 
shells enabled the preparation of 
(PAH/PSS)2
VLPsdrug.  
PAH and poly(styrenesulfonate) (PSS) were selected because they are a well–studied 
combination and the process conditions, including salt concentration, pH and incubation times, 
are well established (Goldenberg et al, 2002; Shenoy et al, 2003; Zahr et al, 2004). The 
PAH/PSS combination was therefore used to form a degradable polyelectrolyte shell on the 
eVLPs capsid. Both PAH and PSS were selected as they are salt and pH responsive, this 
property might be vital in acting as a release mechanism for the encapsulated drug molecules. 
The release time was dependent on the thickness of the assembled polyelectrolyte layers. 
Thicker shells led to longer release times; this was measured by the time it took polyelectrolyte–
coating on the particles to dissolve and the return of the native form of particles as shown by 
agarose gel electrophoresis Figure 6.34. 
 
 
Figure 6.32– Charge reversal on alternate adsorption of polyelectrolyte on (PAH/PSS)1–2VLPsgemcitabine. 
 
To visually determine whether LBL assembly successfully encapsulated the drug 
particles, TEM was used to examine the surface characteristics, integrity, and size of the 
polyelectrolyte coated eVLPs. Figure 6.33 shows no morphological change of 
(PAH/PSS)2
VLPsdrug 
and that the particles remain intact and monodisperse. The diameter of the virus is 
approximately 30–31 nm indicating an increase of ~2–3 nm in diameter as measured from TEM 
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images. This was in agreement with the measured DLS data, which showed an increase in 2 nm 
per layer. 
 
 
Figure 6.33– Stained TEM images of polyelectrolyte coated VLPsdrug. (A)  (PAH/PSS)2VLPsgemcitabine; 
(B) (PAH/PSS)2VLPscisplatin. The particles are intact and narrowly distributed without any significant 
morphological changes. The particle diameter increased by 2–3 nm and no aggregation was 
recorded on any of the samples prepared. 
 
In addition, due to the fluorescence property of gemcitabine, the integrity of the 
(PAH/PSS)2
VLPsgemcitabine particles was confirmed by agarose gel electrophoresis. Figure 6.34–A 
shows an unstained agarose gel of wild–type CPMV, a positive control of VLPsgemcitabine and the 
polyelectrolyte coated 
(PAH/PSS)2
VLPsgemcitabine. According to their migration in an electric field 
towards the anode, intact virions of CPMVwt can be separated into a higher– and lower–
mobility form. The 
(PAH/PSS)2
VLPsgemcitabine
 
particles show no mobility on agarose gel Figure 
6.34–lane 3. This is not a consequence of the massive increase in the particles size or because of 
particle aggregation but probably due to the presence of the charged electrolytes on the particle 
surface. This was supported by no aggregation being observed in any of the prepared samples 
using TEM as shown in Figure 6.33. Moreover, removing the polyelectrolytes resulted in the 
polyelectrolyte coated particles returning to their native form for either wild–type CPMV or 
eVLPs as confirmed by agarose gel electrophoresis. The fluorescence band on the unstained 
agarose gel resulted from the pyrimidine group on the gemcitabine, indicating successful drug 
encapsulation (Figure 6.34–A). Coomassie stained agarose (Figure 6.34–B) confirms the 
presence of the coat protein and that the particles were intact. 
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Figure 6.34– Agarose gel electrophoresis of gemcitabine loaded VLPs. (A) unstained; (B) 
Coomassie stained. Lane 1; CPMV wild–type, 2; eVLPsgemcitabine, 3; (PAH/PSS)2VLPsgemcitabine. The 
bands on the unstained gel correspond to the successful encapsulation of gemcitabine within the 
(PAH/PSS)2VLPsgemcitabine.  
 
 
In a control experiment, and to demonstrate that the electrolyte is essential for drug 
encapsulation within CPMV eVLPs, gemcitabine was incubated with eVLPs Figure 6.35 lane 2 
following the same procedure described earlier. The agarose gel shows no changes in the bands 
mobility and no fluorescent signal was detected suggesting that the gemcitabine is not 
encapsulated within the eVLPs upon staining with Coomassie blue (Figure 6.35–B). Moreover, 
VLPsgemcitabine did not show any fluorescence bands in unstained gels. This is in agreement with 
the need for the electrolytes to entrap the drug molecules within the VLPs; only wild–type 
particles were visible with ethidium bromide staining (Figure 6.35–A). However, the rhodamine 
and doxorubicin encapsulation within the capsid without the need for the polyelectrolyte was 
based on the electrostatic interaction. This might have to do with the size and the strength of the 
electrostatic interaction within the capsid interior.  
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Figure 6.35– Coomassie stained gel electrophoresis for VLPsgemcitabine (without electrolyte coatings). 
(A) ethidium bromide and (B) Coomassie stained agarose gel electrophoresis. Lane 1: wild–type 
CPMV; 2: eVLPs; 3: VLPsgemcitabine.  
 
 
EDXS elemental analysis for 
(PAH/PSS)2
VLPsgemcitabine and 
(PAH/PSS)2
VLPscisplatin confirmed 
the presence of fluorine (gemcitabine) and platinum (cisplatin), respectively, Figure 6.36. As a 
negative control 
(PAH/PSS)2
VLPs did not reveal any corresponding elements. This confirms that 
both gemcitabine and cisplatin were encapsulated within the VLPs.  
 
 
Figure 6.36– Elemental energy–dispersive X–ray spectroscopy analysis of (A) (PAH/PSS)2VLPsgemcitabine 
(B) (PAH/PSS)2VLPscisplatin (C) negative control (PAH/PSS)2VLPs. The arrows indicate major peaks. 
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6.4.1.6 Release studies 
Evidence that gemcitabine was encapsulated within the polymer coated CPMV eVLPs 
was obtained by deliberately rupturing the polyelectrolyte layers by incubating 
(PAH/PSS)2
VLPsgemcitabine with 0.15 M buffer pH 7.4 at 37 °C. Several different conditions were 
tried before establishing this as the best conditions within the physiological range. Faster release 
was accomplished in the same buffer at pH 9–10 or acetate buffer pH 5.3. Agarose gel 
electrophoresis was a very useful tool in tracking the changes in the polyelectrolyte 
disintegration. Figure 6.37 confirmed the removal of the polyelectrolytes and release of the 
encapsulated drug molecules from within eVLPs. The modified 
(PAH/PSS)2
VLPsgemcitabine particles 
were dialysed against 0.150 M sodium phosphate buffer at pH 7.4 and 37 °C, the first 2 hours 
revealed no visible bands on the gel and there was no free gemcitabine detected in the dialysis 
buffer. However, after 20–24 hours incubation, native intact form of eVLPs was observed in 
lane 3, Figure 6.37–D, and the gemcitabine was detected in the dialysate. However, the lower 
mobility band highlighted in lane 3 indicated the presence of the 24 aa C–terminus extension of 
the particles, which, in recent experiments has been shown to block the pores (see 6.4.1.7). 
Therefore, the same experiment was repeated with “top component particles” (TOP) extracted 
on caesium chloride gradient from wild–type that lack the 24 aa extension.  
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Figure 6.37– Release studies using gel electrophoresis for (PAH/PSS)2VLPsgemcitabine. (A) unstained (B) 
ethidium bromide stained (C) Coomassie stained before the dialysis against 0.15 M sodium 
phosphate buffer pH 7.4, and (D) Coomassie stained after the dialysis.  Lane 1: wild–type CPMV; 
lane 2: CPMV eVLPs (positive control); lane 3: (PAH/PSS)2VLPsgemcitabine. The observed band is in 
agreement with the removal of the polyelectrolyte and release of the drug molecules while the 
eVLPs remain intact. The red arrow indicates the higher mobility band of eVLPs with the 24 aa un–
cleaved. 
 
Agarose gel electrophoresis for native particles was used to monitor the electrolyte 
breakdown at set time points. A lag (delay) in the release of 
(PAH/PSS)2
TOPgemcitabine was observed, 
the first two hours resulted in no gemcitabine molecules being detected in the aqueous solution 
and agarose gel electrophoresis confirmed no changes to the particles pattern. The release 
profile gel is shown in Figure 6.38; the result suggests slow degradation of the electrolyte shell 
in the first six hours as a result of the polyelectrolyte being partially ruptured. As a result, free 
gemcitabine molecules were expelled from the interior of the eVLPs as confirmed 
spectrophotometrically and quantified as described in section 6.2.12. Once the electrolyte 
capsule starts to rupture, the electrostatic interactions between the charged moieties of the 
polymer are probably weakened and this will lead to the degradation of the polyelectrolyte shell. 
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Figure 6.38– (PAH/PSS)2TOPgemcitabine drug release using 0.150 M sodium phosphate buffer at pH 7.4 
and 37 °C. Lane 1, wild–type CPMV; 2, “TOP component”; 3–8, (PAH/PSS)2TOPgemcitabine after 2, 4, 6, 
8, 12 and 24 hours. 
 
6.4.1.7 The effect of the 24 amino acids C–terminus extension on loading 
It has been demonstrated that the pores at the five–fold axis are essential for the loading 
of eVLPs with metals and metal oxides (Aljabali et al, 2010c). These pores were a key factor 
governing the success of material diffusion. Although the size and charge of the encapsulated 
molecules are important and limited by the pore size. However, it was also observed that 
sometimes it was impossible to diffuse material into eVLPs. Further investigation has been 
carried out by the Evans and Lomonossoff groups on this phenomenon and its role in internal 
mineralisation. The external twenty four amino acid residues originating from the carboxyl 
terminus of the S coat protein prevents internal mineralisation of the particle (Sainsbury, F. et 
al, just accepted manuscript in ChemBioChem). Therefore, the removal of the 24 aa extension is 
essential for material diffusion into the eVLPs. This could be achieved by chymotrypsin 
treatment of the particles prior to any loading experiment. 
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6.5 Conclusions 
The synthesis of metal and metal oxides within readily available CPMV eVLPs is both 
size and shape–constrained by the inner cavity of the virus. Evidently, small molecules have 
access to the interior of the virus through pores at the 5–fold axis, this was supported by the 
observation that the addition of a methionine residue to the N–terminus of the S protein prevents 
penetration by cobalt ions, presumably by occluding the channel with a bulky side chain 
(Aljabali et al, 2010c). The charge on the internal surface of the capsid is negative, arising from 
glutamic acid and aspartic acid residues. The electrostatic interactions between the internal 
surface and the incorporated metal ions entrap them within the capsid, as are positively charged 
molecules such as rhodamine and doxorubicin. In addition, the LBL self–assembly of 
polyelectrolytes was demonstrated to be successful in encapsulating gemcitabine and cisplatin 
within eVLPs. The stepwise assembly of alternating charged electrolytes, PAH and PSS, was 
confirmed by zeta potential experiments. TEM images confirmed the integrity of the particles 
and EDXS confirmed the presence of the drug molecules within eVLPs. The surface of the 
polyelectrolyte–coated eVLPs may be further functionalised with PEG molecules, to reduce the 
immune response, or with A20FMDV2 peptide for targeting. This approach offers a very 
promising method to generate multifunctional nanoparticles for targeting, imaging and 
specificity. 
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7 Electroactive CPMV nanoparticles  
7.1 Introduction 
Miniaturisation of electronically active moieties may play a major role in the 
nanoelectronics field to develop future electronic devices. However, the miniaturisation (top–
down) approach presents a major challenge due to the physical size limitation of materials. 
Alternatively, bottom–up nanofabrication of electronically active molecules holds great 
potential in developing large–scale devices that are organised at the molecular level and are 
stable. One of the key issues is the controlled immobilisation of molecules onto well–defined 
surfaces. This could be achieved by the synthesis of highly monodisperse synthetic 
nanostructures such as dendrimers. Ferrocene and ferrocene–modified dendrimers hold great 
potential for the development of molecular electrochemical batteries (Astruc et al, 2009). For 
practical purposes, the chemical modification with ferrocene must be site–directed and 
controlled. Ferrocenes, viologens, quinones, and transition metals (e.g. Ni and Cu) have 
reversible electrochemical properties. Therefore, these redox centres are frequently used as 
active electrochemical components (Nijhuis et al, 2007). Ferrocene–based applications have 
raised considerable interest in many fields of analytical chemistry and recently in nanoscience. 
This is because of the well–established chemistry of ferrocenes and that the redox–responsive 
molecules are compatible with existing semiconductor–based microelectronic technology (Lee, 
2008).  
Ferrocene is stable in aerobic aqueous media and allows rapid and easy access to many 
derivatives. Besides, the electrochemical properties of ferrocenes both at the surface and in 
solution are attractive with respect to their detection and quantification (Seiwert & Karst, 2008). 
Ferrocene derivatives are of much interest in various areas of research and application, for 
example non–linear optics (Togni & Rihs, 1993), molecular sensors and receptors (Lopez et al, 
2004; Newkome et al, 1999), as ferromagnets (Yang et al, 2007) and for electrochemistry and 
catalysis (Balzani, 2001; Togni & Hayashi, 1995). Further, ferrocenes have been incorporated 
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into dendrimers (Astruc et al, 2009) and coupled to silica nanoparticles (Beasley & Murray, 
2009) for a range of applications. 
Ferrocene molecules are organometallic compounds with two stable oxidation states. 
The chemical structure consists of two cyclopentadienyl rings bound on opposite sides of an 
iron atom (Staveren & Metzler–Nolte, 2004). Ferrocenes exhibit a reversible one–electron 
oxidation/reduction at low potentials. The ferrocene molecule is a typical example of a charge–
storage molecule (Oms et al, 2005). The iron atom in ferrocene is Fe
2+
 and the ferrocene 
molecule is neutral. On removing an electron to the adjacent electrode, the iron atom becomes 
Fe
3+
 and the ferrocene molecule has an overall +1 charge. This charging/discharging property is 
of great importance in designing nanoelectronics devices or components (Tamura et al, 2008). 
7.1.1 Ferrocene functionalised CPMVwt particles (FcCPMV) 
Ferrocene
CPMV and 
Fc
CPMV will be used to refer to ferrocene conjugated to the capsid 
(superscript refers to molecules bound to the exterior of the capsid). The incorporation of 
ferrocene moieties to CPMV provided motivation for the synthesis of dendrimer–like structures 
with well–defined sizes and functionalities (Steinmetz et al, 2006d). CPMV capsids are highly 
monodisperse, bearing functional surface exposed groups at the periphery of the capsid. 
Moreover, viruses are highly monodisperse in comparison to their synthetic counterparts. 
Furthermore, the dendrimer–like FerroceneCPMV combines the unique and valuable redox 
properties of ferrocene moieties with the high symmetrical three–dimensional (3–D) 
architecture of the virus capsid. This allows precise positioning of the ferrocene onto the virus 
capsid and makes CPMVwt an ideal scaffold for the synthesis of electro–active viral 
nanoparticles. 
As part of the Evans group’s continuing effort to develop CPMV–based sensors, this 
chapter describes how various coupling strategies can be employed to give a range of 
Fc
CPMV 
derivatives (Figure 7.1) in which the separation distance between ferrocene and virus surface 
can be controlled (Aljabali et al, 2010a). This maybe important for the control of electron 
hopping to solid electrode surfaces and the development of nanoelectronic components. To 
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generate electroactive CPMVwt particles, solvent–exposed amines and carboxylates on the 
surface of CPMVwt particles were utilised as binding sites for ferrocene moieties. The 
electrochemical behaviour of the modified particles was assessed in solution to select the best 
candidates for immobilisation onto a solid electrode surface. 
 
 
Figure 7.1– FcCPMV derivative nomenclature. 
Subscript N represents linkage to virus surface amine; C represents linkage to surface carboxylate; 
numeral gives number of atoms in link between ferrocene and virus surface, where virus surface is 
taken to be the ε C of the lysine side chain, the β C of aspartate and the γ C of glutamate. 
Reproduced from Aljabali et al, 2010. 
 
7.2 Materials and Methods 
7.2.1  Materials 
All general reagents, 1–ethyl–3–(3–dimethlyaminopropyl)carbodiimide hydrochloride 
(EDC) was purchased from Novabiochem, N–hydroxysuccinimide (NHS) from Fluka, N–
succinimidyl–3–(2–pyridyldithio)propionate (SPDP) from Pierce, 2–(2–
pyridinyldithio)ethaneamine hydrochloride (PDEA) from GE Healthcare, sulfo–succinimidyl 4–
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formylbenzoate sodium salt (sulfo–S–4FB) from Solulink and aminoferrocene from TCI 
Europe. N–(ferrocenylmethyl)–6–aminocaproic acid (Padeste et al, 2000) and 11–
(ferrocenylcarbonyloxy)undecanethiol (Chidsey et al, 1990) were synthesised by published 
methods and their purity confirmed by 
1
H–NMR and mass spectrometry by Mrs Elaine Barclay. 
7.2.2 Methods: Coupling of ferrocene derivatives to CPMV 
All 
Ferrocene
CPMV modified particles were prepared freshly and used within a week. The 
samples were stored at 4 °C. Longer storage times resulted in a visible aggregation and 
precipitation. 
7.2.2.1 EDC/NHS method  
N–(ferrocenylmethyl)–6–aminocaproic acid, Fc6ac, and aminoferrocene, FcNH2 were 
coupled to CPMV surface amine groups and CPMV surface carboxylate groups, respectively, 
by the standard EDC/NHS method (Steinmetz et al, 2006c; Steinmetz et al, 2006d).
 
After 
stirring gently overnight at 4 ºC the 
Fc
CPMV conjugates were purified either by gel filtration on 
a Sephacryl S–500 column (GE Healthcare) or by dialysis using 100 kDa molecular weight cut–
off membranes (Float–A–Lyzer G2, Spectrum Laboratories) against 10 mM sodium phosphate 
buffer. The samples were concentrated on 100 kDa cut–off columns (Millipore) and the 
concentration of 
Fc
virus conjugate was determined photometrically at 260 nm with 60–70 % 
recovery based on the starting materials. Agarose gel electrophoresis, TEM and DLS confirmed 
the integrity of the modified virus. 
7.2.2.2 SPDP method  
The ferrocene–thiols 6–(ferrocenyl)hexanethiol, Fc6SH, and 11–
(ferrocenylcarbonyloxy)undecanethiol, Fc11SH, (Figure 7.2) were coupled to CPMV surface 
amine groups using N–succinimidyl–3–(2–pyridyldithio)–propionate (SPDP), the scheme is 
depicted in Figure 7.2. For detailed procedure, see section 2.14. 
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Figure 7.2– SPDP was used to modify the amine groups of CPMV to form amide bond linkages. 
The subsequent addition of thiolated ferrocene moieties resulted in disulfide bond formation. 
 
7.2.2.3 PDEA method:  
The method is adapted from (Frederix et al, 2004).The ferrocene–thiol Fc6SH was 
coupled to CPMV surface carboxylate groups with 2–(2–pyridinyldithio)ethaneamine 
hydrochloride (PDEA). To pre–activate the surface carboxylate groups, CPMV particles (10 mg 
ml
–1
), suspended in 10 mM sodium phosphate buffer pH 7.0, were reacted with a freshly 
prepared solution of EDC (1000 molar excess) and NHS (4000 molar excess) for 2 hours at 
ambient temperature with gentle stirring. The pre–activated 2–(2–
pyridinyldithio)ethaneamine
CPMVparticles were purified on PD–10 Desalting Columns (GE Healthcare). 
The eluted sample was reacted with a solution of PDEA (1000 molar excess) in Milli–Q water 
overnight, purified on a 100 kDa cut–off column and washed thoroughly to remove any 
unreacted materials. PDEA derivatised CPMV particles were reacted overnight at 4 °C with 
Fc6SH (1000 molar excess) dissolved in DMSO, the final DMSO concentration being adjusted 
to 20 % (v/v), purified by gel filtration (Sephacryl S–500 column), and the eluted fractions 
collected and concentrated on 100 kDa cut–off columns. The FcCPMV particle integrity was 
established by agarose gel electrophoresis, TEM and DLS. 
7.2.3 Electrochemical measurements 
Fc
CPMV in solution: Cyclic voltammetry was conducted with an AUTOLAB PGSAT 
30 potentiostat in a conventional three–electrode cell with the sample in 10 mM sodium 
phosphate buffer, pH 7.0 at room temperature (ca. 25 ºC). The working electrode was a 
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pyrolytic graphite edge (PGE) disc with a diameter of 3 mm; Ag/AgCl (saturated KCl) was the 
reference electrode and platinum wire the counter electrode (all experiments were conducted 
with the same electrodes unless otherwise indicated). Analysis of the free ferrocene moieties 
was typically performed with a concentration of 5–10 mM (with 10% DMSO or DMF as 
necessary for solubility). Modified virions were typically studied at concentrations of 1 to 11 
mg ml
–1
. For each sample, cyclic voltammograms were recorded at scan rates from 5 to 200 mV 
s
–1 
in duplicate sets with the working electrode polished by abrasion with an aqueous slurry of 
0.3 µm Al2O3 immediately prior to measuring each set. Consecutive voltammograms at each 
scan rate overlaid each other from the fourth scan onwards and these ‘steady–state’ 
voltammograms were analysed to determine peak potentials (Ep
a
 and Ep
c
 for the anodic and 
cathodic scans respectively) and peak current magnitudes (ip
a
 and ip
c
 for the  anodic and 
cathodic scans respectively) at each scan rate. Analysis of 20 mV s
–1
 voltammetry performed at 
various times during the collection of each set of scan rates confirmed that the response was 
independent of time. Plots of peak current versus the square root of scan rate were found to be 
linear. The gradients were determined by linear regression and analysed by the Randles–Sevcik 
equation to determine the concentration of ferrocene in the sample and ultimately the number of 
ferrocene moieties per virus particle (Steinmetz et al, 2006d). 
7.2.4 Methods: Coupling of FcCPMV onto solid surfaces 
7.2.4.1 Cleaning gold electrode 
The gold surface (3 mm in diameter) was polished with 0.03 and 0.01 µm alumina 
slurry successively and then sonicated in a Milli–Q water bath for a minimum of two minutes. 
The electrode was cleaned in a freshly prepared piranha solution (70% H2SO4 : 30% H2O2), 
rinsed thoroughly with Milli–Q water, dried under a stream of argon and placed in a sealed vial 
containing 10 mM of the thiolated ligand in 50% ethanolic solution for 8–18 hours. Another 
cleaned surface was used as a control. 
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7.2.4.2 Cystamine and thioctic acid SAMs on gold surface 
Gold electrode was immersed into 0.1M cystamine (in 50% ethanol: 50% Milli–Q 
water) or 0.1 M thioctic acid solutions prepared in 100 mM sodium phosphate buffer pH 7.0 and 
incubated overnight (12–15 hours) at 4 °C while gently stirring. The electrode was thoroughly 
washed with 50% (v/v) ethanol solution followed by sonication and washing again with 50% 
(v/v) ethanol solution to ensure removal of all the contaminants. SAMs formation was 
characterised by CV in 100 mM sodium phosphate buffer pH 7.0 at 0.1 V s
–1
 vs (Ag/AgCl) as a 
reference electrode. Optimised SAM formation conditions were repeated, assuming in the 
subsequent experiments that equivalent SAMs were formed under the same conditions.  
7.2.4.3 FcC2CPMV immobilisation onto gold surface  
A clean gold electrode was first soaked in 66.6 % ethanolic solution (v/v) thioctic acid 
for 8–15 hours at room temperature to form the SAM. After an ethanol rinse, to remove 
adsorbed thioctic acid, the doubly–functionalised FcC2CPMVNHS–ester, previously prepared and 
fully characterised in solution, was directly attached to the ester group of the thioctic acid. In 
brief, CPMV surface carboxylates were first activated with EDC/NHS and ferrocene bound to 
the lysines. The gold modified surface was immersed into 5–10 mg ml–1 of modified CPMV 
particles with stirring. The electrode was thoroughly washed before conducting any 
measurements.  CV measurements were recorded at various time points from 2–15 hours.  
7.2.4.4 Graphite electrode modification 
Surface modification of freshly clean graphite surface was carried out at room 
temperature in a degassed solution (argon) of 0.1 M HCl (2 ml) containing 3 mM 4–
azidobenzene diazonium  tetrafluroborate, [N3C6H4N2](BF4). The amperometric reduction for 
the aryl diazonium salt was accomplished by scanning from 0 to –0.1V. The modified electrode 
surface was thoroughly washed with Milli–Q water followed by ethanol and sonicated in a 
water bath for 2–3 minutes. The electrode was kept in 10 mM sodium phosphate buffer prior to 
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the second step of the modification (incubation with the doubly functionalised virus). As a 
control experiment to establish if there is any signal in the absence of the virus, 0.5 mg of sulfo–
NHS–phosphine (Thermo Scientific) dissolved in DMSO was prepared just before use and 
added to 3 ml 10 mM sodium phosphate buffer in a vial. The electrode was left on a shaker at 
200 rpm at 4 °C overnight (16 hours) before being washed thoroughly with Milli–Q water and 
DMSO to remove any adsorbed excess. The electrode was then incubated with solution 
containing aminoferrocene (DMSO–buffer) for 14–16 hours the CV was then recorded after 
that. 
7.2.4.5 CPMV modification for PGE electrode 
7.2.4.5.1 PGE electrode modification 
Surface functionalisation of the graphite electrode was carried out at ice–cold 
temperature in a deaerated solution (with argon); 3 ml of 0.1M HCl containing 2 mM of 4–
azidobenzene diazonium or 4–ethyl–benzene diazonium (BF4 salts). The reductive 
electrodeposition of the aryl diazonium salts was achieved amperometrically. The working 
electrode potential was set between minus 1 and 0 V. After the functionalisation, the electrode 
surface was thoroughly washed with Milli–Q water followed by ethanol to remove any adsorbed 
species. 
7.2.4.5.2 Surface coupling of FcCPMV by “click” chemistry  
The modified electrode as described above was immersed in a 15 ml Milli–Q water 
solution containing 10 mM final concentration CuSO4 , L–ascorbic acid (10 mM), and the 
corresponding half of the “click” reaction (azide or alkyne). The “click” reaction was 
accomplished overnight before reacting 
Fc
CPMV particles to the modified surface. The 
electrode was rinsed thoroughly with Milli–Q water and ethanol to ensure that any adsorbed 
species were washed off. Finally, the modified electrode was incubated in 0.1M sodium 
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phosphate buffer pH 7.0 with the doubly–functionalised particles Ferrocenecarboxylic acidCPMVNHS–ester. 
The electrode was rinsed rigorously with buffer before being scanned by CV.  
Alternatively, virus azide particles 
Ferrocenecarboxylic acid
CPMV
Azidorpropylamine
 were reacted 
with previously functionalised graphite surface as described in Figure 7.3. The protocol was 
provided by Prof. M. G. Finn, the Scripps research Institute (personal communication with Prof. 
Dave Evans). The final reaction conditions for the “click” chemistry with the modified virus in 
0.1M sodium phosphate buffer pH 7.0 were: 0.25 mM CuSO4 in Milli–Q water, 1.25 mM ligand 
tris[(1–benzyl–1H–1,2,3–triazol–4–yl)methyl] amine (TBTA–OH) in water, 5 mM  sodium 
ascorbate freshly prepared,  and 5 mM amino guanidine. The reaction was mixed well and was 
left to proceed for 1–2 hours followed by dialysis overnight ~16 hours. 
 
 
Figure 7.3– Doubly–functionalised Ferrocene carboxylic acidCPMVAzidopropylamine particles. Where (m) refers 
to the number of azidopropylamine coupled to the virus and (n) refers to the number of ferrocenes 
bound to the virus. 
 
7.3 Results and discussion   
This chapter describes and evaluates several strategies for coupling of ferrocene onto 
CPMV capsid, to both amine and carboxylate groups of the surface exposed amino acids, using 
a range of conjugation strategies.  
CPMV surface amine groups, arising from exposed lysines, can be readily coupled to 
ferrocene–carboxylate derivatives using EDC/NHS methods (Steinmetz et al, 2006d)  and to 
ferrocene–thiols using SPDP reagent. The SPDP reagent in the current work was first coupled to 
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the amine groups of the virus by reaction with the succinimidyl group of the reagent. The 
N–
succinimidyl–3–(2–pyridyldithio)propionate
CPMV derivative was isolated and purified. The pyridyl disulfide 
group of this derivative was then reacted with ferrocene–thiol; pyridine was liberated and a 
disulfide bond was formed between the ferrocene and the modified virus (Figure 7.1). Further, 
CPMV surface carboxylate groups, from exposed aspartic and glutamic acids, can be coupled to 
aminoferrocene, using EDC/NHS, or to ferrocene–thiol, Fc6SH, with PDEA (Figure 7.1). Prior 
to coupling of PDEA to the virus, the surface carboxylates were pre–activated with EDC/NHS; 
these react with the amine group on the PDEA reagent to form a stable amide bond. Ferrocene–
thiol can then be coupled to the modified CPMV by thiol–disulfide exchange. In all cases, the 
ferrocene reagents were used in a large excess to ensure maximum coupling. Virus particles 
were recovered in approximately 70 – 80% yield based on initial wild–type concentration as 
determined spectrophotometrically. In each case, and as described below, ferrocenylation of the 
virus capsid occurs with retention of virus integrity, as was established by uranyl acetate 
negatively stained TEM which shows that the virus particles remain intact and that they are 
monodisperse with a diameter of approximately 28 nm (for example, Figure 7.4).  
 
 
Figure 7.4– Transmission electron microscopy images of chemically modified particles after staining 
with 2% uranyl acetate. (A) CPMVwt; (B) AminoferroceneCPMV, FcC12. Particles are monodisperse 
with ~28 nm diameter. Reproduced from (Aljabali et al, 2010). 
 
 
 
DLS measurements gave the average diameter of the 
Ferrocene
virus particles and 
confirmed monodispersity (Table 7.1). The DLS and the correlation data are presented in Figure 
7.5.  
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FerroceneCPMV Diameter (nm) Polydispersity (%) 
           FcN2 29.8 24.5 
           FcN9 30.0 10.7 
           FcN12 32.0 20.6 
           FcN19 33.0 20.8 
           FcC2 29.4 11.8 
           FcC12 31.8 19.6 
Table 7.1–Diameter and polydispersity of FerroceneCPMV as determined by dynamic light scattering. 
Reproduced from Aljabali et al, 2010. Subscript N represents linkage to virus surface amine; C 
represents linkage to surface carboxylate 
 
 
  
 
Figure 7.5–DLS of FerroceneCPMV. Comparison of hydrodynamic radii (A) and correlation plots (B). 
FerroceneCPMV particles at approximately 0.5 mg ml–1 in 10 mM sodium phosphate buffer pH 7.0 
after filtration through 0.1 μm filters immediately prior to analysis. Measurements were taken every 
10 seconds and 10 measurements were averaged from 3 runs at 21 °C. (Reproduced from (Aljabali 
et al, 2010a). 
 
 
Intact virions of wild–type CPMV can be separated into a higher– and lower–mobility 
form by native gel electrophoresis according to their migration towards the anode. These forms 
are derived from the slow and fast form of the small subunit of the virus capsid and are a 
consequence of a carboxy–terminal cleavage of 24 amino acids of the small subunit (Sainsbury 
F. et al, 2011; Taylor et al, 1999). The higher–mobility band in the agarose gel represents 
virions with a cleaved small subunit. 
Ferrocene
CPMV derivatives with shorter linker length, 
whether coupled through amine or carboxylate groups, FcC2 and FcN9, exhibit retarded mobility 
of the ferrocene–modified virus particles compared to wild–type CPMV (Figure 7.6), as has 
been previously observed for FcN2 (Steinmetz et al, 2006d), and is consistent with an increase in 
size and, therefore, decoration of the virions with ferrocene molecules. Surprisingly, 
Ferrocene
CPMV particles with longer linker length and coupled via a disulfide linkage, FcN12, 
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FcC12 and FcN19, show enhanced mobility toward the anode as does a 
N–succinimidyl–3–(2–
pyridyldithio)propionate
CPMV derivative positive control (Figure 7.6–C). This unexpected behaviour is 
thought to arise because of a combination of size and charge effects perturbing mobility through 
the gel. However, they all migrate to a different extent than wild–type confirming that the 
particles have been modified.  
 
 
Figure 7.6– Wild–type and FerroceneCPMV particles on a 1.2% agarose gel. (A) Lane 1, wild–type 
CPMV; 2, CPMVNHS ester; 3, FcC2; 4, FcN9. (B) Lane 1, CPMVwt; N–succinimidyl–3–(2–
pyridyldithio)propionateCPMV derivative; 6, FcN12; 7, FcN19. (C) Lane 1, CPMVwt; 2, NHS–esterCPMV; 8, 2–
(2–pyridinyldithio)ethaneamideCPMV derivative; 9, FcC12. 
 
 
Cyclic voltammetry established that the modified 
Ferrocene
CPMV are redox–active 
nanoparticles, (e.g. Figure 7.7–A&B). The ratio of the peak currents, ip
a
/ip
c
, is close to unity 
showing the ferrocene/ferrocenium couple is electrochemically reversible. Ferrocene 
dendrimers showed similar properties due to fast rotation of the dendrimer compared to the 
electrochemical timescale, so that all the redox centres come close to the electrode within this 
timescale (Green et al, 1998). The peak currents were proportional to the square root of the scan 
rate, 
½
, showing that oxidation and reduction were diffusion controlled (e.g. Figure 7.7). 
Plotting the measured peak currents ip versus the square root of the scan rate confirmed that the 
oxidation and reduction was diffusion controlled as seen in (Figure 7.7–A2 and B2). 
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Figure 7.7– Cyclic voltammogram for some FerroceneCPMV modified particles. 
(A.1) Cyclic voltammograms of FcN9 at scan rates from 5 mV to 200 mV s–1; (A.2) Variation of 
peak current with the square root of the scan rate. (B.1) Cyclic voltammogram of FcC2 at scan rates 
from 5 mV to 200 mV s–1; (B.2) Variation of peak current with the square root of the scan rate. 
Reproduced from (Aljabali et al, 2010). 
 
 
The concentration of ferrocene molecules in the ferrocene conjugated CPMV samples 
was determined using the Randles–Sevcik equation (Figure 7.8). The peak current, ip, is directly 
proportional to the analyte concentration (ferrocene) at 25 °C. The number of ferrocene 
molecules attached to CPMV was calculated from the slope equation depicted in Figure 7.8, 
using the CPMV diffusion coefficient from the reference (Steinmetz et al, 2006d); the results 
are summarised in Table 7.2. The minimum and maximum numbers for the attached ferrocene 
moieties per virion was based on an error of ± 5 % in the electrode area to give a more realistic 
estimation of the ferrocene moieties per virus. The complete set of data and the detailed 
calculation of all 
Ferrocene
CPMV derivatives are attached as an appendix to this thesis.  
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Figure 7.8– Randles–Sevcik equation. 
In this equation , ip= current in amps, and is directly proportional to the analyte concentration, the 
temperature is assumed to be 25 °C , n=1; n is the number of electrons transferred per molecule, A 
is the surface area of the working electrode = 0.07 cm2, D is the diffusion coefficient of CPMV 
particles in aqueous buffer solution = 0.16 x 10–6 cm2 sec–1 (Steinmetz et al 2006);  k is a constant of 
2.69 x 105 C mol–1 V–1/2 and v= scan rate over a range from v= 5 to 200 mV sec–1; CFC is ferrocene 
concentration. 
 
 
 
Ferrocene reagent E½ (V)(± 0.015) FerroceneCPMV E½ (V) (± 0.015) Number of 
ferrocenes per 
virion (± 5%) 
    FcCOOH  0.322            FcN2 0.233 240 
    FcAC 0.425            FcN9 0.373 246 
    Fc6SH 0.455            FcN12 0.325 250 
    Fc11SH 0.450            FcN19 0.344 193 
     
    FcNH2 0.380            FcC2 0.210 174 
    Fc6SH 0.455            FcC12 0.320 101 
Table 7.2– Reduction potential (E½) of ferrocene and FerroceneCPMV vs Ag/AgCl (saturated KCl) 
and the average number of ferrocenes per CPMV virion as calculated from the linear plots of 
current versus the square–root of the scan rate and the Randles–Sevcik equation. In the case of 
FcCOOH the values are reproduced from Steinmetz et al, 2006c.  
 
 
The asymmetric unit of CPMV can be maximally labelled, under standard conditions, at 
four of the five accessible lysines presented on the outer surface (Lys 38, 82 of S subunit and 
Lys 34, 99, 199 of L subunit). This provides a maximum of 240 addressable lysine sites on the 
CPMV virion surface (Evans, 2008; Manchester & Steinmetz, 2009; Steinmetz & Evans, 2007). 
FcN2, FcN9 and FcN12 show maximum coverage. However, when the linker length is increased 
further, as in FcN19, there is a decrease in the number of ferrocenes bound from about 240 to 
193. Similarly, the maximum number of addressable carboxylates at the virion surface has been 
determined to be 180 of the 420 aspartate and glutamate residues on the outer surface (Asp 26, 
44, 45, 85, and Glu 135 on the S subunit, and Asp 273 and Glu 319 of the L subunit) (Steinmetz 
et al, 2006a). The 
Ferrocene
CPMV with a short linker, FcC2, shows maximum coverage, whereas 
that with a longer linker, FcC12, exhibits reduced coverage. The decrease in the number of 
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bound ferrocenes as a function of linker length is likely to be a consequence of the longer linker 
length molecules folding back onto the surface and blocking some of the other coordination 
sites. It is less likely to be a consequence of the different coupling strategies employed, as the 
conditions used should favour maximum coverage.  
The distances between side chains of the surface–exposed lysines are depicted in Figure 
7.9. Wang et al established lysine 38 (S) as the most reactive surface lysine (Wang et al, 2002a). 
FcC12
CPMV particles showed a notably decreased number of ferrocene moieties per virus. 
Assuming FcC12 is coupled to lysine 38, the most reactive lysine, this could block the reactivity 
of adjacent lysine 99 (L). This is consistent with the quantitative data, which suggests the 
modification of three lysines per asymmetric unit. In addition, the FcC12 linker molecule as 
shown in Figure 7.10 with minimized energy revealed a molecule length of 22.16 Å. As the 
distance between the most reactive lysines is 18.1 Å, it is expected that FcC12 block the 
availability of the adjacent lysine. This effect equates to 60 ferrocene molecules per virus less 
than when shorter ferrocene derivatives are used.  
 
 
Figure 7.9– Addressable lysine residues on the exterior surface of the CPMV capsid with the 
separation distances. The asymmetric unit is composed of the small (S) subunit (green), and large 
(L) subunit. Depicted are addressable surface lysine residues with separation distance (Å); Lys 38 
and Lys 82 on the S subunit, Lys 199 on the B domain of the L subunit, and Lys 34 and Lys 99 on 
the C domain of L. Images generated with PyMOL–1_2B8eval version. The accessible surface 
profile of CPMV capsid file is available at http://viperdb.scripps.edu with PDB–ID (1NY7). 
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Figure 7.10– Schematic representation of FcC12 linker. The drawing was generated by 
MarvinSketch and MarvinSpace 5.3.2 software. The linear distance between the two peripheral 
carbons (1 and 2) is 22.18 Å, whereas the distance between the two most reactive lysines is 18.1 Å. 
R1 represents SPDPCPMV and R2 the ferrocene group. 
 
Reduction potentials (E½) determined for the free and conjugated ferrocene moieties 
from the average peak potentials are shown in Table 7.2. Conjugation to the virus results in 
destabilisation of the ferrocenium form as reflected in the lower E½ for the conjugated form. In 
each case, and for all scan rates studied, the peak separation |Ep
a–Ep
c
| ranged from 55 to 70 (± 5) 
mV, which is close to the theoretical value expected for a one–electron process (59 mV at 25 
°C). Thus, the voltammetry indicates that the ferrocenyl centres coupled to the CPMV surface 
behave as independent and electronically isolated units with apparently homogeneous redox 
properties. Electronic isolation is likely to reflect a spacing of the ferrocene units across the 
virion surface that prevents their close approach for electron transfer. Given that the ferrocene 
units are conjugated to multiple environments on the surface of the asymmetric unit, the 
homogeneity of the redox properties suggests the ferrocenes exhibit similar reduction potentials 
at all of these sites. 
7.4 FcCPMV immobilisation on electrode surface 
Here are outlined results of preliminary studies on surface modification for future 
applications in the fabrication of functional nanodevices. The aim was to couple 
Fc
CPMV to a 
solid electrode surface to obtain electron flow. According to the literature, the most commonly 
used method for chemical modification of surfaces is the deposition of self–assembled 
monolayers (SAMs) and Langmuir–Blodgett (LB) films, which generate ultrathin films 
(Tredgold, 1991). SAMs commonly achieve covalent modification of surfaces. Some examples 
are thiolated and disulfides on gold; silanes on oxide surfaces; carboxylic acids on metal oxides 
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(Ulman, 1996). Dendritic macromolecules have been used to modify gold or carbon electrodes 
(Lojou & Bianco, 2006).    
Willner and colleagues demonstrated the ability to construct multi–layered nanoparticle 
electrodes that are porous (Lahav et al, 1999). The immobilisation or covalent attachment of 
molecules to a surface, at a precise location, to generate highly defined miniaturised 
nanodevices is of great interest in nanoelectronics and biofuel cells that utilise enzymes to 
convert chemical energy into electrical energy (Pizzariello et al, 2002).  
Dendrimers modified with redox–active ferrocenyls were used for the construction of a 
multilayered assembly of enzymes via LBL deposition (Jang et al, 2009). 
Ferrocene
CPMV 
immobilisation on a suitable solid surface provides unique features for the generation of ordered 
nanoparticle assembly, which is essential in nanoelectronic applications and development. Also 
important is efficient electron exchange between the immobilised ferrocene and the electrode.  
A gold solid surface is one of the easiest materials to use as a solid support; thiols and 
disulfide adsorb easily to form SAMs. A SAM is essentially an organization of molecules at the 
solid–liquid interface induced by the affinity between the surface and the ligand, and can be 
easily prepared by immersing a freshly cleaned gold surface in a solution of appropriate thiol. 
7.4.1 Coupling onto solid surfaces 
One of the important advantages of SAM is that it can be prepared very easily and 
simply. The surface is dipped into a solution containing the appropriate ligand molecules 
followed by thorough washing with the same solvent as the ligand was prepared in. Modified 
virus immobilisations to SAM functionalised surfaces, presented here are based on monolayer 
formation of SAMs onto solid surfaces. Thiol–terminated ligands, such as cystamine and 
thioctic acid, react efficiently with gold surfaces leaving amine or ester groups to couple to the 
virus surface. Schematic representation of this approach is depicted in Figure 7.11. 
Rigorous cleaning and pre–treatment of gold surfaces was necessary to facilitate 
formation of well–defined monolayers onto the surfaces. Piranha solution (70% H2SO4: 30% 
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H2O2) (Bain et al, 1989) and electrochemical treatment to remove oxide contamination by 
cycling the potential range from +0.5 to –1.4V in 0.5 M H2SO4 electrolyte were adopted here. 
 
 
Figure 7.11– Schematic of FerroceneCPMV particles immobilised onto gold surface through cystamine 
SAM formed on Au surface. 
 
7.4.2 Results and discussion of FcCPMV onto solid surfaces   
Gold electrode cleanliness was monitored by cyclic voltammetry (CV) in 0.1 M H2SO4, 
the CV of clean gold surface shows an oxidation peak at +1.3 V (vs. Ag/AgCl in saturated KCl 
for all experiments presented here) and a reduction peak at +0.9 V (vs. Ag/AgCl) corresponding 
to metal oxide formation and reduction (Figure 7.12). Cyclic voltammetry was finished with the 
electrode at a negative potential to ensure an oxide–free gold surface. A typical cyclic 
voltammogram of clean gold surface free from any contaminants is shown in Figure 7.12.  
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Figure 7.12– Typical CV of a clean gold electrode in 0.1M H2SO4 at 100 mV s–1. This shows a 
characteristic anodic peak at +1.3 V and a cathodic peak at +0.9 V. 
 
7.4.2.1 SAMs formation and characterisation on gold surface 
The simplest way to confirm adsorption of thiol–based moieties on a gold surface is the 
disruptive reduction of the formed cystamine SAM in 0.1 M sodium phosphate buffer, 0.15 M 
NaCl, pH 7.0 at 100 mV s
–1
. This is illustrated in Figure 7.13 where the CV showed a reduction 
peak at –0.7 V (vs. Ag/AgCl) indicating the presence of cystamine SAM. Subsequent scans 
showed no such peak, which is consistent with the disruption of the thiols bound to the gold and 
consequent loss of the assembled monolayer. The aforementioned property, although useful in 
quantifying and confirming the SAMs formation, demonstrates the limitation of the use of gold 
surfaces and does not allow further use of the electrodes. However, it was used to optimise the 
SAM formation assuming in the subsequent experiments that equivalent SAMs were formed 
under the same conditions. 
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Figure 7.13– Cyclic voltamograms for the removal of cystamine SAM from the Au surface by the 
electroreduction. 1st and 2nd CVs showing the reduction of the Au–S bond in 0.1M sodium 
phosphate buffer pH 7.0 at 100 mV s–1.  
 
Initially, ferrocenecarboxylic acid was coupled onto the cystamine–functionalised Au 
surface to establish the feasibility of using 
Ferrocene
CPMV particles for surface modification. A 
very weak electrochemical signal resulted (Figure 7.14). This was very difficult to reproduce as 
the voltammetric response of the Au electrode in the absence of ferrocene often showed features 
in the region where the ferrocene signal is expected, most likely due to impurities adsorbed onto 
the Au electrode surface. 
 
Figure 7.14– Ferrocenecarboxylic acid attached to cystamine functionalised Au surface.  
A represents cystamine–functionalized Au surface (unmodified) and B represents ferrocene 
attached to Au surface at scan rate of 20 mV s–1. 
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It was initially proposed to modify Au surfaces with different thiolated moieties (i.e. 
cystamine and thioctic acid) to which 
Fc6ac
CPMV and 
FcC2
CPMV particles could be coupled. The 
ferrocene moieties used for this work had different linker lengths (see section 7.1.1) in order to 
establish which ferrocene moieties on the virus capsid could transfer electrons to the Au surface. 
The coupling reaction of 
Ferrocene
CPMV to the Au surface was conducted in 0.1 M sodium 
phosphate pH 7.0 overnight. The electrochemical results showed no communication between 
the presumably immobilised 
Ferrocene
CPMV and the Au electrode. 
To investigate whether the 
Ferrocene
CPMV is actually coupled to the SAM functionalised 
Au surface, fluorescent labelling and IR spectroscopy was attempted. However, due to the 
nature of the electrode used for the experiments, IR spectroscopy could not be pursued further. 
Fluorescent labelling of CPMV particles followed by immobilisation on an NHS terminated Au 
surface (via thioctic acid) resulted in no significant signal being detected using fluorescence 
microscopy. In addition, in an attempt to confirm modification of the Au surface with 
Fc6ac
CPMV particles, CV was performed in 0.1 M H2SO4, as shown in Figure 7.15, and a shift in 
the oxidation peak was observed. This suggests that the surface is modified maybe with the 
SAM but does not conclusively confirm CPMV attachment.  
 
 
Figure 7.15– CV scans of Au surface before and after attachment of Fc6acCPMV particles.  
A, CV scans before attaching FerroceneCPMV and B, after the immobilisation of Fc6acCPMV particles. 
Scan rate of 100 mV s–1 in 0.1M H2SO4. 
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The electrochemical analysis of 
Ferrocene
CPMV in aqueous solution revealed a reversible 
one–electron signal as explained in detail at the beginning of this chapter. However, no electron 
transfer through 
Fc6ac
CPMV and 
FcC2
CPMV to the gold surface was observed; repetition of this 
approach did not result in any CV response. Due to the poor quality of the data obtained 
repeatedly, it is not clear whether the ferrocene centres are not close enough to the electrode or 
the modified virus particles are acting as insulators and preventing electron hopping. Another 
possibility is that the 
Ferrocene
CPMV was not successfully attached to the electrode surface 
because of a very low reactivity of the NHS terminated monolayer.  
 
7.4.2.2 SAMs formation and characterisation on graphite electrode 
As evidence for electroactive 
Fc6ac
CPMV and 
FcC2
CPMV on gold could not be obtained, 
it was desirable to try a graphite surface. It has been reported in the literature that chemical 
treatment of a graphite surface resulted in a stronger and faster covalent attachment of an azide– 
or acetylene–terminated layer on the electrode surface (Evrard et al, 2008). Generating an aryl 
radical that couples with the graphite electrode to form a C–C bond is a well accepted 
mechanism (Allongue et al, 1997).  The graphite surface activation procedure is depicted in 
Figure 7.16. 
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Figure 7.16– Schematic illustration of carbon electrode functionalisation. Electroreduction of 
phenylazide or phenylacetelyene for immobilisation on PGE electrode. 2 mM (fixed for all 
experiments) of diazonium salts in 0.1M HCl at scan rate of 0.1Vs–1 at ice–cold temperature. The 
electrodeposition time was ≥ 1minute. 
 
 
This approach offers several advantages over thiolate SAMs: strong linkage of the 
linker to the electrode surface, fast surface modification (obtained in under a minute), and easy 
control over functionalisation coverage (Evrard et al, 2008). The SAM formation on the PGE 
surface was coupled with acetylene or azide–bearing molecules attached to the virus capsid by 
“click” chemistry (Allongue et al, 1997; Evrard et al, 2008). 
CV monitored the SAMs deposition onto the graphite surface. The CV was recorded of 
2 mM diazonium salt at PGE electrode in 0.1 M HCl solution at ice–cold temperature. The first 
CV scans exhibited a well–defined, reproducible, and irreversible reduction peak at ~ –550 mV. 
This characteristic corresponds to the typical electroreduction of diazonium salts, leading to the 
elimination of a nitrogen molecule and the production of an aryl radical, Figure 7.17 line D. 
This radical has been reported in the literature to attack the surface and to form a covalent bond 
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between the aryl group and the carbon surface of the electrode (Corgier et al, 2005; Vakurov et 
al, 2004). The second and third CV scans revealed very low currents, evidence of surface 
saturation and a result of a very fast deposition processes (<1 min) suggesting that a monolayer 
was achieved.  
 
 
Figure 7.17– CV scans for the confirmation of successful modification of PGE electrode before 
and after the modification. (A) PGE clean electrode before the modification, (B) PGE after 
modification, (C) second scan and (D) first scan. 2 mM of either N3C6H4N2+ or 
HC C C6H4 N2  in 0.1M HCl and scan rate of 0.1V s–1 on ice cold temperature. 
 
 
To demonstrate the utility of “click” chemistry, the incorporation of aryl diazonium 
salts to the graphite surface was exploited. The subsequent azide–alkyne cycloaddition reaction 
was investigated using two approaches: Firstly, “click” reaction between the functionalised PGE 
surface and the doubly functionalised virus 
Fc6ac
 
or
 
FcC2
CPMV
azide or alkyne
. Secondly, the “click” 
reaction was accomplished prior to coupling 
Fc6ac
 
or
 
FcC2
CPMV to the assembled SAM on PGE 
surface. However, performing “click” reaction in the presence of the virus was difficult as in 
most trials disassembly of the particles or aggregate formation resulted. Therefore, the “click” 
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chemistry was performed on the solid surface first, followed by the addition of the modified 
virus.  
Although the graphite surface modification was relatively easy and quick, the 
subsequent “click” reaction proved to be difficult. As a control experiment, the aminoferrocene 
(no virus) was used to assess if it is possible for electron communication with the graphite 
surface. The PGE surface was functionalised with alkyne salt followed by the “click” reaction to 
esterified monopropargylamide derivative of glutaric acid (PRGL–ac); this in turn was reacted 
with aminoferrocene. The obtained CV scans are shown in Figure 7.18. The optimum condition 
that generates the ferrocene signal was subsequently used for all immobilisations of the 
modified CPMV particles onto the PGE surface. 
 
 
 
Figure 7.18– CV scans for aminoferrocene conjugated to SAM layer formed via “click” chemistry 
reaction. A is clean surface and B is the aminoferrocene functionalised PGE surface, scan rate of 
0.020 V s–1. 
 
 
However, the best results obtained from 
Aminoferrocene
CPMV are shown in Figure 7.19. 
The signal was so weak and there was a reproducibility issue. It is still not known whether the 
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entire PGE surface was covered with the modified virus or if there is insufficient electron 
hopping and exchanging with the surface. Further work is required to investigate whether the 
virus is acting as an electron insulator and preventing electron hopping. 
 
 
 
 
Figure 7.19– CV scans for AminoferroceneCPMV conjugated to PGE surface. Blue line is clean surface 
and red line is the AminoferroceneCPMV conjugated to the functionalised PGE surface. Scan rate of 0.1 
V s–1 in 0.1M sodium phosphate buffer pH 7.0 at ambient temperature ~ 25 °C. 
 
7.5 Conclusions 
Viral nanoparticles offer a level of monodispersity almost far beyond the chemist’s 
capabilities. The incorporation of relatively complex and fragile viral nanoparticles in nanoscale 
electronic devices or components is still far–fetched with major complications. In this chapter, 
the concept of chemical modification of viral nanoparticles was employed to position redox–
active molecules via covalent modification.  
It has been shown that both amine and carboxylate groups on the surface of CPMV can 
be decorated with ferrocene, with various linker lengths, utilising a range of conjugation 
strategies. The number of ferrocenes, determined electrochemically, per virus particle decreases 
with the length of the linker. Several ferrocene immobilisation strategies have been adopted to 
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generate 
Ferrocene
CPMV hybrids. Cyclic voltammetry was used to both verify and quantify the 
active functionalities of immobilised ferrocene moieties onto the virus capsid. The multiple 
redox–active ferrocene moieties on the virus capsid are electrochemically independent, with a 
reduction potential window of 0.16 V that is dependent on the site of modification and the 
length of the ferrocene derivatives. The number of ferrocenes coupled to each virus ranged from 
about 100–240 dependent on the conjugation site and the linker length. 
The ferrocene moieties on the outer surface of the virus are electrochemically 
independent and can act as multielectron reservoirs. The modified virus particles provide a 
selection of redox active nano–components. The goal was to explore how these can be 
assembled onto solid electrode surfaces and take advantage of the relay–mechanism from the 
ferrocene centre to the next moiety (hopping electron transfer); these hybrids may act as 
electron transfer mediators for the development of redox catalysts, biosensors and 
nanoelectronic devices. 
From the obtained results, it was not clear whether the ferrocene centres are not close 
enough to the electrode surface or the modified virus particles are acting as insulators and 
preventing electron hopping. Another possibility is that the 
Ferrocene
CPMV was not successfully 
attached to the electrode surface because of a very low reactivity of the NHS terminated 
monolayer. It might be useful to look for different PGE electrode that could be charachtirised by 
the available spectroscopy methods at the University of East Anglia facilities. It might be also 
worth trying 
Fc
AuNp attached to PGE electrode prior to use 
Ferrocene
CPMV particles. 
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8 EnzymeCPMV nanoparticles 
8.1 Introduction 
Enzyme–nanoparticle conjugates that take advantage of the catalytic ability of the 
bound enzyme have been reported in the literature for various applications (Katz & Willner, 
2004; Niemeyer, 2001). For example, the enzymes horseradish peroxidase (HRP) and glucose 
oxidase (GOX) have been sequentially co–immobilized in polyelectrolyte multilayers on silica 
nanoparticles to facilitate the overall enzymatic reaction; the GOX layer generating hydrogen 
peroxide in the presence of β–D–glucose that diffuses toward the HRP layer to be reduced to 
water in the presence of o–dianisidine (HRP substrate) (Pescador et al, 2008). The objective 
described here was to examine the use of CPMV as a solid support to construct enzyme–based 
functional virus particles. Two well-studied enzymes were employed as model enzymes: HRP 
and GOX. The preparation of 
Enzyme
CPMV conjugate was by covalent modification of wild–type 
CPMV. 
HRP is a hemoprotein enzyme of molecular weight 40 kDa that can catalyze the 
reaction of hydrogen peroxide with certain organic, electron–donating substrates to yield highly 
coloured products. The presence of the heme group gives the enzyme its characteristic brown 
colour and maximum absorption at 403 nm. HRP is a glycoprotein that contains significant 
amount of carbohydrate. Thus mild oxidation of the enzyme sugar residues with sodium 
periodate generates reactive aldehyde groups that can be used for conjugation to amine 
containing molecules (Hermanson, 2008).  
GOX is a flavoenzyme that catalyses the oxidation of ß–D–glucose to D–glucono–1,5–
lactone and hydrogen peroxide, using molecular oxygen as the electron acceptor. The enzyme 
consists of two identical subunits (MW 80 kDa each) bound together by disulfide linkages 
(O'Malley & Weaver, 1972). GOX contains two tightly bound flavin adenine dinucleotide 
(FAD) cofactors, one per subunit. GOX contains 16 % carbohydrate by weight that could be 
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oxidised with sodium periodate to generate aldehyde groups. GOX is widely used in diagnostic 
assays for the determination of glucose concentration in physiological fluids (Hermanson, 
2008). 
Enzymes possess unique catalytic properties compared to chemical catalysts: 
biocompatibility, higher efficiency and specific selectivity toward substrates. These particular 
properties make enzymes suitable as biocatalysts for in vitro reactions. Enzymes have been 
successfully immobilized on many surfaces, e.g., gold nanoparticles (Yáñez–Sedeño & 
Pingarrón, 2005), magnetic nanoparticles (Caruso & Schüler, 2000) and carbon nanotubes (Lin 
et al, 2004). 
Enzyme immobilization restricts the movement of the enzymes, which in turn provides 
a physical support through the covalent binding of the enzymes to the virus capsid and therefore 
prevents the aggregation of the enzyme particles. The immobilisation techniques represented 
here use covalent attachment of two frequently used enzymes, HRP and GOX, as a starting 
point to demonstrate the possibilities for virus–enzyme hybrids. Different immobilisation 
strategies were exploited to couple the enzymes to the virus capsid through covalent attachment 
with various length linkers, which could result in different performances for the immobilized 
enzyme.  
The activation method (periodate method), which has been used here to generate 
functional groups on the surface of the glycosylated enzymes (HRP and GOX), takes advantage 
of the carbohydrates present on the enzyme to generate aldehyde groups. These groups could be 
used directly or subsequently modified to add longer spacers such as adipic acid dihydrazide 
(ADH) (Basu et al, 2003a; Hermanson, 2008). This method is still gentle enough not to lose the 
enzymatic activity. However, enzyme immobilisation often results in the undesirable alteration 
of the enzymes’ 3D conformation (Grunes et al, 2003; Willner et al, 2007).  
This chapter describes preliminary studies to evaluate several strategies for enzyme 
immobilisation on the virus capsid. Enzyme immobilisation is defined here as the restriction of 
the enzyme mobility in a fixed space by covalent attachment to the surface of CPMV. 
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8.2  Materials and Methods 
8.2.1 Materials 
All general reagents, HRP (type VI–A, Product code P6782), glucose oxidase (GOX 
from Aspergillus niger), D–glucose and 6–(ferrocenyl)hexanethiol were purchased from Sigma–
Aldrich UK and used without further purification. 1–ethyl–3–(3–
dimethlyaminopropyl)carbodiimide hydrochloride (EDC) was purchased from Novabiochem, 
N–hydroxysuccinimide (NHS) from Fluka. 
8.2.2 Enzyme activation (periodate method) 
HRP or GOX (10 mg) was dissolved in 10 mM sodium phosphate buffer pH 7.0 (1 ml) 
and a freshly prepared aqueous solution of sodium periodate was added to a final concentration 
of 10 mM. The reaction solution was left to react for 30 minutes with stirring, protected from 
light in a brown vial at 4 °C to prevent periodate breakdown. The reaction was accompanied by 
a colour change from brownish/gold to light green in the case of HRP. The activated enzyme 
was purified using a Sephadex G–25 matrix (PD–10 column) equilibrated with 10 mM sodium 
phosphate buffer pH 7.0. Eluted samples (200 µl) were collected and monitored for GOX at 280 
nm and for HRP at 403 nm and were quantified by measuring the absorbance at 403 nm using 
an extinction coefficient of ε = 102 mM–1 cm–1 (Dunford, 1979). Activated enzyme was used 
immediately after activation or stored for no more than two weeks at –20° C. Fresh samples 
were prepared as and when required.  
8.2.3 Enzyme–adipic acid dihydrazide (E–ADH) 
The method was adapted from (Basu et al, 2003a) in which  ADH (100 mg) was mixed 
with the freshly prepared periodate–oxidised enzyme (HRP or GOX) , followed by the addition 
of 10 µl of 5 M sodium cyanoborohydride in 1 M NaOH (Sigma) per millilitre of the reaction 
solution to stabilise the hydrazone bond. The reaction was left to proceed while gently stirring 
overnight at 4 °C. Excess and unbound reagents were purified as described above, followed by 
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dialysis against 10 mM sodium phosphate buffer pH 7.2 using 10 kDa cut–off membrane 
(Pierce). 
8.2.4  EnzymeCPMV  
Varieties of methods were employed to immobilise activated HRP or GOX onto the 
CPMV capsid. 
8.2.4.1 Allylamine linkageCPMV (Schiff Base) 
A generated aldehyde group on the HRP enzyme can react with primary amines on the 
virus surface to form an allylamine linkage (Hermanson, 2008). The Schiff base has a relatively 
labile bond that is readily reversed by hydrolysis in aqueous solution. Therefore, the product is 
stabilised by sodium cyanoborohydride reduction (Hermanson, 2008), as depicted in Figure 8.1. 
A 2000 molar excess of freshly oxidised HRP was incubated with 1 mg ml
–1 
CPMV particles suspended in 0.1M sodium phosphate buffer pH 8.5. 10 µl of 5 M 
sodium cyanoborohydride in 1 N NaOH was then added. The reaction was allowed to proceed 
for 2 hours at ambient temperature. The modified particles were purified on PD–10 columns 
followed by dialysis against 0.1 M sodium phosphate buffer pH 7.0 for 2 days. A quantity of 5 
mg ml
–1
 esterified enzyme was incubated with CPMV particles (10 mg ml
–1
, 1.5 ml) in 10 mM 
sodium phosphate buffer pH 7.0. The reaction was left overnight (16 hours) at 4 °C to react. 
HRP
CPMV particles were purified on a Sephacryl S–500 gel filtration column followed by 
further washing and concentration on 100 kDa cut–off columns until no HRP activity was 
detected in the supernatant (by addition of H2O2 and TMB) in order to ensure the removal of all 
unbound enzymes. 
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Figure 8.1– Aldehyde groups generated on the enzyme surface can react with amine nucleophiles to 
form reversible Schiff base intermediates. In the presence of suitable reductant, such as sodium 
cyanoborohydride, the Schiff base is stabilised to a secondary amine bond. The scheme is 
reproduced from (Hermanson, 2008). R1 refer to enzyme and R2 refers to CPMVwt. 
 
8.2.4.2 HRP–streptavidin–BiotinCPMV  
Biotin
CPMV was made following our standard protocol (Steinmetz et al, 2006a) and see 
section 6.2.7. Commercially available streptavidin–HRP (Upstate) was mixed in a 200:1 molar 
ratio to 
Biotin
CPMV particles; the reaction was left to proceed overnight at 4 °C while gently 
stirring. 
HRP–streptavidin–Biotin
CPMV hybrid was purified on a Sephacryl S–500 column; the eluent 
was monitored at 280 nm. Fractions were collected, concentrated and further analysed. 
8.2.4.3 HRP–ADH + DyLight488–NHSester  
Previously prepared HRP–ADH (1mg, 1ml) was incubated with DyLight488–NHS 
ester. HRP in a ratio of 1:10 with DyLight488–NHS ester to ensure partial modification. Dye–
labelled enzyme was dialysed against 10 mM sodium phosphate buffer to remove all unbound 
dye for 36 hours with buffer change approximately every 12 hours. Dye–labelled enzyme was 
incubated in a 200 molar ratio to CPMVwt particles and the reaction left to proceed as described 
in section 7.2.8.4. 
8.2.4.4 Enzyme–ADHCPMV 
This approach was employed for both HRP and GOX enzymes. The virus particles 
suspended in 10 mM sodium phosphate buffer pH 7.0 were activated via EDC/NHS as reported 
previously, followed by either purification on PD–10 or through column filtration on 300K 
MWCO membranes (Sartorius Stedim). The esterified virus was concentrated and further 
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incubated with enzyme–ADH in a 200 molar excess. The reaction mixture was left to proceed 
overnight at 4 °C while gently stirring. The 
Enzyme
CPMV hybrid was purified on a gel–filtration 
column (Sephacryl S–500), fractions were collected, concentrated and further analysed. 
8.2.4.5 (Fc6ac)–GOX–ADHCPMVFc6ca 
GOX–ADH
CPMV particles prepared as above were incubated with N–(ferrocenylmethyl)–
6– aminocaproic acid (Fc6ac), a mediator for amperometric enzymatic analysis. This was found 
to be a better approach than modifying the CPMV particles with ferrocene carboxylic acid first, 
bearing in mind that the ferrocene could be bound to both the virus and the enzyme. Doubly–
functionalised particles 
(Fc6ac)–GOX–ADH
CPMV
Fc6ac
 were purified as described earlier. 
8.2.4.6 BenzaldehydeCPMV  approach 
The protocol is adapted from (Brunel et al, 2010). Sulfo–succinimidyl 4–
formylbenzoate sodium salt (sulfo–S–4FB) (Solulink) in Milli–Q water was added in 2000 
molar excess to CPMV (10 mg ml
–1
, 1 ml) suspended in 10 mM sodium phosphate buffer pH 
7.0 for 20 hours at ambient temperature (25 °C). CPMV was desalted as described (section 
2.14.2). The eluted sample was concentrated on 100 kDa cut–off membranes before being 
layered onto 5 ml 10%–50% sucrose gradient (section 2.14.1). The BenzaldehydeCPMV conjugate 
was incubated with 200 molar excess of freshly oxidised HRP and incubated at ambient 
temperature (12–15 hours). Modified particles were then purified by gel filtration (section 
2.14.2). The concentration was determined by UV–vis spectrophotometry with a recovery yield 
of 80–90% based on the initial virus concentration. Particle integrity was confirmed by agarose 
gel electrophoresis and TEM. 
8.2.4.7 SATPCPMV approach 
N–Succinimidyl–S–acetylthiopropionate (SATP) was prepared according to the 
manufacturer’s instruction and as has been published previously (Steinmetz et al, 2007). After 
the deprotection on the chemically introduced thiol group, the particles were incubated with 
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HRP–maleimide (commercially obtained). HRP–maleimide–SATPCPMV particles were purified as 
described earlier. 
8.2.5 Electrochemical measurements 
For 
(Fc6ac)–GOX–ADH
CPMV
Fc6ac
: Particles suspended in 0.1M sodium phosphate buffer pH 
7.0 were added to the three–electrode cell (described in section 7.2.3). The clean PGE electrode 
was immersed in 0.1 M sodium phosphate buffer, pH 7.0 and the electrochemical response was 
allowed to stabilise before adding the doubly–functionalised particles. The current response to 
the glucose concentration change was measured while gently stirring. 10 µl of glucose stock 
solution (0.5 M in 0.1 M phosphate buffer pH 7.0) was added typically at time intervals of 1 
minute. The change in current is proportional to the apparent activity of enzyme immobilised on 
the virus particles. The amperometric studies were performed at ambient temperature (25° C). 
8.2.6 HRP concentration using UV–vis analysis  
The concentration of HRP stock solutions was determined using the characteristic 
absorbance of the heme group at 403 nm and an extinction coefficient of 102 mM
–1
 cm
–1
 
(Dunford, 1979).  
8.2.6.1  Catalytic activity of EnzymeCPMV and free enzymes 
HRP–ADH
CPMV: The catalytic activity of 
HRP–ADH
CPMV and free HRP was tested using 
3,3’,5,5’–tetramethylbenzidine (TMB) substrate catalyzed by HRP in the presence of H2O2.  
Briefly, one tablet of TMB was dissolved in 10 ml of 10 mM sodium phosphate buffer pH 7.0 
so the subsequent analysis of 
HRP–ADH
CPMV would be under the same buffer conditions. 2 µl of 
fresh 30% hydrogen peroxide was added just prior to use to the TMB substrate solution. The 
reaction was carried out in 96–well Elisa plates. 50 µl of 2 M H2SO4 per 100 µl reaction mixture 
was used to stop the reaction. A multi–well reader at 450 nm quantified the generated colour. 
Averaging the 12 replicates from each known HRP concentration was plotted using Excel 2007 
software to generate a calibration curve. The absorbance of three independent plates was used to 
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generate the calibration curve. Data was plotted and the concentration of HRP from the sample 
was obtained.  
GOX–ADH
CPMV: Amplex Red Glucose/Glucose Oxidase assay kit (Invitrogen, cat. No 
A22189). The kit was used according to the manufacturer’s instruction. The reaction was 
protected from light at all times. 
8.3 Results and discussion 
8.3.1 Enzyme oxidation (activation) with periodate  
Sodium metaperiodate is used to oxidize hydroxyl groups on adjacent carbon atoms of 
the polysaccharide residues in the glycoproteins, forming reactive aldehyde residues suitable for 
coupling with amines or hydrazide–containing molecules. For example, HRP contains 21% by 
mass carbohydrate according to the PDB data bank (1H58). The reaction cleaves the carbon–
carbon bond between two adjacent (vicinal) secondary hydroxyls to create two terminal 
aldehyde groups (Hermanson, 2008). Herein, the approach was used to oxidize hydroxyl–
containing carbohydrate within the HRP and GOX to create reactive aldehyde groups, which 
could be further modified with suitable linker such as ADH, this process is depicted in Figure 
8.2. 
CHAPTER 8 
 
209 
 
 
Figure 8.2– Enzymes that are glycoproteins, like HRP and GOX, may be oxidised with sodium 
metaperiodate to produce reactive aldehyde residues. The oxidation by metaperiodate of vicinal 
hydroxyl groups of the carbohydrate moieties generate aldehyde groups followed by hydrazone 
bond formation between enzyme and ADH; and subsequently the conjugation of ADH–enzyme 
onto NHS–esterCPMV surface–exposed carboxylate forms an amide bond. 
 
8.3.2 EnzymeCPMV  
The reaction of the preactivated enzyme with CPMV particles resulted in the formation 
of 
HRP or GOX
CPMV. Intact virions of 
Enzyme
CPMV were characterised by native gel 
electrophoresis according to their migration towards the anode. 
Enzyme
CPMV derivatives joined 
by various length linkers, exhibited various mobility patterns as shown in Figure 8.3. This 
behaviour is thought to arise because of a combination of size and charge effects perturbing the 
mobility through the gel. However, all migrate to a different extent than wild–type (negative 
control) and positive controls (
NHS–ester
CPMV) confirming that the particles have been modified 
and that the particles remain intact after bioconjugation.  
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Figure 8.3– Wild–type and EnzymeCPMV particles separated on a 1.2% agarose gel using various 
coupling chemistries stained with ethidium bromide. (A) Schiff base approach to couple oxidised 
enzyme to the surface lysines, (B) HRP–ADH coupled to the surface carboxylate, (C) SATPCPMV 
and commercially activated maleimide HRP, (D) SF4CPMV and HRP–ADH, and (E) NHS–LC–LC 
biotinCPMV and streptavidin–HRP. Lane 1, CPMVwt; 2, NHS–esterCPMV; 3, HRPCPMV; 4, HRP–
ADHCPMV; 5, SATPCPMV protected; 6, SATPCPMV unprotected; 7, Mal–HRP–SATPCPMV; 8, SF4CPMV; 
9, HRP–ADH–SF4CPMV; 10, NHS–LC–LC–biotinCPMV; 11, HRP–SA–BiotinCPMV, and M is marker 1.5 kb.  
 
 
 
Further evidence to support the successful bioconjugation of the enzyme to the virus 
capsid was provided by comparison of the SDS–PAGE of denatured modified and unmodified 
CPMV particles. The clearest results were obtained with the HRP–ADH approach as shown in 
Figure 8.4. SDS–PAGE revealed two extra bands on the modified particles at approximately 62 
and 80 kDa (, lane 3), corresponding to the size of one conjugated enzyme (~ 40 kDa) to the S 
and L proteins respectively. This suggests partial modification to the L or the S and there is no 
preference to which lysine the enzyme will be coupled to, in addition unmodified L and S are 
observed.  However, the Schiff base approach resulted in only one extra band matching the 62 
kDa (i.e successful modification of S). After much optimisation, only the HRP–ADH approach 
was pursued further. Tryptic digest and further analysis using Mass Spectrometry TOF–MS and 
OptiPrep on the extra bands highlighted in Figure 8.4 did not reveal any fragments of HRP 
sequence, the mass spectral peaks of 
HRP–ADH
CPMV were barely detectable. This was possibly to 
do with the trypsin used for digestion being unable to cleave in the presence of heme group; 
acid treatment prior to the tryptic digest may be needed to overcome this (Personal 
communication with Dr. Mike Naldrett, JIC) (Kvaratskhelia et al, 1999). The SDS–PAGE also 
revealed that unmodified S and L coat protein is also present in the modified particles, which 
means that not all of the protein subunits are coupled with enzymes. This could be because the 
dimensions of the enzyme are possibly blocking some binding sites. It is worth mentioning that 
none of the intermediate controls revealed any extra bands. This eliminates any suspicion of 
cross–linking between the subunits or that the particles are unmodified. Furthermore, 
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fluorescent labelling of HRP–ADH enzyme with DyLight 488–NHS Ester was carried out as 
described in section 7.2.8.3. After rigorous purification, the labelled enzyme was conjugated to 
the virus capsid. Doubly labelled particles 
HRP–ADH
CPMV
DyLight488 
were rigorously purified and 
the particles were found to be fluorescent, suggesting the enzyme is coupled to the capsid. The 
number of dyes per HRP was determined spectrophotometrically as shown in Figure 8.5 and 
estimated to be 2.45 dye per enzyme and 14 ± 3 enzymes per virus. The extinction coefficients 
used are: εHRP, 102 mM
–1
 cm
–1, εDyLight488, 70000 M
–1
 cm
–1
 and εCPMV, 8.1 mg ml
–1
 cm
–1
. The 
molecular mass for HRP is 40 kDa and for the CPMVwt is 56 kDa.  
 
 
Figure 8.4–SDS–PAGE of HRP–ADHCPMV particles. Modified particles were purified on sucrose 
gradient followed by gel filtration on Sephacryl–S500 column. (A) Modified particles were pooled 
and were separated by 4–12% SDS–PAGE and Coomassie stained. Asterisk denotes bands that 
were submitted for mass spectrometry. Lane 1, CPMVwt; 2, HRP–ADH; and 3, HRP–ADHCPMV; M 
is prestained protein marker. (B) HRP–ADHCPMVDyLight 488 image dried on coverslip and viewed by 
Leica SP2 inverted confocal microscope (image was taken by Mr. Grant Calder). 
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Figure 8.5– UV–vis spectrum for the fluorescently labelled HRP conjugated to CPMV particles. 
The number of dyes per virus was determined to be 32 dyes per virus while there are 2 ± 0.45 dyes 
per enzyme as calculated according to the manufacturer’s instruction. This equates to 14 ± 3 
enzymes per virus. 
 
 
The TEM images for 
HRP–ADH
CPMV Figure 8.6–A revealed intact, monodisperse, 
CPMV particles of ca. 38.5 ± 0.5 nm in diameter, which is in agreement with the measured 
particles of ~ 40 ± 0.3 nm by DLS, Figure 8.6–B. This confirms that the particles are modified 
and that the increase in the particle size of ~ 10 nm corresponds to the expected particle size 
with the enzyme bound to the exterior of the particles. Furthermore, TEM was used to detect the 
remaining aldehyde groups on the 
HRP–ADH
CPMV by staining with AgNO3 as shown in Figure 
8.7–A. It has been reported that the silver staining technique (also known as Tollens’ reagent) 
can be used for selective staining of exposed polysaccharides in the cell wall. The specificity of 
this staining is dependent on the production of aldehyde groups after periodate oxidation of the 
polysaccharide (Hanker & Giammara, 1983). It is proposed that the remaining unreacted 
aldehyde groups on the 
HRP–ADH
CPMV
 
react with silver nitrate, causing a deposition of silver on 
specific sites. The pattern observed in Figure 8.7–A does not resemble any patterns obtained 
from the negative controls as shown in Figure 8.7–B, C and D and that the black dots in Figure 
8.7–A (metallic silver) are localized on the spherical particles of the same size of modified virus 
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particles. This confirms that the oxidised enzyme is coupled to the virus capsid. Metallic silver 
was not seen on any parts of the grids.  
 
 
Figure 8.6–TEM image of HRP–ADHCPMV particles stained with 2% UA (A) and the corresponding 
DLS data in (B). Both characterisation methods confirmed independently the successful coupling 
of HRP to the virus capsid and shows particles of ~ 40 nm in diameter. 
 
 
 
Figure 8.7– TEM images of HRP–ADHCPMV particles stained with 1% AgNO3 solution. Particles 
were washed thoroughly with Milli–Q water after deposition on TEM grids and after the addition 
of 5–10 µl of 1% AgNO3 solution. (A) HRP–ADHCPMV particles; inset confirms the localization of 
the metallic silver on the virus capsid; (B) CPMVwt; (C) NHS–esterCPMV; and (D) free HRP–ADH. 
The pattern observed in panel C corresponds to the same size and pattern observed in panel A 
confirming the successful modification of the virus capsid. 
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Further, zeta potential for suspensions of the 
HRP–ADH
CPMV particles in buffer are 
considerably more negative than that for CPMVwt, Figure 8.8–A, of ca. –(12 ± 1.5) mV. 
Additionally, 
NHS–ester
CPMV,
 
as a positive control, has a zeta potential value of –(19.5 ± 1.2) mV 
Figure 8.8–B. Zeta potential values of –(36 ± 2.1) mV for HRP–ADHCPMV are expected since 
HRP molecules are much smaller than CPMV particles and HRP molecules are composed of 
charged and uncharged residues. HRP contains 21% carbohydrate according to the PDB data 
bank (1H58) and 308 amino acid residues in which 60% are hydrophilic and 40% are 
hydrophobic residues (Veitch, 2004). 
 
 
Figure 8.8– Zeta potential measurement of (A) CPMVwt (B) NHS–esterCPMV and (C) HRP–ADHCPMV 
particles. 
 
8.3.3 Enzyme quantification  
The enzymatic activity of the immobilised HRP was investigated in the presence of 
H2O2 and TMB as substrates. Incubation with 
HRP–ADH
CPMV particles resulted in the production 
of various degrees of blue colour depending on the enzyme concentration; in comparison to 
CPMVwt particles that did not catalyse a colour change. This confirmed that the immobilised 
HRP retained their catalytic activity. When the enzymatic activity experiment was repeated on 
particles stored at 4 ºC for 7 days, approximately the same absorbance was observed suggesting 
that no structural changes to the HRP particles had occurred during the storage period. 
To quantify the number of enzymes coupled to the virus, 
HRP–ADH
CPMV calibration 
curves were obtained using different working standard solutions of free HRP prepared by serial 
dilution. The HRP concentration was determined independently as explained in section 7.2.2.5. 
Each enzyme concentration was prepared and used on the same day, 12 activity measurements 
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for each enzyme concentration were recorded and the absorbance was averaged. The HRP 
concentration was plotted versus the absorbance of the substrate (TMB) at 450 nm. The data 
was fitted with linear regression with slope y= 4.208E+05 (R=0.9536). The absorbance recorded 
at 450 nm for 
HRP–ADH
CPMV (treated as unknown) was 0.9069 and from the calibration curve 
depicted in Figure 8.9, the corresponding HRP concentration was 1.83 µg. By measuring, the 
concentration of CPMV particles by UV–vis the number of immobilized enzymes was then 
calculated to be approximately 11±1 per virion. This assumes that HRP activity on the virion is 
the same as the HRP activity in solution (i.e., no enzymatic activity loss). The data is in 
agreement with the number of enzyme per virus subsequently calculated from the HRP 
calibration curve (Figure 8.9).  
 
 
Figure 8.9– Calibration curve plotting known HRP concentrations against their corresponding 
absorbance at 450 nm. The error bars represent standard deviation. The red point is the absorbance 
of HRP–ADHCPMV at 450 nm used to obtain the HRP concentration. 
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It was found that the maximum number of enzyme was a third of that expected for 
theoretical full coverage. If HRP is considered as a solid sphere with a radius of gyration of 2.65 
nm, as calculated by molecular dynamics simulation based on its crystal structure (Laberge et al, 
2003), then the surface area (4πr2) of HRP is approximately 88.24 nm2 (Silva et al, 2007). 
Therefore, the area of 11 HRP molecules amount to ca. 970 nm
2
 in comparison to 2463 nm
2
 for 
a CPMV particle with a 14 nm radius; the maximum coverage is approximately 28 enzymes per 
virus. These estimates are not accurate because CPMV is not a perfect sphere and neither is 
HRP. Therefore, the overall CPMV surface area might not represent the actual available area for 
enzyme coupling. Furthermore, three assumptions had to be taken into consideration: 1, the 
immobilised enzymes retained their enzymatic activity without any changes; 2, all immobilised 
enzymes contribute equally to the overall enzymatic activity detected by TMB; 3, the structural 
conformation of the enzymes remains the same and the active site is accessible by the substrate, 
while keeping in mind that access for the substrate maybe more difficult than to free enzymes.  
8.3.3.1 GOX–ADHCPMV 
Glucose oxidase (GOX) from the fungus Aspergillus niger is a highly specific enzyme 
for D–glucose; it is a dimeric protein with a molecular weight of 160 kDa. GOX was selected 
for the possible development of a selective glucose sensor, which might be useful for blood 
glucose monitoring. The enzyme was activated via the periodate method as previously described 
and the ADH linker was added to the enzyme. The integrity of the modified particles was 
confirmed by agarose gel electrophoresis (Figure 8.10–A) and TEM (Figure 8.10–B). Figure 
8.10–A shows an ethidium bromide stained agarose gel of wild–type, a positive control of NHS–
ester
CPMV, 
GOX–ADH
CPMV, and 
GOX–ADH
CPMV
Fc6ac
 conjugates. According to their migration in 
an electric field towards the anode, the 
NHS–ester
CPMV particles migrate more slowly toward the 
anode than wild–type and each of the GOX–ADHCPMV and GOX–ADHCPMVFc6ac. 
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Figure 8.10– Agarose gel (1.2%) electrophoresis of GOX–ADHCPMV particles visualised by ethidium 
bromide staining. Lane1 represents a 1–kbp DNA ladder 2, CPMVwt; 3, NHS–esterCPMV; 4, GOX–
ADHCPMV; 4, GOX–ADHCPMVFc6ac doubly functionalised particles. 
 
SDS–PAGE, Figure 8.11, revealed an extra band on the modified particles of 
approximately 65–70 kDa, which possibly corresponds to the small coat protein and one 
monomer of the enzyme.  
 
 
Figure 8.11– SDS–PAGE of GOX–ADHCPMV particles. Modified particles were purified on sucrose 
gradient followed by gel filtration on Sephacryl–S500 column as described. Lane 1, wild–type 
CPMV; 2, ADH–GOX; and 3, GOX–ADHCPMV; M is prestained protein marker. The extra band in 
GOX–ADHCPMV lane may correspond to one enzyme monomer conjugated to the small subunit. 
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The particle size in buffer as measured by DLS shows an increase in average 
hydrodynamic diameter to ca. 38 nm following enzyme coupling as shown in Figure 8.12. 
 
 
Figure 8.12– DLS data comparing CPMVwt and GOX–ADHCPMV. 
 
To quantify the number of enzymes coupled to the virus in 
GOX–ADH
CPMV sample, 
calibration curves were obtained using different standard solutions of free GOX prepared from 
stock solution. The reactivity was determined photometrically using Amplex Red 
Glucose/Glucose Oxidase Assay Kit (Invitrogen, cat No A22189) according to the 
manufacturer’s instructions. In the case of Amplex Red assay, the added hydrogen peroxide 
reacts with 10–acetyl–3,7–dihydroxyphenoxazine (the Amplex Red reagent) in the presence of 
HRP (provided with the kit) to form the oxidation product resorufin. Resorufin has an 
absorption peak at approximately 571 nm at a pH of 7.4.  
The free GOX concentration was determined from the serial dilution values. Each 
enzyme concentration was prepared and used on the same day, 12 activity measurements for 
each enzyme concentration were recorded and the absorbance was deducted from the empty 
well values and averaged. The GOX concentration was plotted versus the absorbance of the 
substrate (Amplex Red) at 571 nm. The data was fitted with linear regression with slope y= 
0.0852(R² = 0.9161). From the absorbance recorded at 571 nm for 
GOX–ADH
CPMV (treated as 
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unknown) and from the calibration curve depicted in Figure 8.13, the corresponding free GOX 
concentration was 3.598 µg. By comparison to the concentration of CPMV particles by UV–vis 
(0.0546 mg). The number of immobilized GOX enzymes was found to be approximately 2–3 ±1 
per virion. This assumes that GOX activity on the virion equals GOX activity in solution (no 
enzymatic activity loss). 
 
Figure 8.13– Calibration curve plotting known GOX concentrations against their corresponding 
absorbance at 571 nm. The red point is the absorbance of GOX–ADHCPMV at 571 nm used to obtain 
the GOX concentration 
 
8.3.4 GOX–ADHCPMV and electrochemistry studies in solution 
The resulting 
GOX–ADH
CPMV was characterised by cyclic voltammetry. Covalently 
coupled ferrocene was used as a redox mediator to increase the electron transfer speed. The 
amperometric study was conducted in 0.1 M sodium phosphate buffer pH 7.0, the 
electrochemical cell was set as described in the experimental section. The current response to 
the glucose concentration change was measured as a consequence of the addition of small 
aliquots of glucose stock solution. The ferrocene that is coupled to both of the enzyme and the 
virus previously described in chapter 7 (
(Fc6ac)GOX–ADH
CPMV) particles gave voltammograms 
consistent with a reversible one–electron redox reaction as shown in Figure 8.14 . The number 
y = 0.0852 
R² = 0.9161 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 2 4 6 8 10 12 14
A
b
 4
5
0
 n
m
 
GOX concentration (µg)  
CHAPTER 8 
 
220 
 
of ferrocene was verified as explained at the beginning of this chapter and found to be ~ 400 ± 
11 ferrocene per 
GOX–ADH
CPMV complex. Under the same reaction conditions, neither free 
glucose nor glucose oxidase exhibited any observable electrochemistry. Figure 8.14–A shows a 
voltammogram of 
(Fc6ac)GOX–ADH
CPMV
 
in buffer. Upon addition of D–glucose to the solution a 
remarkable change in the voltammogram occurs as shown in Figure 8.14–B, no standard 
ferrocene peaks are observed, the increase in the catalytic current corresponding to the increase 
in the GOX substrate concentration. This is very significant as it shows the ability to exchange 
electrons between the ferrocene and the enzyme. 
 
Figure 8.14– Current–potential profiles of (Fc6ac)GOX–ADHCPMV suspended in 0.1M sodium 
phosphate buffer pH 7.0 and 25 °C. The catalytic response of the modified particles upon addition 
of 50 µM to 1 mM of D–glucose. The scan rate was 100 mV s–1. The inset shows the standard 
ferrocene signal and the saturated GOX signal and in (B) as for (A), but with the addition of 
glucose oxidase. 
 
8.4  Conclusions 
HRP and GOX were covalently coupled to the CPMV capsid. 
HRP
CPMV or 
GOX–
ADH
CPMV particles could be useful building blocks for catalytic devices. The number of 
enzymes conjugated to the virus capsid was determined to be ~ 11 HRP and 2–3 GOX per virus.  
Moreover, 
GOX–ADH
CPMV showed that the ferrocene/ferrocenium couple can act as an effective 
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mediator between reduced glucose oxidase and a graphite electrode surface. This needs to be 
studied further to develop a possible biosensor. 
The aim of this section was focused on building on our lab’s success in the construction 
of multilayer assemblies of viral particles on solid surfaces (Steinmetz et al, 2006a; Steinmetz et 
al, 2006b). The possibility of incorporating 
Enzymes
CPMV mono/multilayers holds great potential. 
Therefore, as HRP is involved in many applications such as diagnostic assays (Gosling, 1990), 
biosensors (Lindgren et al, 2000). These applications take advantage of the immobilization of 
HRP on a solid support. Therefore, the immobilisation of 
HRP
CPMV on the solid surface 
remains the goal to be pursued. 
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9 Applications of chemical modifications  
9.1 Introduction  
Nanoparticles are playing a pivotal role in the field of drug delivery because they have 
the ability to deliver a wide range of drugs with a high potential for specificity to the diseased 
cells. The potential advantages include high drug payload, improving drug solubility and the 
ability to introduce ligands for targeted delivery (Petros & DeSimone, 2010; Pokorski et al, 
2011).  
Chemical bioconjugation has been applied to modify a wide range of biomolecules, 
including carbohydrates, polysaccharides, nucleic acids, peptides, proteins, antibodies, and 
viruses. Viruses are used as building blocks by conjugating the desired functional moieties to 
the surface exposed amino acids, some approaches are currently under investigation for possible 
nanomedicinal application (Evans, 2008; Evans, 2010; Fischer et al, 2010; Steinmetz, 2010). 
Virus nanoparticles and chemical modification offers a convenient and simple route to design 
nanoparticles with multi–functionalities for targeting, imaging, and drug delivery. The size of 
CPMV virus particles is ideal for a drug carrier; it has been reported that nanoparticles of ~25–
30 nm radius are optimal for internalisation via endocytic pathway (Zhang et al, 2009). The 
relatively acidic environments of endosomal and lysosomal compartments (pH 4.5–5.5) is most 
often used as the trigger for drug release, mainly by cleavage of hydrozone linkages (Bae et al, 
2003; Ulbrich et al, 2004; Ulbrich & Subr, 2004). The development of readily accessible CPMV 
eVLPs has stimulated interest in using such particles for drug delivery.  
9.1.1 Drug coupling and targeting on CPMV  
The development of methods for targeting diseased cells with therapeutic molecules, 
whilst avoiding healthy cells, is an important goal in nanomedicine. The destination–specific 
delivery of therapeutic moieties will limit the undesired side effects of drugs. Tumour–specific 
markers and their ligands that specifically recognise receptors over–expressed on diseased cells 
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have been used (Nanda & St Croix, 2004). CPMV has been identified as having natural 
specificity toward vimentin (Koudelka et al, 2009). Vimentin was found to have a role in 
tumour development and progression (Kokkinos et al, 2007) and it is over–expressed in tumour 
cells (Griffioen et al, 2006). However, some diseased cells express different types of receptors, 
such as the protein transferrin, integrins or folic acid receptors, on their surface compared to 
healthy cells. Therefore, different strategies were explored for possible diseased cell targeting. 
A peptide derived from VP1 of foot–and–mouth disease virus (FMDV) of a type called 
A20FMDV2 peptide, with the sequence depicted in Figure 9.1, which was developed by Dr. 
John Marshall (Centre for Tumour Biology, Institute of Cancer, Barts and the London, Queen 
Mary's School of Medicine and Dentistry) and co–workers. They have studied FMDV and its 
binding to cell surface integrins, α5β3, specifically via the RGD motif (DiCara et al, 2008). 
Integrins are over–expressed on the surface of many types of tumour cells, thus the 
incorporation of this peptide on to a delivery vehicle could confer tumour–targeting properties. 
The RGD is a popular targeting sequence and has been chemically attached to CPMV (Sen G. S. 
et al, 2005) and TMV (Wang et al, 2008). Therefore, chemical modification of virus particles 
with targeting agents opens the door for the development of “smart bomb” nanocarriers for drug 
targeting. 
Chemical conjugation of the A20FMDV2 peptide offers a very promising approach for 
the introduction of this targeting peptide to the virus capsid without the need for genetic 
modification(see chapter 3). The custom–made peptide (Figure 9.1) has cysteine at the C–
terminus for attachment to CPMV surface exposed lysines, either by a bifunctional linker 
(SPDP) or by the EDC/NHS method, and the amino–terminus is blocked with biotin, which 
enables easy detection. The lysine within the peptide is acetylated (protected) to prevent self–
polymerisation.   
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Figure 9.1– A20FMDV2 peptide sequence for α5β3 integrin targeting. The RGD motif is shown in 
brown. Ac refers to the acetylated lysine to prevent self polymerisation. 
 
Doxorubicin (Dox) is one of the most well-known chemotherapeutic anticancer drugs. It 
is a small molecule (MW=545 Da), and is positively charged (pKa 8.4) (Asadishad et al, 2010). 
Although it kills the cancerous cells by inhibiting the synthesis of nucleic acids within cells, 
three main problems are encountered with Dox: high toxicity, short lifetime in the body, and 
low solubility (Yoo & Park, 2004). To overcome the nonspecificity and high toxicity of Dox, 
many researchers have proposed Dox conjugation to hydrophilic polymers (Mislick et al, 1995). 
In addition, folic acid has been widely used for targeted drug delivery to cancer cells (Destito et 
al, 2007; Manchester & Steinmetz, 2009); this is based on the differential expression of folic 
acid receptors on normal and malignant cancer cells (Lu & Low, 2002). Three approaches to 
prepare 
Dox
CPMV and a method for binding folic acid to the virus surface will be described in 
this Chapter. 
9.2 Experimental  
Following my synthesis and characterisation of 
Dox
CPMV, cell uptake studies and cell 
cultures were conducted in collaboration with Prof. Nicole F. Steinmetz and Dr. Sourabh 
Shukla; (Department of Biomedical Engineering, Case Western Reserve University, USA).  
9.2.1 A20FMDV2CPMV particles 
Carbodiimide EDC/NHS and SPDP methods were used as described in section 2.15 and 
2.16, respectively, to generate 
A20FMDV2
CPMV particles. As has been described in chapter 3. 
Peptide quantification of 
A20FMDV2
VLPs
cascade blue dye
 particles was accomplished as described in 
section 6.2.15. 
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9.2.2 Dox–NHS–esterCPMV 
Surface–exposed carboxylate groups were activated with EDC/NHS, as previously 
described in section 2.13. The modified particles, after purification, were incubated with 2000 
molar excess of Dox–HCl in 20% (v/v) DMSO. The reaction mixture was stirred overnight (16 
hours) at 4 °C. Modified particles (
Dox–NHS–ester
CPMV) were eluted through a PD–10 column, 
fractions collected and concentrated on 100 kDa cut–off columns before being layered onto 5 ml 
10–50% sucrose gradient (as described in section 2.14.1). Fractions were collected and dialysed 
against 10 mM sodium phosphate buffer pH 7.0 for 2–4 days using 100 kDa molecular weight 
cut–off membranes. The Dox–NHS–esterCPMV conjugate concentration was determined by UV–
visible spectrophotometry; the yield of 
Dox–NHS–ester
CPMV conjugate was between 60–80% based 
on the initial virus concentration. The number of Dox molecules was determined by measuring 
the absorbance at 490 nm (extinction coefficient, ε: 13500 M–1 cm–1). 
9.2.3 Dox–BS3CPMV 
Bis(sulfosuccinimidyl)suberate (BS
3
) is an amine–to–amine crosslinker with a 8–carbon 
spacer of 11.4 Å in length that contains sulfo–NHS esters at both ends. A 2000 molar excess of 
freshly prepared aqueous solution of BS
3
 was incubated with 1 equivalent of CPMVwt 
suspended in 20 mM sodium phosphate buffer, 0.15 M NaCl. The reaction was left to proceed at 
ambient temperature while gently stirring. 
BS3
CPMV particles were purified on a PD–10 gel 
filtration column and the eluted fractions were dialysed against 0.1 M sodium phosphate, 0.15 
M NaCl; pH 7.2 for 2 days. The modified 
BS3
CPMV particles were incubated with 2000 molar 
excess of Dox dissolved in DMSO. The DMSO level was adjusted to 20% (v/v) of the reaction 
volume. The reaction was left overnight while gently stirring at 4 °C. 
Dox–BS3
CPMV particles 
were purified on 5 ml 10%–50% sucrose gradients as described in section 2.17.1. The fractions 
containing 
Dox–BS3
CPMV were collected and dialysed against 10 mM sodium phosphate buffer 
for 2–4 days using 100 kDa molecular weight cut–off membranes. The yield of Dox–BS3CPMV 
was 50% relative to the initial CPMV concentration as determined by UV–vis 
spectrophotometry. 
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9.2.4 Dox–DTSSPCPMV 
A homobifunctional sulfo–NHS, dithiobis(sulfosuccinimidyl propionate) (DTSSP) 
crosslinking agent was used. DTSSP contains an 8–atom spacer of 12 Å in length. It is 
symmetrically constructed around a central disulfide group that is cleavable. The reaction 
scheme is simplified in Figure 9.2. CPMV particles suspended in 0.1M sodium phosphate, 0.15 
M NaCl; pH 7.2 was incubated with 2000 molar excess of aqueous DTSSP solution. The 
reaction was left to proceed for 2 hours at ambient temperature. 
DTSSP
CPMV particles were 
purified on a PD–10 gel filtration column and the eluted fractions were dialysed against 0.1 M 
sodium phosphate, 0.15 M NaCl; pH 7.2 for 2 days. Freshly prepared 
DTSSP
CPMV particles were 
incubated with 2000 molar excess of Dox dissolved in DMSO. The DMSO level was adjusted 
to 20% (v/v) of the reaction volume. The reaction was left overnight while gently stirring at 4 
°C. 
Dox–DTSSP
CPMV particles were purified on 5 ml 10%–50% sucrose gradients centrifuged as 
described in section 2.17.1. The fractions containing 
Dox–DTSSP
CPMV were collected and 
dialysed against 10 mM sodium phosphate buffer for 2–5 days using 100 kDa molecular weight 
cut–off membranes. The yield of Dox–DTSSPCPMV was 40–50% relative to the initial CPMV 
concentration as determined by UV–vis spectrophotometry. 
 
Figure 9.2– DTSSP crosslinking two amine–containing molecules through an amide linkage. R1 
represents the virus and R2 represents the Dox molecules. 
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9.2.5 DoxCPMV quantification 
For 
DoxCPMV quantification, the extinction coefficient ε484 used is 13500 M cm
–1
. 
9.2.6 FA–NHSCPMV   
Folate N–hydroxysuccinimidyl ester (FA–NHS) was prepared by dissolving folic acid 
(FA, 1 g) in DMSO. EDC (0.434 g) and NHS (1.151 g) were added to the folic acid solution, 
the mixture was stirred at room temperature for 2 hours. FA–NHS was then incubated with 
CPMVwt in a 2000 molar excess, the reaction was left to proceed overnight while gently 
stirring at 4 °C. The modified 
FA–NHS
CPMV particles were purified by gel–filtration over a 
Sephadex G25 (PD–10 columns) equilibrated with 0.1 M sodium phosphate buffer. The eluted 
samples were collected and concentrated before being layered on 5 ml 10%–50% sucrose 
gradients centrifuged as described in section 2.17.1. The fractions containing 
FA–NHS
CPMV were 
collected and dialysed against 10 mM sodium phosphate buffer for 24 hours using 100 kDa 
molecular weight cut–off membranes. The yield of FA–NHSCPMV was 60% relative to the initial 
CPMV concentration as determined by UV–vis spectrophotometry.  
9.2.7 FA–NHSCPMV quantification  
FA–NHS
CPMV in 10 mM sodium phosphate buffer pH 7 was reacted with a 2000 molar 
excess of NHS ester–activated amine specific dye, DyLight488, in DMSO. The DMSO level 
was adjusted to 20% (v/v) and the reaction left to proceed at 4 °C overnight while gently 
stirring. The doubly functionalised particles (
FA–NHS
CPMV
DyLight488
) were purified on a PD–10 
column equilibrated with 10 mM sodium phosphate buffer pH 7.0, and eluted samples were 
concentrated on 100 kDa cut–off columns before being layered onto 5 ml 10%–50% sucrose 
gradients as described in section 2.17.1. The eluted fractions were collected and dialysed against 
10 mM sodium phosphate buffer pH 7.0 for 3 days, changing buffer every 12 hours. After 
further concentration on 100 kDa cut–off columns, the number of free reactive lysines was 
calculated to be ~ 165 ± 8 per virion. This equates to approximately 75 FA moieties being 
bound to each CPMV virus particle or about one FA molecule per asymmetric unit. 
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9.2.8 Dox–NHS–esterCPMVFA  
Folic acid was conjugated to pre–modified Dox–NHS–esterCPMV particles using the 
EDC/NHS method. A 2000 molar excess of folic acid was incubated with 2000 molar excess of 
EDC and 4000 molar excess of sulfo–NHS to 1 molar equivalent of CPMVwt, the reaction was 
left to proceed while gently stirring at ambient temperature for 2 hours. The mixture was then 
incubated with 1 molar excess of (5 mg ml
–1
, 1 ml) 
Dox–NHS–ester
CPMV particles overnight at 4 
°C. The doubly modified particles (
Dox–NHS–ester
CPMV
FA
) were concentrated on 100 kDa cut–off 
columns and layered onto 5 ml 10–50% sucrose gradients as described in section 2.17.1. 
Fractions were collected and further dialysed on 100 kDa membranes for 24 hours. The 
Dox–NHS–
ester
CPMV
FA 
conjugate concentration was determined by UV–vis spectrophotometry; the yield of 
the conjugated particles was between 70–90% based on the initial virus concentration.  
Modified particles were characterised by agarose gel electrophoresis, TEM and ZP. 
9.3 Results and discussion 
9.3.1 Attachment of targeting molecules 
Successful peptide coupling was monitored using agarose gel electrophoresis (Figure 
9.3). When stained with ethidium bromide a fluorescent intensity from a band of different 
mobility to CPMVwt and to the positive control samples, 
NHS–ester
CPMV and 
SPDP
CPMV, was 
observed, suggesting that the CPMV surface has been modified by the coupling of A20FMDV2. 
Two approaches have been adopted to couple the peptide (A20FMDV2) to the CPMV surface, 
either by using SPDP as described in section 2.16 or alternatively for simplicity, as described in 
section 6.2.14, a one–step reaction to form a thioester bond. Figure 9.3–A shows results from 
the SPDP coupling approach and Figure 9.3–B using the EDC approach. When the gel is stained 
with Coomassie blue no changes in the band position in comparison to the ethidium bromide 
staining was observed (data not shown), this is consistent with the virus protein surface being 
modified with the A20FMDV2 peptide. 
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Figure 9.3– 1.2% agarose gel electrophoresis for A20FMDV2CPMV particles stained with ethidium 
bromide. (A) SPDP approach; Lane 1, CPMVwt; 2, SPDPCPMV; 3, A20FMDV2CPMV, and (B) 
EDC/NHS approach; Lane 1, CPMVwt; 2, NHS–esterCPMV; 3, A20FMDV2–NHS–esterCPMV. 
 
Furthermore, TEM confirmed the integrity of the 
A20FMDV2
CPMV particles. Incubating 
the 
A20FMDV2–NHS–ester
CPMV particles with 
Streptavidin
AuNP nanoparticles resulted in partial 
decoration of 
A20FMDV2–NHS–ester
CPMV particles with gold nanoparticles (AuNP) due to the 
presence of biotin on the peptide as shown in Figure 9.4. The number of AuNP per virus is not 
an accurate representation of the number of peptides being coupled to the virus capsid but it is 
confirmation of the peptide presence.  
 
Figure 9.4– Stained TEM image of A20FMDV2–NHS–esterCPMV particles. The black spheres are 
StreptavidinAuNP attached to the virus capsid as a confirmation of the presence of the peptide but this 
is not quantitative. 
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The number of peptides per particle was determined for 
A20FMDV2–EDC
CPMV as described 
in section 6.2.15. The doubly–functionalised particles A20FMDV2CPMVcascade blue dye were 
rigorously purified. The number of remaining reactive carboxylates was calculated from the 
absorbance of the dye at λ399 and ε = 27000 M
–1
 cm
–1
, to be ~90–105 ± 6 per virion. This 
equates to approximately 40–50 peptides being bound to each CPMV particle similar results 
obtained with 
A20FMDV2
VLPs. Moreover, a control experiment was conducted with unmodified 
CPMV and cascade blue dye and the number of dyes was found to be ~140–150 dye per virus, 
this is almost full coverage of all surface accessible carboxylates. 
The second approach, which was explored for targeting, is the use of folic acid (FA). It 
has been shown that the uptake of FA into cells is mediated by the folate receptor (FR), and 
binding of FA to FR initiates receptor mediated endocytosis and internalisation of FA (Destito 
et al, 2007; Rijnboutt et al, 1996). For example, FA has been used for targeting strategies such 
as; the functionalisation of liposomes (Stephenson et al, 2004; Zhao & Lee, 2004).  
Plant viruses generally lack the inherent ability to target human or mammalian cells. 
Therefore, the ability to modify the virus capsid to carry anticancer drug and seek its target as 
well as evading the immune system. This makes CPMV capsid an ideal template to carry the 
multi functionalities to the diseased cell. To this end, FA moieties were bound to each CPMV 
virus particle in addition to the anticancer drug. Furthermore, the ability to bind PEG molecules 
on the same particle will be something to be explored further in the future for the reduction of 
immunogenicity against the particles. 
The number of FA molecules attached to the virions was determined 
spectrophotometrically for the 
FA–NHS
CPMV
DyLight488
 particles. The number of dyes was 
calculated to be ~ 165 ± 8 per virion. This equates to approximately 75 FA moieties being 
bound to each CPMV virus particle or 1 FA molecule per asymmetric unit. This is within the 
range of previously published data (Destito et al, 2007). The doubly–functionalised FA–
NHS
CPMV
Dox
 particles are developed for both targeting and drug delivery. Particles are currently 
still under investigation. 
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9.3.2 Chemical conjugation of doxorubicin 
The surface–exposed amino acid groups can be used as anchoring points to modify 
CPMV particles with drug molecules. Here, the anti–tumour drug Dox was bound covalently to 
the surface exposed carboxylates on the virus capsid. 
9.3.3 Conjugation of doxorubicin to CPMV capsid 
Dox has two major functional groups in its structure, a primary amine group and a 
primary hydroxyl group. Both can be utilised for conjugation to the CPMV capsid. Herein, only 
the amine group has been exploited for coupling. The conjugation schemes using EDC/NHS or 
BS
3
 linker are illustrated in Figure 9.5. The CPMV particles were further modified with folic 
acid to demonstrate the ability to introduce a targeting agent as well as drug moieties on the 
same particle. 
 
 
Figure 9.5– Illustration of the chemical coupling of Dox to the CPMV capsid. Carboxylate groups 
on the virus capsid were activated with EDC/NHS followed by Dox coupling. Alternatively, BS3 
was used to extend the spacer length between Dox and the virus capsid.  
 
 
9.3.4 DoxCPMV characterisation 
Successful Dox coupling was monitored using agarose gel electrophoresis (Figure 9.6–
A), unstained agarose gel shows a fluorescent intensity from a band of different mobility to free 
Dox which migrated to the cathode, while 
Dox–NHS–ester
CPMV had moved in the opposite 
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direction. This suggests that the 
Dox–NHS–ester
CPMV surface has been modified, with the Dox 
moieties being bound to the virus capsid. Furthermore, staining the gel with ethidium bromide 
revealed a different mobility of the bands in comparison to positive (
NHS–ester
CPMV) and 
negative (CPMVwt) controls as shown in Figure 9.6–B. In addition, staining with Coomassie 
blue confirmed the presence and modification of the coat protein. This is consistent with the 
particles being modified with both the drug and the targeting agent (Figure 9.6–C). Furthermore, 
after rigorous purification, 
Dox–NHS–ester
CPMV particles have a raspberry colouring, arising from 
bound Dox. 
Dox–BS3
CPMV was characterised in the same way.  
 
 
Figure 9.6– Native 1.2% agarose gel electrophoresis (A) unstained; (B) ethidium bromide stained; 
(C) Coomassie blue stained and (D) is a camera image of Dox–NHS–esterCPMV particles, (a), image of 
CPMVwt and (b), Dox–NHS–esterCPMV particles. Lane 1, CPMVwt; 2, NHS–esterCPMV; 3, Dox–NHS–
esterCPMV conjugate; 4, free Dox; 5, doubly functionalised Dox–NHS–esterCPMVFA particles.  
 
 
The number of Dox molecules per virus particle was determined for both coupling 
approaches to evaluate the effect of the longer linker length on the Dox coupling. The 
functionalised particles were purified rigorously and the number of Dox molecules was 
determined by measuring the absorbance at 484 nm (extinction coefficient, ε484: 13500 M
–1
 cm
–
1
). From the absorbance spectrum (Figure 9.7), the number of Dox molecules were calculated to 
be ~ 30 ± 3 per virion using the EDC/NHS coupling method and 42 ± 5 using BS
3
 as a linker.  It 
is expected that the length of the linker will have some affect on the number of Dox moieties 
coupled to the virus. The number of Dox moieties coupled to the virus surface was slightly 
higher using BS
3
 as a linker. This is possibly to do with the efficiency of coupling due to the 
stability of the linker in aqueous solution. It has been suggested that coupling with BS
3
 
generates a hydrophilic–region, which might play a role in the increased number of Dox 
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molecules bound to the virus capsid (Hermanson, 2008) in comparison to the EDC/NHS 
approach. 
  
 
Figure 9.7– UV–visible spectrum of Dox–NHS–esterCPMV particles. CPMVwt (blue line), free Dox 
(green line) and Dox–NHS–esterCPMV (red line) using the EDC/NHS approach. The number of Dox 
bound to the virus capsid was 30 ± 3 per virus. 
 
 
For drug nanocarriers, the size and the stability are important properties that might 
influence their in vivo performance. In this case, the size and size distribution of 
Dox–NHS–
ester
CPMV conjugates were examined by DLS (Figure 9.8). The particle size distribution was 
found to be monodisperse with a polydispersity index of 14.5 %; the particle size increased by 
2.2 nm compared to CPMVwt. 
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Figure 9.8– DLS data comparing CPMVwt and Dox–NHS–esterCPMV. 
 
 
The size and morphology of the 
Dox–NHS–ester
CPMV particles were evaluated further by 
TEM. (Figure 9.9), 
Dox–NHS–ester
CPMV particles are monodisperse with an average diameter of 32 
nm. The particles tend to aggregate within 10 days of preparation, which makes it crucial to 
prepare fresh particles for subsequent experiments. 
 
 
Figure 9.9– Stained TEM image of Dox–NHS–esterCPMV particles. 
 
 
The zeta potential for suspensions of 
Dox–NHS–ester
CPMV particles in buffer are 
considerably more negative at –38.1 ± 1.5 mV than that of CPMVwt , of ca. – 12 mV and – 
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14.8 mV for the 
NHS–ester
CPMV particles, and show that the modified particles have good 
colloidal stability and no propensity to aggregate.  
The cellular uptake of 
Dox–NHS–ester
CPMV and confocal microscopy studies were 
conducted in collaboration with Prof. Nicole F. Steinmetz and Dr. Sourabh Shukla; (Department 
of Biomedical Engineering, Case Western Reserve University, USA). The preliminary results of 
confocal microscopy confirmed the uptake of 
Dox–NHS–ester
CPMV by Hela cell lines. However, the 
fluorescence was not concentrated in the nuclei but in many bright small spots in the cytoplasm 
Figure 9.10. This is an indication that the 
Dox–NHS–ester
CPMV are not falling apart in the 
lysosomes and therefore Dox molecules are not reaching the nucleus. Disappointingly, the 
uptake and cell viability of 
Dox–NHS–ester
CPMV suggested that this is not an efficient delivery 
system for cancer chemotherapy. Therefore, another approach was attempted using 
Dox–
DTSSP
CPMV, which relies on the in vivo cleavage of the disulfide bond linking Dox to the virus 
capsid. This is currently being evaluated and the preliminary results indicate this approach has 
great potential. 
 
 
Figure 9.10– Fluorescence analysis of Dox–NHS–esterCPMV in Hela cells after 24 hours.  (A) Hela cells 
in the absence of Dox–NHS–esterCPMV (B) Dox–NHS–esterCPMV (C) Dox–NHS–esterCPMV incubation with 
Hela cells. Dox–NHS–esterCPMV was mainly detected in the cytoplasmic and outside the nucleus 
suggesting. Dr. Sourabh Shukla (Department of Biomedical Engineering, Case Western Reserve 
University, USA) took the images. 
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9.4  Conclusion 
This chapter investigated the use of CPMV capsid as a scaffold for drug delivery and 
targeting. A20FMDV peptide was successfully coupled to both CPMV wt and CPMV eVLPs 
capsid; some work is still needed to fully study this process. Preliminary cell studies on 
FMDV
CPMV particles are currently under investigation by (Prof. John F. Marshall Institute of 
Cancer, Centre for Tumour Biology, Barts and the London Queen Mary's School of Medicine 
and Dentistry, London). The chemical modification of the virus capsid with Dox was attempted 
to generate a high–payload, targeted, delivery agent for anticancer drugs. Fluorescence imaging 
showed 
Dox–NHS–ester
CPMV can be internalized by Hela cancer cells. Free doxorubicin distributed 
mainly into the nucleus and cytoplasm of cells, while 
Dox–NHS–ester
CPMV was localized around 
the nucleus, suggesting the conjugated doxorubicin was taken up by endocytosis. However, 
relying on the virus disassembly was not the right choice in this case. Alternative methods are 
currently being tested. CPMV properties demonstrate that the attachment of targeting peptides 
and other agents can be accomplished in geometrically regular structures. The ordered array can 
be presented to the target cell surface to maximise the probability of endocytosis. 
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10 Conclusions and future work 
The overall aim of this thesis was to develop the potential uses of CPMV as a naturally 
occurring nanoparticle. I started my research by building on previous knowledge regarding the 
addressability of amino acids on the exterior of the virus. I have extended these addressability 
studies and demonstrated that the length of the linker plays a role in the number of ferrocene 
moieties bound to the virus. Additionally, the thesis explores various moieties (ferrocenes, dyes, 
enzymes, peptides and drug molecules) that could be coupled to the virus exterior capsid to 
generate desired nanoparticles.  
CPMVwt has been utilised as a template for mineralization process using peptides 
generated by phage–display–peptide library to initiate the nucleation on the virus surface. The 
chemical coupling of such peptides was favoured over complicated genetic modification 
approaches that were discussed in this thesis; the same method was used to couple FMDV for use 
as a therapeutic targeting agent. Besides, these approaches proved to be general to any modifiable 
surface. As proof of principle, MWCNT was mineralized with CoPt, which generated 
monodisperse coating. The process was scalable and generated particles with a size that one 
normally difficult to be obtained by any other methods. Studying the properties of the particles was 
difficult and although some collaborations were established they were not always fruitful. 
To further advance our knowledge in understanding the control and the specificity of the 
peptides discussed above, CPMV particles were chemically modified to carry a higher negative 
charge than CPMVwt. It was later utilised as a template for mineralization with cobalt and iron 
oxide. The magnetic properties of iron oxide–CPMV were established and the particles were 
further modified as proof of concept. This approach is very simple and it does not require the need 
of expensive peptides to generate monodisperse metallic nanoshells. 
The metallization of CPMV particles using the electrostatic adsorption of palladium anions 
to the surface exposed lysines and upon reduction to generate Pd
0–CPMV which acted as template 
for the subsequent metal deposition from solution in the absence of an external electrical current. 
This approach was also successful in generating monodisperse metallic nanoparticles. The 
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metallization process provided some control over the thickness of the metallic layer based on the 
incubation times. 
CPMV was further used as a template for the deposition of an ultra-thin layer of polycation 
(
PA
CPMV) that was further incubated with gold hydroxide to generate Au–CPMV particles. This 
was the only successful approach I have tried to generate Au–CPMV particles. The particles were 
monodisperse and were further modified with thiolated moieties. Surprisingly, the incubation of 
PA
CPMV particles with citrate capped AuNPs. This reaction resulted in tightly packed, beautiful, 
self–assembled, tessellated–spheres. All of the control experiments showed that the polycation is 
essential for this assembly. The control over the size of Au–CPMV nanoparticles was controlled by 
the amount of gold solution added. The properties of Au–CPMV nanoparticles need to be studied 
further and developed to produce photothermal agents.  
During my studies, our group developed and successfully generated for the first time 
CPMV eVLPs. Therefore, I have extended the use of CPMV eVLPs as nanocontainers for the 
synthesis of highly monodisperse cobalt and iron oxide within the eVLPs. The properties were 
investigated for eVLPsiron oxide and the magnetic properties were confirmed. While writing this thesis 
I am still working toward measuring the thermal measurements of VLPsiron oxide and developing the 
particles for possible hyperthermia treatment. This work is still on–going. 
Furthermore, CPMV eVLPs were explored as nanocontainers to package small dye 
molecules and drug molecules. The layer–by–layer approach to assemble alternating polycation 
and polyanion layers onto the VLPsdrug was explored. The polyelectrolytes were selected 
specifically to be pH– and salt–sensitive in order to explore the use of CPMV eVLPs for controlled 
drug release. VLPsgemcitabine was explored for its fluorescent properties. There is still a lot of work to 
do on this and to further develop the cisplatin anticancer drug/eVLP system. The drug charge and 
size might be very useful in maximising the payload delivered to diseased cells. Furthermore, the 
Polyelectrolyte
VLPs could be further functionalised with targeting or imaging agents.  
It was proposed that immobilisation studies of VNPs on electrode surfaces might be 
achievable using CPMVwt. The stability of ferrocene, accessibility to a wide range of derivatives 
and its electrochemical reversibility made it an ideal moiety for possible applications in 
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nanoelectronics. The immobilisation of 
Ferrocene
CPMV on different electrode materials was reported 
in this thesis. Ferrocene immobilisation on SAMs did not affect the electrochemical properties of 
ferrocene or its stability. However, 
Ferrocene
CPMV immobilisation was a challenge, the 
reproducibility was a big issue using this approach. Although I think, the virus may act as an 
insulator and prevent electron hopping I was not able to prove this. Some further work is still 
needed to confirm or defy this assumption. Furthermore, it was confirmed that by increasing the 
spacer length between the ferrocene moieties and the virus a decrease in the amount of the 
covalently bound moieties was observed. Different chemistries were explored to generate 
Enzyme
CPMV nanoparticles. Two enzymes (HRP and GOX) were selected as proof of principle. 
Quantifying the number of the active enzymes coupled to the capsid was tricky but successful and 
took almost the first two years of my PhD. I will be pursing this work for the coming few months 
of my remaining time at JIC. 
Additionally, 
Ferrocene
CPMV
GOX
 was investigated as a possible approach to generate 
digitalised glucose sensing devices. In such systems, ferrocene generally acts as a mediator and the 
GOX enzyme interacts with the substrate. During the electrochemical detection of glucose using 
Ferrocene
CPMV
GOX
 particles in solution, glucose binds to the active site of the immobilized enzyme, 
which induces an increase in catalytic current, resulted in a measurable shift in the redox potential, 
and alters the current intensity of the Fc/Fc
+
 redox couple. The preliminary results indicated that 
the detection of the analyte (glucose) sensitive and the detection of minor differences in electrode 
potential are possible. In light of the sensory approach for 
Ferrocene
CPMV
GOX
 it is obvious that this 
system represents one useful platform for the design of digitalised sensors and is required to be 
pursued further. 
The potential applications of the chemically modified CPMV particles to carry multivalent 
functionalities are of great potential in developing CPMV as a drug carrier and delivery agent. I 
demonstrated that CPMVwt could be functionalised with anticancer drugs (e.g. Doxorubicin) and 
be functionalised with targeting agents. 
Dox
CPMV delivery potential is being investigated at the 
time of writing this thesis with Prof. Nicole Steinmetz.  
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To conclude, VNPs have proven to be valuable scaffolds for the construction of desired 
new materials with precise positioning and control, and CPMV, in particular, is an excellent 
template of choice to be developed further in the field of bionanoscience. 
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Appendix  
 
